<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2311200287
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Beovu
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        Brolucizumab
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        120
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravitreal use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        0
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled syringe
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store in a refrigerator (2°C – 8°C), do not freeze
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        2754.151
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="NOVARTIS Pharma Stein AG" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            NOVARTIS Pharma Stein AG
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 439]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Novartis Saudi Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Novartis Europharm Limited
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        S01LA
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p><strong>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What Beovu is and what it is used for</strong></p><p>&nbsp;</p><p>What Beovu is</p><p>Beovu contains the active substance brolucizumab, which belongs to a group of medicines called antineovascularisation agents. Beovu is injected into the eye by your doctor to treat eye conditions which may impact your vision.</p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Abnormal blood vessels that leak fluid or blood into the macula</p></td></tr></tbody></table></td></tr></tbody></table><p><!--[if gte vml 1]><v:shapetype id="_x0000_t75" coordsize="21600,21600"
 o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f"
 stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Content_x0020_Placeholder_x0020_5" o:spid="_x0000_i1025"
 type="#_x0000_t75" style='width:243pt;height:122.25pt;visibility:visible;
 mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/alshoma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <o:lock v:ext="edit" grouping="t"/>
</v:shape><![endif]--><img width="324" height="163" src="file:///C:/Users/alshoma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image002.png" /></p><p>&nbsp;</p><p>&nbsp;</p><p>What Beovu is used for</p><p>Beovu is used to treat eye conditions in adults which occur when abnormal blood vessels form and grow underneath the macula. The macula, which is at the back of the eye, is responsible for clear vision. The abnormal blood vessels may leak fluid or blood into the eye and interfere with the macula&rsquo;s function, resulting in diseases which may cause decreased vision such as:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; wet age‑related macular degeneration (wet AMD)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diabetic macular oedema (DME)</p><p>&nbsp;</p><p>How Beovu works</p><p>Beovu may slow down disease progression and thereby maintain, or even improve, your vision.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Before you use Beovu</strong></p><p>&nbsp;</p><p><strong>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Do not use Beovu:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to brolucizumab or any of the other ingredients of this medicine (listed in section&nbsp;6).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have an active or suspected infection in or around the eye.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have pain or redness in your eye (eye inflammation).</p><p>If any of these applies to you, tell your doctor. You should not be given Beovu.</p><p>&nbsp;</p><p><strong>b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Take special care with Beovu</strong></p><p>Talk to your doctor before you are given Beovu if any of the following applies to you:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have glaucoma (an eye condition usually caused by high pressure in the eye).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a history of seeing flashes of light or floaters (dark floating spots) and if you have a sudden increase in the size and number of floaters.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have had eye surgery in the last 4&nbsp;weeks or if eye surgery is planned in the next four weeks.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have ever had any eye diseases or eye treatments.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a history of sudden vision loss due to blockage of blood vessels in the back of the eye (retinal vascular occlusion) or inflammation of blood vessels in the back of the eye (retinal vasculitis) in the last year.</p><p>&nbsp;</p><p><strong>Tell your doctor immediately</strong> if you:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; develop redness of the eye, eye pain, increased discomfort, worsening eye redness, blurred or decreased vision, an increased number of small particles in your vision, increased sensitivity to light.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; develop sudden vision loss, which could be a sign of retinal vascular occlusion.</p><p>Any of the above symptoms may result in your doctor discontinuing your treatment with Beovu.</p><p>&nbsp;</p><p>Furthermore it is important for you to know that:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the safety and efficacy of Beovu when administered to both eyes at the same time has not been studied and use in this way may lead to an increased risk of experiencing side effects.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; injections with Beovu may cause an increase in eye pressure (intraocular pressure) in some patients within 30&nbsp;minutes of the injection. Your doctor will monitor this after each injection.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; your doctor will check whether you have other risk factors that may increase the chance of a tear or detachment of one of the layers at the back of the eye (retinal detachment or tear, and retinal pigment epithelial detachment or tear), in which case Beovu must be given with caution.</p><p>&nbsp;</p><p>The systemic use of VEGF inhibitors, substances similar to those contained in Beovu, is potentially related to the risk of blood clots blocking blood vessels (arterial thromboembolic events), which may lead to heart attack or stroke. There is a theoretical risk of such events following injection of Beovu into the eye.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>Beovu is not used in children and adolescents.</p><p>&nbsp;</p><p><strong>c.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Other medicines and Beovu</strong></p><p>Tell your doctor if you are using, have recently used or might use any other medicines.</p><p>&nbsp;</p><p><strong>d.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant or breast‑feeding, think that you may be pregnant or are planning to have a baby, ask your doctor for advice before this medicine is given to you.</p><p>&nbsp;</p><p>Breast‑feeding is not recommended during treatment with Beovu and for at least one month after stopping treatment with Beovu because it is not known whether Beovu passes into human milk.</p><p>&nbsp;</p><p>Women who could become pregnant must use an effective method of birth control during treatment and for at least one month after stopping treatment with Beovu. If you become pregnant or think you are pregnant during treatment, tell your doctor right away.</p><p>&nbsp;</p><p><strong>e.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Driving and using machines</strong></p><p>After your injection with Beovu, you may have temporary vision problems (for example blurred vision). Do not drive or use machines as long as these last.</p><p>&nbsp;</p><p><strong>f.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Important information about some of the ingredients of Beovu</strong></p><p><strong>Beovu contains sodium</strong></p><p>The medicine contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per dose, that is to say essentially &ldquo;sodium‑free&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>How much and how often Beovu is given</strong></p><p>The recommended dose is 6&nbsp;mg brolucizumab.</p><p>&nbsp;</p><p><strong><em>Wet AMD</em></strong></p><p><em>Starting treatment (also called loading treatment)</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You will be treated with one injection every month for the first 3&nbsp;months.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alternatively, you could be treated with one injection every 6&nbsp;weeks for the first two doses. Your doctor will determine if a third injection is needed 12&nbsp;weeks after treatment start based on the condition of your eye(s).</p><p><em>Maintenance treatment</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[if gte vml 1]><o:wrapblock><v:group
  id="Canvas_x0020_121" o:spid="_x0000_s1035" editas="canvas" style='position:absolute;
  left:0;text-align:left;margin-left:1.1pt;margin-top:56.5pt;width:522.05pt;
  height:217.05pt;z-index:251698176;mso-width-relative:margin;
  mso-height-relative:margin' coordsize="66300,27565" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
  <v:shapetype id="_x0000_t75" coordsize="21600,21600" o:spt="75"
   o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
   <v:stroke joinstyle="miter"/>
   <v:formulas>
    <v:f eqn="if lineDrawn pixelLineWidth 0"/>
    <v:f eqn="sum @0 1 0"/>
    <v:f eqn="sum 0 0 @1"/>
    <v:f eqn="prod @2 1 2"/>
    <v:f eqn="prod @3 21600 pixelWidth"/>
    <v:f eqn="prod @3 21600 pixelHeight"/>
    <v:f eqn="sum @0 0 1"/>
    <v:f eqn="prod @6 1 2"/>
    <v:f eqn="prod @7 21600 pixelWidth"/>
    <v:f eqn="sum @8 21600 0"/>
    <v:f eqn="prod @7 21600 pixelHeight"/>
    <v:f eqn="sum @10 21600 0"/>
   </v:formulas>
   <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
   <o:lock v:ext="edit" aspectratio="t"/>
  </v:shapetype><v:shape id="_x0000_s1036" type="#_x0000_t75" style='position:absolute;
   width:66300;height:27565;visibility:visible;mso-wrap-style:square'>
   <v:fill o:detectmouseclick="t"/>
   <v:path o:connecttype="none"/>
  </v:shape><v:shape id="Freeform_x0020_5" o:spid="_x0000_s1037" style='position:absolute;
   left:43084;top:9010;width:4699;height:4242;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' coordsize="553,498" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m502,498r,l51,498c23,498,,476,,448l,50c,23,23,,51,l502,v28,,51,23,51,50l553,448v,28,-23,50,-51,50xe"
   fillcolor="black" strokeweight="0">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="426564,424180;426564,424180;43336,424180;0,381592;0,42588;43336,0;426564,0;469900,42588;469900,381592;426564,424180"
    o:connectangles="0,0,0,0,0,0,0,0,0,0"/>
  </v:shape><v:shape id="Freeform_x0020_6" o:spid="_x0000_s1038" style='position:absolute;
   left:43408;top:10261;width:4051;height:2667;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' coordsize="477,313" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m447,313r,l30,313c13,313,,300,,283l,,477,r,283c477,300,464,313,447,313xe"
   fillcolor="#fefefe" strokeweight="0">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="379650,266700;379650,266700;25480,266700;0,241138;0,0;405130,0;405130,241138;379650,266700"
    o:connectangles="0,0,0,0,0,0,0,0"/>
  </v:shape><v:shape id="Freeform_x0020_7" o:spid="_x0000_s1039" style='position:absolute;
   left:44030;top:8299;width:712;height:1295;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' coordsize="84,152" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m42,152r,c19,152,,133,,109l,42c,19,19,,42,,65,,84,19,84,42r,67c84,133,65,152,42,152xe"
   fillcolor="black" strokeweight="0">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="35560,129540;35560,129540;0,92894;0,35794;35560,0;71120,35794;71120,92894;35560,129540"
    o:connectangles="0,0,0,0,0,0,0,0"/>
  </v:shape><v:shape id="Freeform_x0020_8" o:spid="_x0000_s1040" style='position:absolute;
   left:43942;top:8223;width:882;height:1448;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' coordsize="104,170" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m52,r,c23,,,23,,51r,67c,147,23,170,52,170v28,,52,-23,52,-52l104,51c104,23,80,,52,xm52,19r,c70,19,84,33,84,51r,67c84,136,70,151,52,151,34,151,19,136,19,118r,-67c19,33,34,19,52,19xe"
   fillcolor="#fefefe" strokeweight="0">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="44133,0;44133,0;0,43434;0,100494;44133,144780;88265,100494;88265,43434;44133,0;44133,16181;44133,16181;71291,43434;71291,100494;44133,128599;16125,100494;16125,43434;44133,16181"
    o:connectangles="0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0"/>
   <o:lock v:ext="edit" verticies="t"/>
  </v:shape><v:shape id="Freeform_x0020_9" o:spid="_x0000_s1041" style='position:absolute;
   left:46208;top:8299;width:718;height:1295;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' coordsize="84,152" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m42,152r,c18,152,,133,,109l,42c,19,18,,42,,65,,84,19,84,42r,67c84,133,65,152,42,152xe"
   fillcolor="black" strokeweight="0">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="35878,129540;35878,129540;0,92894;0,35794;35878,0;71755,35794;71755,92894;35878,129540"
    o:connectangles="0,0,0,0,0,0,0,0"/>
  </v:shape><v:shape id="Freeform_x0020_10" o:spid="_x0000_s1042" style='position:absolute;
   left:46126;top:8223;width:876;height:1448;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' coordsize="103,170" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m52,r,c23,,,23,,51r,67c,147,23,170,52,170v28,,51,-23,51,-52l103,51c103,23,80,,52,xm52,19r,c70,19,84,33,84,51r,67c84,136,70,151,52,151,34,151,19,136,19,118r,-67c19,33,34,19,52,19xe"
   fillcolor="#fefefe" strokeweight="0">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="44240,0;44240,0;0,43434;0,100494;44240,144780;87630,100494;87630,43434;44240,0;44240,16181;44240,16181;71465,43434;71465,100494;44240,128599;16165,100494;16165,43434;44240,16181"
    o:connectangles="0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0"/>
   <o:lock v:ext="edit" verticies="t"/>
  </v:shape><v:shape id="Freeform_x0020_11" o:spid="_x0000_s1043" style='position:absolute;
   left:18046;top:9010;width:4687;height:4242;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' coordsize="552,498" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m502,498r,l50,498c22,498,,476,,448l,50c,23,22,,50,l502,v27,,50,23,50,50l552,448v,28,-23,50,-50,50xe"
   fillcolor="black" strokeweight="0">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="426182,424180;426182,424180;42448,424180;0,381592;0,42588;42448,0;426182,0;468630,42588;468630,381592;426182,424180"
    o:connectangles="0,0,0,0,0,0,0,0,0,0"/>
  </v:shape><v:shape id="Freeform_x0020_12" o:spid="_x0000_s1044" style='position:absolute;
   left:18364;top:10261;width:4051;height:2667;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' coordsize="477,313" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m447,313r,l30,313c14,313,,300,,283l,,477,r,283c477,300,464,313,447,313xe"
   fillcolor="#fefefe" strokeweight="0">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="379650,266700;379650,266700;25480,266700;0,241138;0,0;405130,0;405130,241138;379650,266700"
    o:connectangles="0,0,0,0,0,0,0,0"/>
  </v:shape><v:shape id="Freeform_x0020_13" o:spid="_x0000_s1045" style='position:absolute;
   left:18980;top:8299;width:717;height:1295;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' coordsize="84,152" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m42,152r,c19,152,,133,,109l,42c,19,19,,42,,65,,84,19,84,42r,67c84,133,65,152,42,152xe"
   fillcolor="black" strokeweight="0">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="35878,129540;35878,129540;0,92894;0,35794;35878,0;71755,35794;71755,92894;35878,129540"
    o:connectangles="0,0,0,0,0,0,0,0"/>
  </v:shape><v:shape id="Freeform_x0020_14" o:spid="_x0000_s1046" style='position:absolute;
   left:18897;top:8223;width:883;height:1448;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' coordsize="104,170" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m52,r,c24,,,23,,51r,67c,147,24,170,52,170v29,,52,-23,52,-52l104,51c104,23,81,,52,xm52,19r,c70,19,85,33,85,51r,67c85,136,70,151,52,151,34,151,20,136,20,118r,-67c20,33,34,19,52,19xe"
   fillcolor="#fefefe" strokeweight="0">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="44133,0;44133,0;0,43434;0,100494;44133,144780;88265,100494;88265,43434;44133,0;44133,16181;44133,16181;72140,43434;72140,100494;44133,128599;16974,100494;16974,43434;44133,16181"
    o:connectangles="0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0"/>
   <o:lock v:ext="edit" verticies="t"/>
  </v:shape><v:shape id="Freeform_x0020_15" o:spid="_x0000_s1047" style='position:absolute;
   left:21164;top:8299;width:711;height:1295;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' coordsize="84,152" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m42,152r,c19,152,,133,,109l,42c,19,19,,42,,65,,84,19,84,42r,67c84,133,65,152,42,152xe"
   fillcolor="black" strokeweight="0">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="35560,129540;35560,129540;0,92894;0,35794;35560,0;71120,35794;71120,92894;35560,129540"
    o:connectangles="0,0,0,0,0,0,0,0"/>
  </v:shape><v:shape id="Freeform_x0020_16" o:spid="_x0000_s1048" style='position:absolute;
   left:21082;top:8223;width:882;height:1448;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' coordsize="104,170" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQCLv4JiwwAAANsAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI/NasMw
EITvhb6D2EJvjZxCfupGCSUmkFMgTh5gsTa2E2slJNlx3r4KFHocZuYbZrUZTScG8qG1rGA6yUAQ
V1a3XCs4n3YfSxAhImvsLJOCBwXYrF9fVphre+cjDWWsRYJwyFFBE6PLpQxVQwbDxDri5F2sNxiT
9LXUHu8Jbjr5mWVzabDltNCgo21D1a3sjQL9Vc36g9PL82Vw2+JxLUrfF0q9v40/3yAijfE//Nfe
awWLKTy/pB8g178AAAD//wMAUEsBAi0AFAAGAAgAAAAhANvh9svuAAAAhQEAABMAAAAAAAAAAAAA
AAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEAWvQsW78AAAAVAQAACwAA
AAAAAAAAAAAAAAAfAQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEAi7+CYsMAAADbAAAADwAA
AAAAAAAAAAAAAAAHAgAAZHJzL2Rvd25yZXYueG1sUEsFBgAAAAADAAMAtwAAAPcCAAAAAA==
" path="m52,r,c23,,,23,,51r,67c,147,23,170,52,170v28,,52,-23,52,-52l104,51c104,23,80,,52,xm52,19r,c70,19,85,33,85,51r,67c85,136,70,151,52,151,34,151,19,136,19,118r,-67c19,33,34,19,52,19xe"
   fillcolor="#fefefe" strokeweight="0">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="44133,0;44133,0;0,43434;0,100494;44133,144780;88265,100494;88265,43434;44133,0;44133,16181;44133,16181;72140,43434;72140,100494;44133,128599;16125,100494;16125,43434;44133,16181"
    o:connectangles="0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0"/>
   <o:lock v:ext="edit" verticies="t"/>
  </v:shape><v:shape id="Freeform_x0020_17" o:spid="_x0000_s1049" style='position:absolute;
   left:2889;top:9010;width:4686;height:4242;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' coordsize="552,498" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQDZMfyTxQAAANsAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9fS8NA
EMTfBb/DsYIvxV6M1pbYaxHBUkEf+gf6uuTWJDS3F+7WJv32XqHg4zAzv2Hmy8G16kQhNp4NPI4z
UMSltw1XBva7j4cZqCjIFlvPZOBMEZaL25s5Ftb3vKHTViqVIBwLNFCLdIXWsazJYRz7jjh5Pz44
lCRDpW3APsFdq/Mse9EOG04LNXb0XlN53P46A5v953m0oueJBDp+9/nkSVZfB2Pu74a3V1BCg/yH
r+21NTDN4fIl/QC9+AMAAP//AwBQSwECLQAUAAYACAAAACEA2+H2y+4AAACFAQAAEwAAAAAAAAAA
AAAAAAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQBa9CxbvwAAABUBAAAL
AAAAAAAAAAAAAAAAAB8BAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQDZMfyTxQAAANsAAAAP
AAAAAAAAAAAAAAAAAAcCAABkcnMvZG93bnJldi54bWxQSwUGAAAAAAMAAwC3AAAA+QIAAAAA
" path="m502,498r,l50,498c22,498,,476,,448l,50c,23,22,,50,l502,v28,,50,23,50,50l552,448v,28,-22,50,-50,50xe"
   fillcolor="black" strokeweight="0">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="426182,424180;426182,424180;42448,424180;0,381592;0,42588;42448,0;426182,0;468630,42588;468630,381592;426182,424180"
    o:connectangles="0,0,0,0,0,0,0,0,0,0"/>
  </v:shape><v:shape id="Freeform_x0020_18" o:spid="_x0000_s1050" style='position:absolute;
   left:3200;top:10261;width:4051;height:2667;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' coordsize="477,313" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m447,313r,l30,313c14,313,,300,,283l,,477,r,283c477,300,464,313,447,313xe"
   fillcolor="#fefefe" strokeweight="0">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="379650,266700;379650,266700;25480,266700;0,241138;0,0;405130,0;405130,241138;379650,266700"
    o:connectangles="0,0,0,0,0,0,0,0"/>
  </v:shape><v:shape id="Freeform_x0020_19" o:spid="_x0000_s1051" style='position:absolute;
   left:3822;top:8299;width:711;height:1295;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' coordsize="84,152" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m42,152r,c19,152,,133,,109l,42c,19,19,,42,,65,,84,19,84,42r,67c84,133,65,152,42,152xe"
   fillcolor="black" strokeweight="0">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="35560,129540;35560,129540;0,92894;0,35794;35560,0;71120,35794;71120,92894;35560,129540"
    o:connectangles="0,0,0,0,0,0,0,0"/>
  </v:shape><v:shape id="Freeform_x0020_20" o:spid="_x0000_s1052" style='position:absolute;
   left:3746;top:8223;width:870;height:1448;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' coordsize="103,170" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQACl2x7xQAAANsAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9Ba8JA
FITvgv9heYXedFNrY4muIqGKwVNtKfT2yD6TYPZtml2T+O+7hYLHYWa+YVabwdSio9ZVlhU8TSMQ
xLnVFRcKPj92k1cQziNrrC2Tghs52KzHoxUm2vb8Tt3JFyJA2CWooPS+SaR0eUkG3dQ2xME729ag
D7ItpG6xD3BTy1kUxdJgxWGhxIbSkvLL6WoU0Pfhx5yzPLXZ26Lfz19mz8f5l1KPD8N2CcLT4O/h
//ZBK1jE8Pcl/AC5/gUAAP//AwBQSwECLQAUAAYACAAAACEA2+H2y+4AAACFAQAAEwAAAAAAAAAA
AAAAAAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQBa9CxbvwAAABUBAAAL
AAAAAAAAAAAAAAAAAB8BAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQACl2x7xQAAANsAAAAP
AAAAAAAAAAAAAAAAAAcCAABkcnMvZG93bnJldi54bWxQSwUGAAAAAAMAAwC3AAAA+QIAAAAA
" path="m51,r,c23,,,23,,51r,67c,147,23,170,51,170v29,,52,-23,52,-52l103,51c103,23,80,,51,xm51,19r,c69,19,84,33,84,51r,67c84,136,69,151,51,151,33,151,19,136,19,118r,-67c19,33,33,19,51,19xe"
   fillcolor="#fefefe" strokeweight="0">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="43075,0;43075,0;0,43434;0,100494;43075,144780;86995,100494;86995,43434;43075,0;43075,16181;43075,16181;70947,43434;70947,100494;43075,128599;16048,100494;16048,43434;43075,16181"
    o:connectangles="0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0"/>
   <o:lock v:ext="edit" verticies="t"/>
  </v:shape><v:shape id="Freeform_x0020_21" o:spid="_x0000_s1053" style='position:absolute;
   left:6000;top:8299;width:718;height:1295;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' coordsize="84,152" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m42,152r,c19,152,,133,,109l,42c,19,19,,42,,65,,84,19,84,42r,67c84,133,65,152,42,152xe"
   fillcolor="black" strokeweight="0">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="35878,129540;35878,129540;0,92894;0,35794;35878,0;71755,35794;71755,92894;35878,129540"
    o:connectangles="0,0,0,0,0,0,0,0"/>
  </v:shape><v:shape id="Freeform_x0020_22" o:spid="_x0000_s1054" style='position:absolute;
   left:5918;top:8223;width:882;height:1448;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' coordsize="104,170" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m52,r,c24,,,23,,51r,67c,147,24,170,52,170v29,,52,-23,52,-52l104,51c104,23,81,,52,xm52,19r,c70,19,85,33,85,51r,67c85,136,70,151,52,151,34,151,20,136,20,118r,-67c20,33,34,19,52,19xe"
   fillcolor="#fefefe" strokeweight="0">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="44133,0;44133,0;0,43434;0,100494;44133,144780;88265,100494;88265,43434;44133,0;44133,16181;44133,16181;72140,43434;72140,100494;44133,128599;16974,100494;16974,43434;44133,16181"
    o:connectangles="0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0"/>
   <o:lock v:ext="edit" verticies="t"/>
  </v:shape><v:rect id="Rectangle_x0020_23" o:spid="_x0000_s1055" style='position:absolute;
   left:31;top:15627;width:11589;height:2654;visibility:visible;
   mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span style='color:black'>For the first 3&nbsp;doses, </span><o:p></o:p></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_24" o:spid="_x0000_s1056" style='position:absolute;
   left:958;top:17125;width:9170;height:2655;visibility:visible;
   mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span style='color:black'>1&nbsp;injection every </span><o:p></o:p></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_25" o:spid="_x0000_s1057" style='position:absolute;
   left:3117;top:18624;width:4655;height:2654;visibility:visible;
   mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span style='color:black'>4&nbsp;weeks</span><o:p></o:p></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:shape id="Freeform_x0020_26" o:spid="_x0000_s1058" style='position:absolute;
   left:29095;top:10414;width:8789;height:1289;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' coordsize="1744,190" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m1739,84r,l1636,7c1624,,1618,4,1616,17r,54l18,71c8,71,,80,,91v,10,8,19,18,19l1616,110r,59c1617,187,1624,190,1636,183l1739,97v5,-4,5,-8,,-13xe"
   fillcolor="#111112" strokeweight="0">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="876320,56990;876320,56990;824416,4749;814338,11534;814338,48170;9071,48170;0,61739;9071,74629;814338,74629;814338,114658;824416,124156;876320,65809;876320,56990"
    o:connectangles="0,0,0,0,0,0,0,0,0,0,0,0,0"/>
  </v:shape><v:rect id="Rectangle_x0020_27" o:spid="_x0000_s1059" style='position:absolute;
   left:2647;top:13449;width:4655;height:2673;visibility:visible;
   mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><b><span style='font-family:"Times New Roman Bold",serif;
      mso-bidi-font-family:"Times New Roman Bold";color:black'>WEEKS</span></b><o:p></o:p></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_28" o:spid="_x0000_s1060" style='position:absolute;
   left:4533;top:10731;width:1086;height:3696;visibility:visible;
   mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><b><span style='font-size:17.0pt;line-height:107%;
      font-family:"Times New Roman Bold",serif;mso-bidi-font-family:"Times New Roman Bold";
      color:black'>4</span></b><o:p></o:p></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_29" o:spid="_x0000_s1061" style='position:absolute;
   top:4648;width:679;height:2654;visibility:visible;mso-wrap-style:none;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><o:p>&nbsp;</o:p></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_30" o:spid="_x0000_s1062" style='position:absolute;
   left:958;top:4711;width:5430;height:2674;visibility:visible;
   mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><b><span style='font-family:"Times New Roman Bold",serif;
      mso-bidi-font-family:"Times New Roman Bold";color:black'>3&nbsp;DOSES, </span></b><o:p></o:p></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_31" o:spid="_x0000_s1063" style='position:absolute;
   left:768;top:6280;width:7506;height:2673;visibility:visible;
   mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQAz1RtxwQAAANsAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI/NigIx
EITvC75DaMHbmtHD7jBrFBEEXbw47gM0k54fTDpDEp3x7Y0g7LGoqq+o1Wa0RtzJh86xgsU8A0Fc
Od1xo+Dvsv/MQYSIrNE4JgUPCrBZTz5WWGg38JnuZWxEgnAoUEEbY19IGaqWLIa564mTVztvMSbp
G6k9DglujVxm2Ze02HFaaLGnXUvVtbxZBfJS7oe8ND5zv8v6ZI6Hc01Oqdl03P6AiDTG//C7fdAK
8m94fUk/QK6fAAAA//8DAFBLAQItABQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAAAAAAAAAAAAA
AAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAAAA
AAAAAAAAAAAAHwEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhADPVG3HBAAAA2wAAAA8AAAAA
AAAAAAAAAAAABwIAAGRycy9kb3ducmV2LnhtbFBLBQYAAAAAAwADALcAAAD1AgAAAAA=
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><b><span style='font-family:"Times New Roman Bold",serif;
      mso-bidi-font-family:"Times New Roman Bold";color:black'>ONCE EVER</span></b><o:p></o:p></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_32" o:spid="_x0000_s1064" style='position:absolute;
   left:8763;top:6280;width:914;height:2673;visibility:visible;
   mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><b><span style='font-family:"Times New Roman Bold",serif;
      mso-bidi-font-family:"Times New Roman Bold";color:black'>Y</span></b><o:p></o:p></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_33" o:spid="_x0000_s1065" style='position:absolute;
   left:342;width:28848;height:5346;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal align=center style='text-align:center'><b><span
      style='font-family:"Times New Roman Bold",serif;mso-bidi-font-family:
      "Times New Roman Bold";color:black;background:yellow;mso-highlight:yellow'>STARTING
      TREATMENT<o:p></o:p></span></b></p>
      <p class=MsoNormal align=center style='text-align:center'><b><span
      style='font-family:"Times New Roman Bold",serif;mso-bidi-font-family:
      "Times New Roman Bold";color:black;background:yellow;mso-highlight:yellow'>(ALSO
      CALLED LOADING TREATMENT</span></b><b><span style='font-family:"Times New Roman Bold",serif;
      mso-bidi-font-family:"Times New Roman Bold";color:black'>)</span></b><o:p></o:p></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_34" o:spid="_x0000_s1066" style='position:absolute;
   left:12299;top:1498;width:680;height:2654;visibility:visible;
   mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><o:p>&nbsp;</o:p></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_35" o:spid="_x0000_s1067" style='position:absolute;
   left:38646;top:50;width:23012;height:2674;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><b><span style='font-family:"Times New Roman Bold",serif;
      mso-bidi-font-family:"Times New Roman Bold";color:black'>MAINTENANCE
      TREATMENT<o:p></o:p></span></b></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_36" o:spid="_x0000_s1068" style='position:absolute;
   left:15284;top:15627;width:11589;height:2654;visibility:visible;
   mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span style='color:black'>For the first 2&nbsp;doses, </span><o:p></o:p></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_37" o:spid="_x0000_s1069" style='position:absolute;
   left:16205;top:17125;width:15513;height:2655;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span style='color:black'>1&nbsp;injection every </span><o:p></o:p></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_38" o:spid="_x0000_s1070" style='position:absolute;
   left:18370;top:18624;width:4655;height:2654;visibility:visible;
   mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQBG3hPbwQAAANsAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI/NigIx
EITvC75DaMHbmlFk0dEoIggqe3H0AZpJzw8mnSHJOrNvb4SFPRZV9RW12Q3WiCf50DpWMJtmIIhL
p1uuFdxvx88liBCRNRrHpOCXAuy2o48N5tr1fKVnEWuRIBxyVNDE2OVShrIhi2HqOuLkVc5bjEn6
WmqPfYJbI+dZ9iUttpwWGuzo0FD5KH6sAnkrjv2yMD5zl3n1bc6na0VOqcl42K9BRBrif/ivfdIK
Vgt4f0k/QG5fAAAA//8DAFBLAQItABQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAAAAAAAAAAAAA
AAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAAAA
AAAAAAAAAAAAHwEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhAEbeE9vBAAAA2wAAAA8AAAAA
AAAAAAAAAAAABwIAAGRycy9kb3ducmV2LnhtbFBLBQYAAAAAAwADALcAAAD1AgAAAAA=
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span style='color:black'>6&nbsp;weeks</span><o:p></o:p></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_39" o:spid="_x0000_s1071" style='position:absolute;
   left:14878;top:20580;width:679;height:2343;visibility:visible;
   mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span style='font-size:8.0pt;line-height:107%;
      color:black'>Y</span><o:p></o:p></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_40" o:spid="_x0000_s1072" style='position:absolute;
   left:15519;top:20580;width:11062;height:2343;visibility:visible;
   mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span style='font-size:8.0pt;line-height:107%;
      color:black'>our doctor will determine </span><o:p></o:p></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_41" o:spid="_x0000_s1073" style='position:absolute;
   left:14693;top:21805;width:12307;height:2344;visibility:visible;
   mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span style='font-size:8.0pt;line-height:107%;
      color:black'>if a third injection is needed </span><o:p></o:p></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_42" o:spid="_x0000_s1074" style='position:absolute;
   left:15030;top:23031;width:13405;height:2343;visibility:visible;
   mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span style='font-size:8.0pt;line-height:107%;
      color:black'>12&nbsp;weeks after treatment start </span><o:p></o:p></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_43" o:spid="_x0000_s1075" style='position:absolute;
   left:13531;top:24263;width:16434;height:2343;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span style='font-size:8.0pt;line-height:107%;
      color:black'>based on the condition of your eye</span><o:p></o:p></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_44" o:spid="_x0000_s1076" style='position:absolute;
   left:17900;top:13449;width:4655;height:2673;visibility:visible;
   mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><b><span style='font-family:"Times New Roman Bold",serif;
      mso-bidi-font-family:"Times New Roman Bold";color:black'>WEEKS</span></b><o:p></o:p></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_45" o:spid="_x0000_s1077" style='position:absolute;
   left:19754;top:10693;width:1086;height:3696;visibility:visible;
   mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><b><span style='font-size:17.0pt;line-height:107%;
      font-family:"Times New Roman Bold",serif;mso-bidi-font-family:"Times New Roman Bold";
      color:black'>6</span></b><o:p></o:p></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_46" o:spid="_x0000_s1078" style='position:absolute;
   left:15157;top:4648;width:679;height:2654;visibility:visible;
   mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQD3hYQCvwAAANwAAAAPAAAAZHJzL2Rvd25yZXYueG1sRE/NagIx
EL4LfYcwhd40cQ9FVqMUQdDixbUPMGxmf2gyWZLobt/eCEJv8/H9zmY3OSvuFGLvWcNyoUAQ1970
3Gr4uR7mKxAxIRu0nknDH0XYbd9mGyyNH/lC9yq1IodwLFFDl9JQShnrjhzGhR+IM9f44DBlGFpp
Ao453FlZKPUpHfacGzocaN9R/VvdnAZ5rQ7jqrJB+e+iOdvT8dKQ1/rjffpag0g0pX/xy300eb4q
4PlMvkBuHwAAAP//AwBQSwECLQAUAAYACAAAACEA2+H2y+4AAACFAQAAEwAAAAAAAAAAAAAAAAAA
AAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQBa9CxbvwAAABUBAAALAAAAAAAA
AAAAAAAAAB8BAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQD3hYQCvwAAANwAAAAPAAAAAAAA
AAAAAAAAAAcCAABkcnMvZG93bnJldi54bWxQSwUGAAAAAAMAAwC3AAAA8wIAAAAA
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><o:p>&nbsp;</o:p></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_47" o:spid="_x0000_s1079" style='position:absolute;
   left:15989;top:4832;width:5429;height:2673;visibility:visible;
   mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><b><span style='font-family:"Times New Roman Bold",serif;
      mso-bidi-font-family:"Times New Roman Bold";color:black'>2&nbsp;DOSES, </span></b><o:p></o:p></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_48" o:spid="_x0000_s1080" style='position:absolute;
   left:15932;top:6280;width:7505;height:2673;visibility:visible;
   mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><b><span style='font-family:"Times New Roman Bold",serif;
      mso-bidi-font-family:"Times New Roman Bold";color:black'>ONCE EVER</span></b><o:p></o:p></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_49" o:spid="_x0000_s1081" style='position:absolute;
   left:23926;top:6280;width:915;height:2673;visibility:visible;
   mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><b><span style='font-family:"Times New Roman Bold",serif;
      mso-bidi-font-family:"Times New Roman Bold";color:black'>Y</span></b><o:p></o:p></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_50" o:spid="_x0000_s1082" style='position:absolute;
   left:11099;top:10052;width:2864;height:3378;visibility:visible;
   mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><b><span style='font-size:15.0pt;line-height:107%;
      font-family:"Times New Roman Bold",serif;mso-bidi-font-family:"Times New Roman Bold";
      color:black'>OR</span></b><o:p></o:p></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:shape id="Freeform_x0020_51" o:spid="_x0000_s1083" style='position:absolute;
   left:12706;top:4699;width:0;height:4787;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="0,562" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l,,,562e" fillcolor="#fefefe" strokeweight="0">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,0;0,0;0,478790"
    o:connectangles="0,0,0"/>
  </v:shape><v:shape id="Freeform_x0020_52" o:spid="_x0000_s1084" style='position:absolute;
   left:12706;top:4699;width:0;height:4787;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' coordsize="0,562" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l,,,562e" filled="f" strokeweight=".85pt">
   <v:stroke joinstyle="miter"/>
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,0;0,0;0,478790"
    o:connectangles="0,0,0"/>
  </v:shape><v:shape id="Freeform_x0020_53" o:spid="_x0000_s1085" style='position:absolute;
   left:12706;top:12788;width:0;height:12573;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' coordsize="0,1476" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l,,,1476e" fillcolor="#fefefe" strokeweight="0">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,0;0,0;0,1257300"
    o:connectangles="0,0,0"/>
  </v:shape><v:shape id="Freeform_x0020_54" o:spid="_x0000_s1086" style='position:absolute;
   left:12706;top:12788;width:0;height:12573;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' coordsize="0,1476" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l,,,1476e" filled="f" strokeweight=".85pt">
   <v:stroke joinstyle="miter"/>
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,0;0,0;0,1257300"
    o:connectangles="0,0,0"/>
  </v:shape><v:rect id="Rectangle_x0020_55" o:spid="_x0000_s1087" style='position:absolute;
   left:39560;top:15627;width:12770;height:2654;visibility:visible;
   mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span style='color:black'>Then, 1&nbsp;injection every
      </span><o:p></o:p></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_56" o:spid="_x0000_s1088" style='position:absolute;
   left:40132;top:17125;width:11791;height:2655;visibility:visible;
   mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span style='color:black'>12&nbsp;weeks
      (3&nbsp;months) </span><o:p></o:p></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_57" o:spid="_x0000_s1089" style='position:absolute;
   left:40455;top:18624;width:11297;height:2654;visibility:visible;
   mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span style='color:black'>or as recommended </span><o:p></o:p></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_58" o:spid="_x0000_s1090" style='position:absolute;
   left:41668;top:20123;width:9671;height:2654;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span style='color:black'>by your doctor</span><o:p></o:p></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_59" o:spid="_x0000_s1091" style='position:absolute;
   left:42837;top:13449;width:4654;height:2673;visibility:visible;
   mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><b><span style='font-family:"Times New Roman Bold",serif;
      mso-bidi-font-family:"Times New Roman Bold";color:black'>WEEKS</span></b><o:p></o:p></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_60" o:spid="_x0000_s1092" style='position:absolute;
   left:44278;top:10731;width:2038;height:3537;visibility:visible;
   mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><b><span style='font-size:16.0pt;line-height:107%;
      font-family:"Times New Roman Bold",serif;mso-bidi-font-family:"Times New Roman Bold";
      color:black'>12</span></b><span style='font-size:16.0pt;line-height:107%'><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_61" o:spid="_x0000_s1093" style='position:absolute;
   left:43230;top:4648;width:680;height:2654;visibility:visible;
   mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQBiK7FHvwAAANwAAAAPAAAAZHJzL2Rvd25yZXYueG1sRE/NisIw
EL4v+A5hBG9rqoddqUYRQdDFi9UHGJrpDyaTkkRb394Iwt7m4/ud1WawRjzIh9axgtk0A0FcOt1y
reB62X8vQISIrNE4JgVPCrBZj75WmGvX85keRaxFCuGQo4Imxi6XMpQNWQxT1xEnrnLeYkzQ11J7
7FO4NXKeZT/SYsupocGOdg2Vt+JuFchLse8XhfGZ+5tXJ3M8nCtySk3Gw3YJItIQ/8Uf90Gn+bNf
eD+TLpDrFwAAAP//AwBQSwECLQAUAAYACAAAACEA2+H2y+4AAACFAQAAEwAAAAAAAAAAAAAAAAAA
AAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQBa9CxbvwAAABUBAAALAAAAAAAA
AAAAAAAAAB8BAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQBiK7FHvwAAANwAAAAPAAAAAAAA
AAAAAAAAAAcCAABkcnMvZG93bnJldi54bWxQSwUGAAAAAAMAAwC3AAAA8wIAAAAA
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><o:p>&nbsp;</o:p></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_62" o:spid="_x0000_s1094" style='position:absolute;
   left:40862;top:6280;width:7505;height:2673;visibility:visible;
   mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><b><span style='font-family:"Times New Roman Bold",serif;
      mso-bidi-font-family:"Times New Roman Bold";color:black'>ONCE EVER</span></b><o:p></o:p></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_63" o:spid="_x0000_s1095" style='position:absolute;
   left:48850;top:6280;width:914;height:2673;visibility:visible;
   mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><b><span style='font-family:"Times New Roman Bold",serif;
      mso-bidi-font-family:"Times New Roman Bold";color:black'>Y</span></b><o:p></o:p></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><w:wrap type="topAndBottom"/>
 </v:group><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="699" height="291" src="file:///C:/Users/alshoma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.png" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--><br />After that, you may get one injection every 3&nbsp;months. Your doctor will determine your treatment interval based on the condition of your eye; some patients may need treatment every 2&nbsp;months. The treatment interval between two doses of Beovu should not be less than every 2&nbsp;months.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong><em>DME</em></strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You will be treated with one injection every six weeks for the first five injections.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After that, you may get one injection every 3&nbsp;months. Your doctor will determine your treatment interval based on the condition of your eye. Some patients may need treatment every 2&nbsp;months. Some patients may receive treatment every 4&nbsp;months.</p><p><!--[if gte vml 1]><v:group id="Group_x0020_19"
 o:spid="_x0000_s1026" style='position:absolute;margin-left:41.85pt;
 margin-top:7pt;width:257.4pt;height:195.6pt;z-index:251697152;
 mso-width-relative:margin;mso-height-relative:margin' coordsize="32701,24865"
 o:gfxdata="UEsDBBQABgAIAAAAIQDI4TOSFQEAAFICAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSSTW7DIBCF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">
 <v:shape id="Picture_x0020_46" o:spid="_x0000_s1027" type="#_x0000_t75"
  style='position:absolute;left:3325;top:5213;width:24085;height:4020;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
">
  <v:imagedata src="file:///C:/Users/alshoma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image002.jpg"
   o:title=""/>
 </v:shape><v:group id="Group_x0020_47" o:spid="_x0000_s1028" style='position:absolute;
  width:32701;height:24865' coordsize="32702,24885" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
">
  <v:shapetype id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
   <v:stroke joinstyle="miter"/>
   <v:path gradientshapeok="t" o:connecttype="rect"/>
  </v:shapetype><v:shape id="Text_x0020_Box_x0020_2" o:spid="_x0000_s1029"
   type="#_x0000_t202" style='position:absolute;left:2666;width:10182;height:8135;
   visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" strokecolor="white [3212]">
   <v:textbox style='mso-fit-shape-to-text:t'>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal align=center style='text-align:center;line-height:
      10.0pt;mso-line-height-rule:exactly'><b style='mso-bidi-font-weight:normal'><span
      style='font-size:10.5pt'>First 5&nbsp;doses, once every<o:p></o:p></span></b></p>
      <p class=MsoNormal align=center style='text-align:center;line-height:
      10.0pt;mso-line-height-rule:exactly'><b style='mso-bidi-font-weight:normal'><span
      style='font-size:10.5pt'><o:p>&nbsp;</o:p></span></b></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="Text_x0020_Box_x0020_26" o:spid="_x0000_s1030" type="#_x0000_t202"
   style='position:absolute;left:4656;top:9471;width:6403;height:6559;
   visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokecolor="white [3212]">
   <v:textbox style='mso-fit-shape-to-text:t'>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal align=center style='text-align:center'><b
      style='mso-bidi-font-weight:normal'><span lang=DE-CH style='font-size:
      10.5pt;line-height:107%;mso-ansi-language:DE-CH'>weeks<o:p></o:p></span></b></p>
      <p class=MsoNormal align=center style='text-align:center'><b
      style='mso-bidi-font-weight:normal'><span lang=DE-CH style='font-size:
      10.5pt;line-height:107%;mso-ansi-language:DE-CH'><o:p>&nbsp;</o:p></span></b></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="Text_x0020_Box_x0020_27" o:spid="_x0000_s1031" type="#_x0000_t202"
   style='position:absolute;top:12041;width:14267;height:12844;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" strokecolor="white [3212]">
   <v:textbox style='mso-fit-shape-to-text:t'>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal align=center style='text-align:center'><b
      style='mso-bidi-font-weight:normal'><span style='font-size:10.5pt;
      line-height:107%'>For the first 5&nbsp;doses, 1&nbsp;injection every<o:p></o:p></span></b></p>
      <p class=MsoNormal align=center style='text-align:center'><b
      style='mso-bidi-font-weight:normal'><span style='font-size:10.5pt;
      line-height:107%'>6&nbsp;weeks<o:p></o:p></span></b></p>
      <p class=MsoNormal align=center style='text-align:center'><b
      style='mso-bidi-font-weight:normal'><span style='font-size:10.5pt;
      line-height:107%'><o:p>&nbsp;</o:p></span></b></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="Text_x0020_Box_x0020_2" o:spid="_x0000_s1032" type="#_x0000_t202"
   style='position:absolute;left:16668;top:535;width:9998;height:6863;
   visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokecolor="white [3212]">
   <v:textbox style='mso-fit-shape-to-text:t'>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal align=center style='text-align:center;line-height:
      10.0pt;mso-line-height-rule:exactly'><b style='mso-bidi-font-weight:normal'><span
      lang=DE-CH style='font-size:10.5pt;mso-ansi-language:DE-CH'>After that,
      once every<o:p></o:p></span></b></p>
      <p class=MsoNormal align=center style='text-align:center;line-height:
      10.0pt;mso-line-height-rule:exactly'><b style='mso-bidi-font-weight:normal'><span
      lang=DE-CH style='font-size:10.5pt;mso-ansi-language:DE-CH'><o:p>&nbsp;</o:p></span></b></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="Text_x0020_Box_x0020_39" o:spid="_x0000_s1033" type="#_x0000_t202"
   style='position:absolute;left:18631;top:9471;width:6404;height:6559;
   visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokecolor="white [3212]">
   <v:textbox style='mso-fit-shape-to-text:t'>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal align=center style='text-align:center'><b
      style='mso-bidi-font-weight:normal'><span lang=DE-CH style='font-size:
      10.5pt;line-height:107%;mso-ansi-language:DE-CH'>weeks<o:p></o:p></span></b></p>
      <p class=MsoNormal align=center style='text-align:center'><b
      style='mso-bidi-font-weight:normal'><span lang=DE-CH style='font-size:
      10.5pt;line-height:107%;mso-ansi-language:DE-CH'><o:p>&nbsp;</o:p></span></b></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="Text_x0020_Box_x0020_40" o:spid="_x0000_s1034" type="#_x0000_t202"
   style='position:absolute;left:13588;top:12041;width:19114;height:12844;
   visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokecolor="white [3212]">
   <v:textbox style='mso-fit-shape-to-text:t'>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal align=center style='text-align:center'><b
      style='mso-bidi-font-weight:normal'><span style='font-size:10.5pt;
      line-height:107%'>Then, 1&nbsp;injection every <o:p></o:p></span></b></p>
      <p class=MsoNormal align=center style='text-align:center'><b
      style='mso-bidi-font-weight:normal'><span style='font-size:10.5pt;
      line-height:107%'>12&nbsp;weeks (3&nbsp;months) or as recommended by your
      doctor<o:p></o:p></span></b></p>
      <p class=MsoNormal align=center style='text-align:center'><b
      style='mso-bidi-font-weight:normal'><span style='font-size:10.5pt;
      line-height:107%'><o:p>&nbsp;</o:p></span></b></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape></v:group><w:wrap type="square"/>
</v:group><![endif]--><img width="349" height="267" src="file:///C:/Users/alshoma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image003.png" /></p><p>&nbsp;</p><p><strong>Method of administration</strong></p><p>Beovu is given as an injection into your eye (intravitreal use) by an eye doctor.</p><p>&nbsp;</p><p>Before the injection, your doctor will clean your eye carefully, to prevent infection. Your doctor will also give you an eye drop (local anaesthetic) to numb the eye to reduce or prevent pain from the injection.</p><p>&nbsp;</p><p><strong>How long does Beovu treatment last for</strong></p><p>Beovu is used to treat chronic eye diseases which require long‑term treatment, possibly continuing for months or years. Your doctor will check that the treatment is working during your regular scheduled visits. Your doctor may also check on your eyes between injections. If you have questions about how long you will receive Beovu, talk to your doctor.</p><p>&nbsp;</p><p><strong>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>If you stop using Beovu </strong></p><p>Speak with your doctor before stopping treatment. Stopping treatment may increase your risk of vision loss and your vision may worsen.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. The side effects with Beovu injection are either from the medicine itself or from the injection procedure and they mostly affect the eye.</p><p>&nbsp;</p><p>Some side effects could be serious</p><p>Get immediate medical help if you have any of the following, which are signs of allergic reactions, inflammations or infections:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a sudden decrease or change in vision</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain, increased discomfort, worsening eye redness</p><p>&nbsp;</p><p>If you have any serious side effects,<strong> tell your doctor immediately.</strong></p><p>&nbsp;</p><p><strong>Other possible side effects</strong></p><p>Other side effects which may occur after Beovu treatment include those listed below.</p><p>&nbsp;</p><p>Most of the side effects are mild to moderate and will generally disappear within a week after each injection.</p><p>&nbsp;</p><p>If these side effects become severe, please tell your doctor.</p><p>&nbsp;</p><p><strong>Common: </strong><em>may affect up to 1 in every 10&nbsp;people</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the middle layer of the eye wall (uveitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; detachment of the gel‑like substance inside the eye (vitreous detachment)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tearing of the retina (the part at the back of the eye that detects light) or one of its layers (retinal pigment epithelial tear)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; reduced sharpness of vision (reduced visual acuity)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding in the retina (retinal haemorrhage)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the iris, the coloured part of the eye (iritis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation in the iris and its adjacent tissue in the eye (iridocyclitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden vision loss due to blockage of blood vessels in the back of the eye (retinal vascular occlusion)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding in the eye (vitreous haemorrhage)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; clouding of the lens of the eye (cataract)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding from small blood vessels in the outer layer of the eye (conjunctival haemorrhage)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; moving spots in your vision (vitreous floaters)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; eye pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase in pressure inside the eye (intraocular pressure increase)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; redness in the white of the eye (conjunctivitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blurred or unclear vision</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; scratched cornea, damage to the clear layer of the eyeball that covers the iris (corneal abrasion)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; damage to the clear layer of the eyeball that covers the iris (punctuate keratitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reactions (hypersensitivity)</p><p>&nbsp;</p><p><strong>Uncommon:</strong><em> may affect up to 1 in every 100&nbsp;people</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe inflammation inside the eye (endophthalmitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blindness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden vision loss due to blockage of an artery in the eye (retinal artery occlusion)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; detachment of the retina (retinal detachment)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; redness of the eye (conjunctival hyperaemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased tear production (lacrimation increased)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal feeling in the eye</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; detachment of one of the layers of the retina (detachment of retinal pigment epithelium)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the gel‑like substance inside the eye (vitritis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the front of the eye (anterior chamber inflammation or flare)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of the cornea, the clear layer of the eyeball (corneal oedema)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of blood vessels in the back of the eye (retinal vasculitis)</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Pre-filled syringe</strong></p><p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton and label after EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Store in a refrigerator (2&deg;C&nbsp;‑&nbsp;8&deg;C).</p><p>&nbsp;</p><p>Do not freeze.</p><p>&nbsp;</p><p>Keep the pre‑filled syringe in the sealed blister and in the outer carton in order to protect from light.</p><p>&nbsp;</p><p>Prior to use, the unopened blister with the pre‑filled syringe may be kept at room temperature (below 30&deg;C) for up to 24&nbsp;hours.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Vial</strong></p><p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton and label after EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Store in a refrigerator (2&deg;C&nbsp;‑&nbsp;8&deg;C).</p><p>&nbsp;</p><p>Do not freeze.</p><p>&nbsp;</p><p>Keep the vial in the outer carton in order to protect from light.</p><p>&nbsp;</p><p>Prior to use, the unopened vial may be kept at room temperature (below 30&deg;C) for up to 24&nbsp;hours.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Pre-filled syringe</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is brolucizumab. One ml solution for injection contains 120&nbsp;mg brolucizumab. Each pre‑filled syringe contains 19.8&nbsp;mg brolucizumab in 0.165&nbsp;ml solution. This provides a usable amount to deliver a single dose of 0.05&nbsp;ml solution containing 6&nbsp;mg of brolucizumab.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are: sodium citrate, sucrose, polysorbate 80, water for injections.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Vial</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is brolucizumab. One ml solution for injection contains 120&nbsp;mg brolucizumab.Each vial contains 27.6&nbsp;mg brolucizumab in 0.23&nbsp;ml solution. This provides a usable amount to deliver a single dose of 0.05&nbsp;ml solution containing 6&nbsp;mg of brolucizumab.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are: sodium citrate, sucrose, polysorbate 80, water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                

•	Pre-filled syringe
	
	Beovu 120 mg/ml solution for injection in a pre filled syringe (injection) is a clear to slightly opalescent, colourless to slightly brownish yellow aqueous solution.
	
	Pack size of 1 pre filled syringe for single use only.
	
•	Vial
Beovu 120 mg/ml solution for injection (injection) is a clear to slightly opalescent, colourless to slightly brownish yellow aqueous solution.

Pack size of 1 vial and 1 blunt filter needle (18G x 1½″, 1.2 mm x 40 mm, 5 μm) for single use only.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorization Holder for this Product is Novartis Europharm Limited, Ireland</p><p>www.Novartis.com</p><p>&nbsp;</p><p><strong>Manufacturers</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Pre-filled syringe</strong></p><p>&nbsp;</p><p>S.A. ALCON-COUVREUR N.V.</p><p>Rijksweg 14</p><p>2870 Puurs</p><p>Belgium</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Vial</strong></p><p>Novartis Pharma AG, Stein, Switzerland</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                d.	This leaflet was last approved by EMA on 29-Jun-2023
	
e.	To report any side effect(s):
•	Saudi Arabia

The National Pharmacovigilance Centre (NPC):

o Fax: +966-11-205-7662
o SFDA call center: 19999
o E-mail: npc.drug@sfda.gov.sa
o Website: https://ade.sfda.gov.sa 

Patient Safety Department Novartis Consulting AG - Saudi Arabia:
o Toll Free Number: 8001240078
o Phone: +966112658100 
o Fax: +966112658107
o Email: adverse.events@novartis.com  

•    Other GCC States:
-  Please contact the relevant competent authority.

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ما هو بيوفيو</p><p dir="RTL">يحتوي بيوفيو على المادة الفعالة برولوسيزوماب، والتي تنتمي إلى مجموعة من الأدوية تسمى العوامل المضادة لتكون الأوعية الدموية. يحقن طبيبك بيوفيو في العين لعلاج حالات العين التي قد تؤثر على رؤيتك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_2" o:spid="_x0000_s1026"
 type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
 margin-left:362.75pt;margin-top:42.6pt;width:108.15pt;height:66.9pt;z-index:251671552;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:3.6pt;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:3.6pt;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
 mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" stroked="f">
 <v:textbox inset="0,0,0,0"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>&nbsp;</p><p dir="RTL">الأوعية الدموية غير الطبيعية التي تسرب السوائل أو الدم إلى البقعة</p></td></tr></tbody></table></td></tr></tbody></table><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Content_x0020_Placeholder_x0020_5" o:spid="_x0000_i1025"
 type="#_x0000_t75" style='width:243pt;height:122.25pt;visibility:visible;
 mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/alshoma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.png"
  o:title=""/>
 <o:lock v:ext="edit" grouping="t"/>
</v:shape><![endif]--><img width="324" height="163" src="file:///C:/Users/alshoma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image002.png" /></p><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">دواعي استعمال بيوفيو</p><p dir="RTL">يُستخدم بيوفيو لعلاج حالات العين لدى البالغين والتي تحدث عندما تتكون أوعية دموية غير طبيعية وتنمو تحت البقعة. تُوجد البقعة في الجزء الخلفي من العين وهي مسؤولة عن الرؤية الواضحة. قد تسرب الأوعية الدموية غير الطبيعية السوائل أو الدم إلى العين وتتداخل مع وظيفة البقعة، مما يؤدي إلى الإصابة بأمراض قد تسبب انخفاضًا في الرؤية مثل:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التنكس البقعي الرطب المرتبط بالتقدم في العمر (AMD الرطب)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الوذمة البقعية المرتبطة بداء السكري (DME)</p><p dir="RTL">&nbsp;</p><p dir="RTL">طريقة عمل بيوفيو</p><p dir="RTL">قد يبطئ بيوفيو تطور المرض وبالتالي يحافظ على رؤيتك أو حتى يحسنها.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&zwnj;أ.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>لا تستخدم بيوفيو:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك حساسية تجاه برولوسيزوماب أو أي من المكونات الأخرى لهذا الدواء (المذكورة في القسم&nbsp;6).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من عدوى نشطة أو مشتبه بها في العين أو حولها.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من ألم أو احمرار في العين (التهاب العين).</p><p dir="RTL">إذا عانيت من أي من هذه الأعراض، فأخبر طبيبك. يجب ألا تتلقى بيوفيو.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&zwnj;ب.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>توخّ الحذر الشديد عند تلقي بيوفيو</strong></p><p dir="RTL">تحدّث إلى طبيبك قبل أن تتلقى بيوفيو إذا كنت تعاني من أي مما يلي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من الزرق (حالة تصيب العين عادةً بسبب ارتفاع الضغط في العين).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك تاريخ من رؤية ومضات الضوء أو الأجسام العائمة (بقع عائمة داكنة) وإذا كان لديك زيادة مفاجئة في حجم وعدد الأجسام العائمة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد خضعت لجراحة في العين في الأسابيع الأربعة الماضية أو إذا كان من المخطط إجراء جراحة في العين في الأسابيع الأربعة القادمة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد عانيت من أي أمراض في العين أو تلقيت علاجات للعين.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك تاريخ من فقدان الرؤية المفاجئ بسبب انسداد الأوعية الدموية في الجزء الخلفي من العين (انسداد الأوعية الدموية الشبكية) أو التهاب الأوعية الدموية في الجزء الخلفي من العين (التهاب الأوعية الدموية الشبكية) في العام الماضي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أخبر طبيبك على الفور</strong> إذا وقع ما يلي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإصابة باحمرار العين، ألم العين، زيادة الانزعاج، تفاقم احمرار العين، عدم وضوح الرؤية أو انخفاضها، زيادة عدد الجسيمات الصغيرة في رؤيتك، زيادة الحساسية للضوء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإصابة بفقدان مفاجئ للرؤية، والذي يمكن أن يكون علامة على انسداد الأوعية الدموية في شبكية العين.</p><p dir="RTL">قد تؤدي أي من الأعراض المذكورة أعلاه إلى توقف طبيبك عن علاجك باستخدام بيوفيو.</p><p dir="RTL">&nbsp;</p><p dir="RTL">علاوةً على ذلك، من المهم أن تعرف ما يلي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لم تتم دراسة سلامة بيوفيو وفعاليته عند إعطائه لكلتا العينين في نفس الوقت وقد يؤدي استخدامه بهذه الطريقة إلى زيادة خطر التعرض لآثار جانبية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تسبب حُقن بيوفيو زيادة في ضغط العين (ضغط داخل العين) لدى بعض المرضى في غضون 30 دقيقة من الحقن. سيراقب طبيبك ذلك بعد كل حقنة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيتحقق طبيبك مما إذا كان لديك عوامل خطر أخرى قد تزيد من فرصة حدوث تمزق أو انفصال إحدى الطبقات في الجزء الخلفي من العين (انفصال الشبكية أو تمزقها، وانفصال ظهارة الصباغ الشبكية أو تمزقها)، وفي هذه الحالة يجب إعطاء بيوفيو&nbsp;بحذر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">من المحتمل أن يرتبط الاستخدام الجهازي لمثبطات عامل النمو البطاني الوعائي (VEGF)، وهي مواد مماثلة لتلك الموجودة في بيوفيو، بخطر جلطات الدم التي تسد الأوعية الدموية (أحداث الانصمام الخثاري الشرياني)، والتي قد تؤدي إلى نوبة قلبية أو سكتة دماغية. هناك خطر نظري لمثل هذه الأحداث بعد حقن بيوفيو في العين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا يُستخدم بيوفيو مع الأطفال والمراهقين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&zwnj;ج.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الأدوية الأخرى وبيوفيو</strong></p><p dir="RTL">أخبر طبيبك إذا كنت تستخدم أو استخدمت مؤخرًا أو قد تستخدم أي أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&zwnj;د.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">إذا كنتِ حاملًا أو مرضعة، أو تعتقدين أنكِ قد تكونين حاملًا أو تخططين للإنجاب، فاطلبي المشورة من طبيبكِ قبل تلقيكِ هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا يُوصى بالرضاعة الطبيعية أثناء العلاج باستخدام بيوفيو ولمدة شهر واحد على الأقل بعد إيقاف العلاج باستخدام بيوفيو لأنه من غير المعروف ما إذا كان بيوفيو ينتقل إلى حليب الأم أم لا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب على النساء القادرات على الحمل استخدام وسيلة فعالة لتحديد النسل أثناء العلاج ولمدة شهر واحد على الأقل بعد إيقاف العلاج باستخدام بيوفيو. إذا أصبحتِ حاملًا أو تعتقدين أنكِ حامل أثناء العلاج، فأخبري طبيبكِ على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&zwnj;ه.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>قيادة السيارة واستعمال الآلات</strong></p><p dir="RTL">بعد حقن بيوفيو، قد تعاني من مشكلات مؤقتة في الرؤية (على سبيل المثال، عدم وضوح الرؤية). لا تقم بقيادة السيارة أو تستخدم الآلات كلما كانت هذه المشكلات موجودة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&zwnj;و.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>معلومات مهمة حول بعض مكونات بيوفيو</strong></p><p dir="RTL"><strong>يحتوي بيوفيو على الصوديوم</strong></p><p dir="RTL">يحتوي الدواء على أقل من 1 مليمول من الصوديوم (23&nbsp;ملغ) لكل جرعة، أي أنه في الأصل &quot;خالٍ من الصوديوم&quot;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مقدار الجرعة وعدد مرات إعطاء بيوفيو</strong></p><p dir="RTL">تبلغ الجرعة الموصى بها 6 ملغ من برولوسيزوماب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><em>AMD</em></strong><strong><em> الرطب</em></strong></p><p dir="RTL"><em>بدء العلاج (يُسمى أيضًا العلاج البدئي)</em></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ستتلقى العلاج بحقنة واحدة كل شهر خلال أول 3 أشهر.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بدلًا من ذلك، يمكن أن تتلقى العلاج بحقنة واحدة كل 6 أسابيع لأول جرعتين. سيحدد طبيبك ما إذا كانت هناك حاجة إلى حقنة ثالثة بعد 12 أسبوعًا من بدء العلاج بناءً على حالة عينك (عينيك).</p><p dir="RTL"><em>علاج المداومة</em></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعد ذلك، قد تحصل على حقنة واحدة كل 3 أشهر. سيحدد طبيبك فترة علاجك بناءً على حالة عينك؛ قد يحتاج بعض المرضى إلى تلقي العلاج كل شهرين. يجب ألا يقل الفاصل الزمني للعلاج بين جرعتين من بيوفيو عن كل شهرين.</p><p dir="RTL"><!--[if gte vml 1]><o:wrapblock><v:group id="Canvas_x0020_121" o:spid="_x0000_s1037"
  editas="canvas" style='position:absolute;left:0;text-align:left;
  margin-left:0;margin-top:12.7pt;width:522.15pt;height:217.15pt;z-index:251680768;
  mso-width-relative:margin;mso-height-relative:margin' coordsize="66306,27571"
  o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
  <v:shapetype id="_x0000_t75" coordsize="21600,21600" o:spt="75"
   o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
   <v:stroke joinstyle="miter"/>
   <v:formulas>
    <v:f eqn="if lineDrawn pixelLineWidth 0"/>
    <v:f eqn="sum @0 1 0"/>
    <v:f eqn="sum 0 0 @1"/>
    <v:f eqn="prod @2 1 2"/>
    <v:f eqn="prod @3 21600 pixelWidth"/>
    <v:f eqn="prod @3 21600 pixelHeight"/>
    <v:f eqn="sum @0 0 1"/>
    <v:f eqn="prod @6 1 2"/>
    <v:f eqn="prod @7 21600 pixelWidth"/>
    <v:f eqn="sum @8 21600 0"/>
    <v:f eqn="prod @7 21600 pixelHeight"/>
    <v:f eqn="sum @10 21600 0"/>
   </v:formulas>
   <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
   <o:lock v:ext="edit" aspectratio="t"/>
  </v:shapetype><v:shape id="_x0000_s1038" type="#_x0000_t75" style='position:absolute;
   width:66306;height:27571;visibility:visible;mso-wrap-style:square'>
   <v:fill o:detectmouseclick="t"/>
   <v:path o:connecttype="none"/>
  </v:shape><v:shape id="Freeform_x0020_5" o:spid="_x0000_s1039" style='position:absolute;
   left:13874;top:9010;width:4699;height:4242;flip:x;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' coordsize="553,498" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" path="m502,498r,l51,498c23,498,,476,,448l,50c,23,23,,51,l502,v28,,51,23,51,50l553,448v,28,-23,50,-51,50xe"
   fillcolor="black" strokeweight="0">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="426564,424180;426564,424180;43336,424180;0,381592;0,42588;43336,0;426564,0;469900,42588;469900,381592;426564,424180"
    o:connectangles="0,0,0,0,0,0,0,0,0,0"/>
  </v:shape><v:shape id="Freeform_x0020_6" o:spid="_x0000_s1040" style='position:absolute;
   left:14198;top:10261;width:4051;height:2667;flip:x;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' coordsize="477,313" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m447,313r,l30,313c13,313,,300,,283l,,477,r,283c477,300,464,313,447,313xe"
   fillcolor="#fefefe" strokeweight="0">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="379650,266700;379650,266700;25480,266700;0,241138;0,0;405130,0;405130,241138;379650,266700"
    o:connectangles="0,0,0,0,0,0,0,0"/>
  </v:shape><v:shape id="Freeform_x0020_7" o:spid="_x0000_s1041" style='position:absolute;
   left:16916;top:8299;width:711;height:1295;flip:x;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' coordsize="84,152" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m42,152r,c19,152,,133,,109l,42c,19,19,,42,,65,,84,19,84,42r,67c84,133,65,152,42,152xe"
   fillcolor="black" strokeweight="0">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="35560,129540;35560,129540;0,92894;0,35794;35560,0;71120,35794;71120,92894;35560,129540"
    o:connectangles="0,0,0,0,0,0,0,0"/>
  </v:shape><v:shape id="Freeform_x0020_8" o:spid="_x0000_s1042" style='position:absolute;
   left:16833;top:8223;width:883;height:1448;flip:x;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' coordsize="104,170" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m52,r,c23,,,23,,51r,67c,147,23,170,52,170v28,,52,-23,52,-52l104,51c104,23,80,,52,xm52,19r,c70,19,84,33,84,51r,67c84,136,70,151,52,151,34,151,19,136,19,118r,-67c19,33,34,19,52,19xe"
   fillcolor="#fefefe" strokeweight="0">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="44133,0;44133,0;0,43434;0,100494;44133,144780;88265,100494;88265,43434;44133,0;44133,16181;44133,16181;71291,43434;71291,100494;44133,128599;16125,100494;16125,43434;44133,16181"
    o:connectangles="0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0"/>
   <o:lock v:ext="edit" verticies="t"/>
  </v:shape><v:shape id="Freeform_x0020_9" o:spid="_x0000_s1043" style='position:absolute;
   left:14732;top:8299;width:717;height:1295;flip:x;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' coordsize="84,152" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m42,152r,c18,152,,133,,109l,42c,19,18,,42,,65,,84,19,84,42r,67c84,133,65,152,42,152xe"
   fillcolor="black" strokeweight="0">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="35878,129540;35878,129540;0,92894;0,35794;35878,0;71755,35794;71755,92894;35878,129540"
    o:connectangles="0,0,0,0,0,0,0,0"/>
  </v:shape><v:shape id="Freeform_x0020_10" o:spid="_x0000_s1044" style='position:absolute;
   left:14655;top:8223;width:877;height:1448;flip:x;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' coordsize="103,170" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m52,r,c23,,,23,,51r,67c,147,23,170,52,170v28,,51,-23,51,-52l103,51c103,23,80,,52,xm52,19r,c70,19,84,33,84,51r,67c84,136,70,151,52,151,34,151,19,136,19,118r,-67c19,33,34,19,52,19xe"
   fillcolor="#fefefe" strokeweight="0">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="44240,0;44240,0;0,43434;0,100494;44240,144780;87630,100494;87630,43434;44240,0;44240,16181;44240,16181;71465,43434;71465,100494;44240,128599;16165,100494;16165,43434;44240,16181"
    o:connectangles="0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0"/>
   <o:lock v:ext="edit" verticies="t"/>
  </v:shape><v:shape id="Freeform_x0020_11" o:spid="_x0000_s1045" style='position:absolute;
   left:38925;top:9010;width:4686;height:4242;flip:x;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' coordsize="552,498" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m502,498r,l50,498c22,498,,476,,448l,50c,23,22,,50,l502,v27,,50,23,50,50l552,448v,28,-23,50,-50,50xe"
   fillcolor="black" strokeweight="0">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="426182,424180;426182,424180;42448,424180;0,381592;0,42588;42448,0;426182,0;468630,42588;468630,381592;426182,424180"
    o:connectangles="0,0,0,0,0,0,0,0,0,0"/>
  </v:shape><v:shape id="Freeform_x0020_12" o:spid="_x0000_s1046" style='position:absolute;
   left:39243;top:10261;width:4051;height:2667;flip:x;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' coordsize="477,313" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m447,313r,l30,313c14,313,,300,,283l,,477,r,283c477,300,464,313,447,313xe"
   fillcolor="#fefefe" strokeweight="0">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="379650,266700;379650,266700;25480,266700;0,241138;0,0;405130,0;405130,241138;379650,266700"
    o:connectangles="0,0,0,0,0,0,0,0"/>
  </v:shape><v:shape id="Freeform_x0020_13" o:spid="_x0000_s1047" style='position:absolute;
   left:41960;top:8299;width:718;height:1295;flip:x;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' coordsize="84,152" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQD0o0G9wgAAANsAAAAPAAAAZHJzL2Rvd25yZXYueG1sRE/LagIx
FN0L/YdwC+5qpiJip0ZRwRe2hdp2f5ncTsZOboYk6ujXm0XB5eG8x9PW1uJEPlSOFTz3MhDEhdMV
lwq+v5ZPIxAhImusHZOCCwWYTh46Y8y1O/MnnfaxFCmEQ44KTIxNLmUoDFkMPdcQJ+7XeYsxQV9K
7fGcwm0t+1k2lBYrTg0GG1oYKv72R6ugevPXQ7Oavazff3aXTTYw24/DXKnuYzt7BRGpjXfxv3uj
FQzT2PQl/QA5uQEAAP//AwBQSwECLQAUAAYACAAAACEA2+H2y+4AAACFAQAAEwAAAAAAAAAAAAAA
AAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQBa9CxbvwAAABUBAAALAAAA
AAAAAAAAAAAAAB8BAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQD0o0G9wgAAANsAAAAPAAAA
AAAAAAAAAAAAAAcCAABkcnMvZG93bnJldi54bWxQSwUGAAAAAAMAAwC3AAAA9gIAAAAA
" path="m42,152r,c19,152,,133,,109l,42c,19,19,,42,,65,,84,19,84,42r,67c84,133,65,152,42,152xe"
   fillcolor="black" strokeweight="0">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="35878,129540;35878,129540;0,92894;0,35794;35878,0;71755,35794;71755,92894;35878,129540"
    o:connectangles="0,0,0,0,0,0,0,0"/>
  </v:shape><v:shape id="Freeform_x0020_14" o:spid="_x0000_s1048" style='position:absolute;
   left:41878;top:8223;width:882;height:1448;flip:x;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' coordsize="104,170" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m52,r,c24,,,23,,51r,67c,147,24,170,52,170v29,,52,-23,52,-52l104,51c104,23,81,,52,xm52,19r,c70,19,85,33,85,51r,67c85,136,70,151,52,151,34,151,20,136,20,118r,-67c20,33,34,19,52,19xe"
   fillcolor="#fefefe" strokeweight="0">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="44133,0;44133,0;0,43434;0,100494;44133,144780;88265,100494;88265,43434;44133,0;44133,16181;44133,16181;72140,43434;72140,100494;44133,128599;16974,100494;16974,43434;44133,16181"
    o:connectangles="0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0"/>
   <o:lock v:ext="edit" verticies="t"/>
  </v:shape><v:shape id="Freeform_x0020_15" o:spid="_x0000_s1049" style='position:absolute;
   left:39782;top:8299;width:711;height:1295;flip:x;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' coordsize="84,152" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQCPDNtmwwAAANsAAAAPAAAAZHJzL2Rvd25yZXYueG1sRE/LSsQw
FN0L/kO4wuycVBl81KalCjojPsCq+0tzbVqbm5LEmc58vVkILg/nXVSzHcWWfOgdKzhbZiCIW6d7
7hR8vN+fXoEIEVnj6JgU7ClAVR4fFZhrt+M32jaxEymEQ44KTIxTLmVoDVkMSzcRJ+7LeYsxQd9J
7XGXwu0oz7PsQlrsOTUYnOjOUPvd/FgF/bM/DNNDfb1++Xzab7KVeXwdbpVanMz1DYhIc/wX/7k3
WsFlWp++pB8gy18AAAD//wMAUEsBAi0AFAAGAAgAAAAhANvh9svuAAAAhQEAABMAAAAAAAAAAAAA
AAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEAWvQsW78AAAAVAQAACwAA
AAAAAAAAAAAAAAAfAQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEAjwzbZsMAAADbAAAADwAA
AAAAAAAAAAAAAAAHAgAAZHJzL2Rvd25yZXYueG1sUEsFBgAAAAADAAMAtwAAAPcCAAAAAA==
" path="m42,152r,c19,152,,133,,109l,42c,19,19,,42,,65,,84,19,84,42r,67c84,133,65,152,42,152xe"
   fillcolor="black" strokeweight="0">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="35560,129540;35560,129540;0,92894;0,35794;35560,0;71120,35794;71120,92894;35560,129540"
    o:connectangles="0,0,0,0,0,0,0,0"/>
  </v:shape><v:shape id="Freeform_x0020_16" o:spid="_x0000_s1050" style='position:absolute;
   left:39693;top:8223;width:883;height:1448;flip:x;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' coordsize="104,170" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m52,r,c23,,,23,,51r,67c,147,23,170,52,170v28,,52,-23,52,-52l104,51c104,23,80,,52,xm52,19r,c70,19,85,33,85,51r,67c85,136,70,151,52,151,34,151,19,136,19,118r,-67c19,33,34,19,52,19xe"
   fillcolor="#fefefe" strokeweight="0">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="44133,0;44133,0;0,43434;0,100494;44133,144780;88265,100494;88265,43434;44133,0;44133,16181;44133,16181;72140,43434;72140,100494;44133,128599;16125,100494;16125,43434;44133,16181"
    o:connectangles="0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0"/>
   <o:lock v:ext="edit" verticies="t"/>
  </v:shape><v:shape id="Freeform_x0020_17" o:spid="_x0000_s1051" style='position:absolute;
   left:54082;top:9010;width:4687;height:4242;flip:x;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' coordsize="552,498" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m502,498r,l50,498c22,498,,476,,448l,50c,23,22,,50,l502,v28,,50,23,50,50l552,448v,28,-22,50,-50,50xe"
   fillcolor="black" strokeweight="0">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="426182,424180;426182,424180;42448,424180;0,381592;0,42588;42448,0;426182,0;468630,42588;468630,381592;426182,424180"
    o:connectangles="0,0,0,0,0,0,0,0,0,0"/>
  </v:shape><v:shape id="Freeform_x0020_18" o:spid="_x0000_s1052" style='position:absolute;
   left:54406;top:10261;width:4052;height:2667;flip:x;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' coordsize="477,313" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m447,313r,l30,313c14,313,,300,,283l,,477,r,283c477,300,464,313,447,313xe"
   fillcolor="#fefefe" strokeweight="0">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="379650,266700;379650,266700;25480,266700;0,241138;0,0;405130,0;405130,241138;379650,266700"
    o:connectangles="0,0,0,0,0,0,0,0"/>
  </v:shape><v:shape id="Freeform_x0020_19" o:spid="_x0000_s1053" style='position:absolute;
   left:57124;top:8299;width:711;height:1295;flip:x;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' coordsize="84,152" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m42,152r,c19,152,,133,,109l,42c,19,19,,42,,65,,84,19,84,42r,67c84,133,65,152,42,152xe"
   fillcolor="black" strokeweight="0">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="35560,129540;35560,129540;0,92894;0,35794;35560,0;71120,35794;71120,92894;35560,129540"
    o:connectangles="0,0,0,0,0,0,0,0"/>
  </v:shape><v:shape id="Freeform_x0020_20" o:spid="_x0000_s1054" style='position:absolute;
   left:57042;top:8223;width:870;height:1448;flip:x;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' coordsize="103,170" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQDCx5TZxAAAANsAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9Ba8JA
FITvBf/D8gRvdaMHjdFVYoulFw9NFDw+ss8kmH2bZrcm/fddoeBxmJlvmM1uMI24U+dqywpm0wgE
cWF1zaWCU354jUE4j6yxsUwKfsnBbjt62WCibc9fdM98KQKEXYIKKu/bREpXVGTQTW1LHLyr7Qz6
ILtS6g77ADeNnEfRQhqsOSxU2NJbRcUt+zEKsJ+n8vv8vtSX1XGfZ/EtjT8ipSbjIV2D8DT4Z/i/
/akVLBfw+BJ+gNz+AQAA//8DAFBLAQItABQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAAAAAAAAA
AAAAAAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsA
AAAAAAAAAAAAAAAAHwEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhAMLHlNnEAAAA2wAAAA8A
AAAAAAAAAAAAAAAABwIAAGRycy9kb3ducmV2LnhtbFBLBQYAAAAAAwADALcAAAD4AgAAAAA=
" path="m51,r,c23,,,23,,51r,67c,147,23,170,51,170v29,,52,-23,52,-52l103,51c103,23,80,,51,xm51,19r,c69,19,84,33,84,51r,67c84,136,69,151,51,151,33,151,19,136,19,118r,-67c19,33,33,19,51,19xe"
   fillcolor="#fefefe" strokeweight="0">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="43075,0;43075,0;0,43434;0,100494;43075,144780;86995,100494;86995,43434;43075,0;43075,16181;43075,16181;70947,43434;70947,100494;43075,128599;16048,100494;16048,43434;43075,16181"
    o:connectangles="0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0"/>
   <o:lock v:ext="edit" verticies="t"/>
  </v:shape><v:shape id="Freeform_x0020_21" o:spid="_x0000_s1055" style='position:absolute;
   left:54940;top:8299;width:717;height:1295;flip:x;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' coordsize="84,152" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m42,152r,c19,152,,133,,109l,42c,19,19,,42,,65,,84,19,84,42r,67c84,133,65,152,42,152xe"
   fillcolor="black" strokeweight="0">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="35878,129540;35878,129540;0,92894;0,35794;35878,0;71755,35794;71755,92894;35878,129540"
    o:connectangles="0,0,0,0,0,0,0,0"/>
  </v:shape><v:shape id="Freeform_x0020_22" o:spid="_x0000_s1056" style='position:absolute;
   left:54857;top:8223;width:883;height:1448;flip:x;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' coordsize="104,170" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m52,r,c24,,,23,,51r,67c,147,24,170,52,170v29,,52,-23,52,-52l104,51c104,23,81,,52,xm52,19r,c70,19,85,33,85,51r,67c85,136,70,151,52,151,34,151,20,136,20,118r,-67c20,33,34,19,52,19xe"
   fillcolor="#fefefe" strokeweight="0">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="44133,0;44133,0;0,43434;0,100494;44133,144780;88265,100494;88265,43434;44133,0;44133,16181;44133,16181;72140,43434;72140,100494;44133,128599;16974,100494;16974,43434;44133,16181"
    o:connectangles="0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0"/>
   <o:lock v:ext="edit" verticies="t"/>
  </v:shape><v:rect id="Rectangle_x0020_23" o:spid="_x0000_s1057" style='position:absolute;
   left:52937;top:15705;width:7011;height:4953;flip:x;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQBoVPmNwwAAANsAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI/NbsIw
EITvlXgHa5F6Kw5VRdsUgxAVP4dcGniAVbxNosbrYC8Q3r6uhNTjaGa+0cyXg+vUhUJsPRuYTjJQ
xJW3LdcGjofN0xuoKMgWO89k4EYRlovRwxxz66/8RZdSapUgHHM00Ij0udaxashhnPieOHnfPjiU
JEOtbcBrgrtOP2fZTDtsOS002NO6oeqnPDsDeCq3hxClFpx9FsVLsdPHfmfM43hYfYASGuQ/fG/v
rYHXd/j7kn6AXvwCAAD//wMAUEsBAi0AFAAGAAgAAAAhANvh9svuAAAAhQEAABMAAAAAAAAAAAAA
AAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEAWvQsW78AAAAVAQAACwAA
AAAAAAAAAAAAAAAfAQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEAaFT5jcMAAADbAAAADwAA
AAAAAAAAAAAAAAAHAgAAZHJzL2Rvd25yZXYueG1sUEsFBgAAAAADAAMAtwAAAPcCAAAAAA==
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal align=center dir=RTL style='text-align:center;
      direction:rtl;unicode-bidi:embed'><span lang=AR-SA style='font-size:10.0pt;
      font-family:"Arial",sans-serif;mso-fareast-font-family:Arial;color:black;
      mso-ansi-language:EN-US'>لأول 3 جرعات،</span><span lang=AR-SA
      style='font-size:10.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
      Arial;color:black;mso-ansi-language:EN-US;mso-bidi-language:HE'> </span><span
      lang=AR-SA style='font-size:10.0pt;font-family:"Arial",sans-serif;
      mso-fareast-font-family:Arial;color:black;mso-ansi-language:EN-US'>حقنة
      واحدة كل ٤ أسابيع</span><span lang=EN-GB dir=LTR><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:shape id="Freeform_x0020_26" o:spid="_x0000_s1058" style='position:absolute;
   left:23774;top:10414;width:8788;height:1289;flip:x;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' coordsize="1744,190" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQCfcviyxAAAANsAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9Ba8JA
FITvBf/D8gRvdaOHINFVtGAJepBGvb9mX5Ol2bchuzVpf71bEDwOM/MNs9oMthE36rxxrGA2TUAQ
l04brhRczvvXBQgfkDU2jknBL3nYrEcvK8y06/mDbkWoRISwz1BBHUKbSenLmiz6qWuJo/flOosh
yq6SusM+wm0j50mSSouG40KNLb3VVH4XP1bBZ2rMX75Ni7x/312Pu2t6PFUHpSbjYbsEEWgIz/Cj
nWsFizn8f4k/QK7vAAAA//8DAFBLAQItABQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAAAAAAAAA
AAAAAAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsA
AAAAAAAAAAAAAAAAHwEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhAJ9y+LLEAAAA2wAAAA8A
AAAAAAAAAAAAAAAABwIAAGRycy9kb3ducmV2LnhtbFBLBQYAAAAAAwADALcAAAD4AgAAAAA=
" path="m1739,84r,l1636,7c1624,,1618,4,1616,17r,54l18,71c8,71,,80,,91v,10,8,19,18,19l1616,110r,59c1617,187,1624,190,1636,183l1739,97v5,-4,5,-8,,-13xe"
   fillcolor="#111112" strokeweight="0">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="876320,56990;876320,56990;824416,4749;814338,11534;814338,48170;9071,48170;0,61739;9071,74629;814338,74629;814338,114658;824416,124156;876320,65809;876320,56990"
    o:connectangles="0,0,0,0,0,0,0,0,0,0,0,0,0"/>
  </v:shape><v:rect id="Rectangle_x0020_27" o:spid="_x0000_s1059" style='position:absolute;
   left:55021;top:13449;width:2895;height:1651;flip:x;visibility:visible;
   mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal dir=RTL style='text-align:right;direction:rtl;
      unicode-bidi:embed'><b><span lang=AR-SA style='mso-bidi-font-size:11.0pt;
      font-family:"Arial",sans-serif;mso-fareast-font-family:Arial;color:black;
      mso-ansi-language:EN-US'>أسابيع</span></b><span lang=EN-GB dir=LTR><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_28" o:spid="_x0000_s1060" style='position:absolute;
   left:55913;top:10261;width:1207;height:2483;flip:x;visibility:visible;
   mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal dir=RTL style='text-align:right;line-height:normal;
      direction:rtl;unicode-bidi:embed'><b><span dir=LTR style='font-size:17.0pt;
      font-family:"Arial",sans-serif;mso-fareast-font-family:Arial;color:black;
      mso-ansi-language:EN-US'>4</span></b><span lang=EN-GB dir=LTR><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_30" o:spid="_x0000_s1061" style='position:absolute;
   left:51582;top:4707;width:9760;height:3302;flip:x;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal align=center dir=RTL style='text-align:center;
      direction:rtl;unicode-bidi:embed'><span dir=RTL></span><b><span
      lang=AR-SA style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;
      mso-fareast-font-family:Arial;color:black;mso-ansi-language:EN-US'><span
      dir=RTL></span>3 جرعات، مرة واحدة</span></b><span lang=AR-SA
      style='font-size:10.0pt;mso-ansi-font-size:11.0pt;mso-bidi-language:HE'> </span><b><span
      lang=AR-SA style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;
      mso-fareast-font-family:Arial;color:black;mso-ansi-language:EN-US'>كل</span></b><span
      lang=AR-SA style='font-size:10.0pt;mso-ansi-font-size:11.0pt'><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_33" o:spid="_x0000_s1062" style='position:absolute;
   left:35885;width:24030;height:3302;flip:x;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal align=center dir=RTL style='text-align:center;
      direction:rtl;unicode-bidi:embed'><b><span lang=AR-SA style='mso-bidi-font-size:
      11.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:Arial;
      color:black;background:yellow;mso-highlight:yellow;mso-ansi-language:
      EN-US'>بدء للعلاج</span></b><b><span lang=AR-SA style='font-size:10.0pt;
      mso-ansi-font-size:11.0pt;font-family:"Times New Roman Bold",serif;
      mso-bidi-font-family:"Times New Roman Bold";color:black;background:yellow;
      mso-highlight:yellow;mso-ansi-language:EN-US'><o:p></o:p></span></b></p>
      <p class=MsoNormal align=center dir=RTL style='text-align:center;
      direction:rtl;unicode-bidi:embed'><b><span lang=AR-SA style='mso-bidi-font-size:
      11.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:Arial;
      color:black;background:yellow;mso-highlight:yellow;mso-ansi-language:
      EN-US'>(يُسمى أيضًا العلاج البدئي</span></b><b><span lang=AR-SA
      style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;
      mso-fareast-font-family:Arial;color:black;mso-ansi-language:EN-US'>)</span></b><span
      lang=AR-SA style='font-size:10.0pt;mso-ansi-font-size:11.0pt'><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_34" o:spid="_x0000_s1063" style='position:absolute;
   left:48723;top:1498;width:635;height:1651;flip:x;visibility:visible;
   mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span lang=EN-GB><o:p>&nbsp;</o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_35" o:spid="_x0000_s1064" style='position:absolute;
   top:50;width:23012;height:1651;flip:x;visibility:visible;mso-wrap-style:square;
   v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQAmLhNxwwAAANsAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9Ba8JA
FITvgv9heYXedGMpotFVSktrD7mY+AMe2dckNPs27r5q/PduodDjMDPfMNv96Hp1oRA7zwYW8wwU
ce1tx42BU/U+W4GKgmyx90wGbhRhv5tOtphbf+UjXUppVIJwzNFAKzLkWse6JYdx7gfi5H354FCS
DI22Aa8J7nr9lGVL7bDjtNDiQK8t1d/ljzOA5/KjClEaweVbUTwXB30aDsY8PowvG1BCo/yH/9qf
1sB6Ab9f0g/QuzsAAAD//wMAUEsBAi0AFAAGAAgAAAAhANvh9svuAAAAhQEAABMAAAAAAAAAAAAA
AAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEAWvQsW78AAAAVAQAACwAA
AAAAAAAAAAAAAAAfAQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEAJi4TccMAAADbAAAADwAA
AAAAAAAAAAAAAAAHAgAAZHJzL2Rvd25yZXYueG1sUEsFBgAAAAADAAMAtwAAAPcCAAAAAA==
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal dir=RTL style='text-align:right;direction:rtl;
      unicode-bidi:embed'><b><span lang=AR-SA style='mso-bidi-font-size:11.0pt;
      font-family:"Arial",sans-serif;mso-fareast-font-family:Arial;color:black;
      mso-ansi-language:EN-US'>علاج المداومة</span></b><b><span dir=LTR
      style='font-family:"Times New Roman Bold",serif;mso-bidi-font-family:
      "Times New Roman Bold";color:black;mso-ansi-language:EN-US'><o:p></o:p></span></b></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_40" o:spid="_x0000_s1065" style='position:absolute;
   left:36922;top:18894;width:9531;height:6604;flip:x;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal align=center dir=RTL style='text-align:center;
      direction:rtl;unicode-bidi:embed'><span lang=AR-SA style='font-size:8.0pt;
      font-family:"Arial",sans-serif;mso-fareast-font-family:Arial;color:black;
      mso-ansi-language:EN-US'>طبيبك سيُحدد</span><span lang=AR-SA
      style='font-size:8.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
      Arial;color:black;mso-ansi-language:EN-US;mso-bidi-language:HE'> </span><span
      lang=AR-SA style='font-size:8.0pt;font-family:"Arial",sans-serif;
      mso-fareast-font-family:Arial;color:black;mso-ansi-language:EN-US'>إذا
      كانت هناك حاجة إلى حقنة ثالثة بعد ١٢ أسبوعًا من بدء العلاج بناءً على حالة
      عينك</span><span lang=EN-GB dir=LTR><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_44" o:spid="_x0000_s1066" style='position:absolute;
   left:40235;top:13449;width:2896;height:1651;flip:x;visibility:visible;
   mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal dir=RTL style='text-align:right;direction:rtl;
      unicode-bidi:embed'><b><span lang=AR-SA style='mso-bidi-font-size:11.0pt;
      font-family:"Arial",sans-serif;mso-fareast-font-family:Arial;color:black;
      mso-ansi-language:EN-US'>أسابيع</span></b><span lang=EN-GB dir=LTR><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_45" o:spid="_x0000_s1067" style='position:absolute;
   left:40674;top:10261;width:1264;height:2483;flip:x;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal dir=RTL style='text-align:right;line-height:normal;
      direction:rtl;unicode-bidi:embed'><b><span dir=LTR style='font-size:17.0pt;
      font-family:"Arial",sans-serif;mso-fareast-font-family:Arial;color:black;
      mso-ansi-language:EN-US'>6</span></b><span lang=EN-GB dir=LTR><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_47" o:spid="_x0000_s1068" style='position:absolute;
   left:37557;top:4746;width:7378;height:3302;flip:x;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal align=center dir=RTL style='text-align:center;
      direction:rtl;unicode-bidi:embed'><b><span lang=AR-SA style='mso-bidi-font-size:
      11.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:Arial;
      color:black;mso-ansi-language:EN-US'>جرعتان،</span></b><b><span
      lang=AR-SA style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;
      mso-fareast-font-family:Arial;color:black;mso-ansi-language:EN-US;
      mso-bidi-language:HE'> </span></b><b><span lang=AR-SA style='mso-bidi-font-size:
      11.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:Arial;
      color:black;mso-ansi-language:EN-US'>مرة واحدة</span></b><span
      lang=AR-SA style='font-size:10.0pt;mso-ansi-font-size:11.0pt;mso-bidi-language:
      HE'> </span><b><span lang=AR-SA style='mso-bidi-font-size:11.0pt;
      font-family:"Arial",sans-serif;mso-fareast-font-family:Arial;color:black;
      mso-ansi-language:EN-US'>كل</span></b><span lang=AR-SA style='font-size:
      10.0pt;mso-ansi-font-size:11.0pt'><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_50" o:spid="_x0000_s1069" style='position:absolute;
   left:49282;top:10052;width:1276;height:1651;flip:x;visibility:visible;
   mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal dir=RTL style='text-align:right;direction:rtl;
      unicode-bidi:embed'><b><span lang=AR-SA style='font-size:15.0pt;
      font-family:"Arial",sans-serif;mso-fareast-font-family:Arial;color:black;
      mso-ansi-language:EN-US'>أو</span></b><span lang=EN-GB dir=LTR><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:shape id="Freeform_x0020_51" o:spid="_x0000_s1070" style='position:absolute;
   left:48952;top:4699;width:0;height:4787;flip:x;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' coordsize="0,562" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l,,,562e" fillcolor="#fefefe" strokeweight="0">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,0;0,0;0,478790"
    o:connectangles="0,0,0"/>
  </v:shape><v:shape id="Freeform_x0020_52" o:spid="_x0000_s1071" style='position:absolute;
   left:48952;top:4699;width:0;height:4787;flip:x;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' coordsize="0,562" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQBdcK5EwwAAANwAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9Bi8JA
DIXvC/6HIYK3daqiSHUUEVdEvLQu7DV0YlvsZEpnVuu/N4eFvSW8l/e+rLe9a9SDulB7NjAZJ6CI
C29rLg18X78+l6BCRLbYeCYDLwqw3Qw+1pha/+SMHnkslYRwSNFAFWObah2KihyGsW+JRbv5zmGU
tSu17fAp4a7R0yRZaIc1S0OFLe0rKu75rzNwPs0OfT5btlf7k9lDnrnd/HI0ZjTsdytQkfr4b/67
PlnBT4RWnpEJ9OYNAAD//wMAUEsBAi0AFAAGAAgAAAAhANvh9svuAAAAhQEAABMAAAAAAAAAAAAA
AAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEAWvQsW78AAAAVAQAACwAA
AAAAAAAAAAAAAAAfAQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEAXXCuRMMAAADcAAAADwAA
AAAAAAAAAAAAAAAHAgAAZHJzL2Rvd25yZXYueG1sUEsFBgAAAAADAAMAtwAAAPcCAAAAAA==
" path="m,l,,,562e" filled="f" strokeweight=".85pt">
   <v:stroke joinstyle="miter"/>
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,0;0,0;0,478790"
    o:connectangles="0,0,0"/>
  </v:shape><v:shape id="Freeform_x0020_53" o:spid="_x0000_s1072" style='position:absolute;
   left:48952;top:12788;width:0;height:12573;flip:x;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' coordsize="0,1476" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" path="m,l,,,1476e" fillcolor="#fefefe" strokeweight="0">
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,0;0,0;0,1257300"
    o:connectangles="0,0,0"/>
  </v:shape><v:shape id="Freeform_x0020_54" o:spid="_x0000_s1073" style='position:absolute;
   left:48952;top:12788;width:0;height:12573;flip:x;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' coordsize="0,1476" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,l,,,1476e" filled="f" strokeweight=".85pt">
   <v:stroke joinstyle="miter"/>
   <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,0;0,0;0,1257300"
    o:connectangles="0,0,0"/>
  </v:shape><v:rect id="Rectangle_x0020_55" o:spid="_x0000_s1074" style='position:absolute;
   left:11062;top:15607;width:10370;height:6604;flip:x;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal align=center dir=RTL style='text-align:center;
      direction:rtl;unicode-bidi:embed'><span lang=AR-SA style='font-size:10.0pt;
      font-family:"Arial",sans-serif;mso-fareast-font-family:Arial;color:black;
      mso-ansi-language:EN-US'>ثم حقنة واحدة كل </span><span dir=LTR></span><span
      dir=LTR style='font-size:10.0pt;font-family:"Arial",sans-serif;
      mso-fareast-font-family:Arial;color:black;mso-ansi-language:EN-US'><span
      dir=LTR></span>12</span><span dir=RTL></span><span lang=AR-SA
      style='font-size:10.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
      Arial;color:black;mso-ansi-language:EN-US'><span dir=RTL></span> أسبوعًا
      (3 أشهر)</span><span lang=AR-SA style='font-size:10.0pt;mso-ansi-font-size:
      11.0pt;mso-bidi-language:HE'> </span><span lang=AR-SA style='font-size:
      10.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:Arial;
      color:black;mso-ansi-language:EN-US'>أو على النحو الموصى به من قِبل طبيبك</span><span
      lang=EN-GB dir=LTR><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_59" o:spid="_x0000_s1075" style='position:absolute;
   left:14891;top:13438;width:3251;height:1651;flip:x;visibility:visible;
   mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQBxQiaKwgAAANwAAAAPAAAAZHJzL2Rvd25yZXYueG1sRE9Li8Iw
EL4L+x/CLHizqS6KVKMsC8riQfABsrfZZmxrm0lpoq3/3giCt/n4njNfdqYSN2pcYVnBMIpBEKdW
F5wpOB5WgykI55E1VpZJwZ0cLBcfvTkm2ra8o9veZyKEsEtQQe59nUjp0pwMusjWxIE728agD7DJ
pG6wDeGmkqM4nkiDBYeGHGv6ySkt91ejoHPm0pbb09dq87/mzYjK858plep/dt8zEJ46/xa/3L86
zB+O4flMuEAuHgAAAP//AwBQSwECLQAUAAYACAAAACEA2+H2y+4AAACFAQAAEwAAAAAAAAAAAAAA
AAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQBa9CxbvwAAABUBAAALAAAA
AAAAAAAAAAAAAB8BAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQBxQiaKwgAAANwAAAAPAAAA
AAAAAAAAAAAAAAcCAABkcnMvZG93bnJldi54bWxQSwUGAAAAAAMAAwC3AAAA9gIAAAAA
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal dir=RTL style='text-align:right;direction:rtl;
      unicode-bidi:embed'><b><span lang=AR-SA style='mso-bidi-font-size:11.0pt;
      font-family:"Arial",sans-serif;mso-fareast-font-family:Arial;color:black;
      mso-ansi-language:EN-US'>أسبوعًا</span></b><span lang=EN-GB dir=LTR><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_60" o:spid="_x0000_s1076" style='position:absolute;
   left:15118;top:10379;width:2260;height:2337;flip:x;visibility:visible;
   mso-wrap-style:none;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQCBkLj9wwAAANwAAAAPAAAAZHJzL2Rvd25yZXYueG1sRE9Na4NA
EL0X+h+WKfTWrKYgxWYjpZAQPBRqA6G3iTtRozsr7lbNv88WArnN433OKptNJ0YaXGNZQbyIQBCX
VjdcKdj/bF7eQDiPrLGzTAou5CBbPz6sMNV24m8aC1+JEMIuRQW1930qpStrMugWticO3MkOBn2A
QyX1gFMIN51cRlEiDTYcGmrs6bOmsi3+jILZmfPUfh1eN/lxy/mS2tOvaZV6fpo/3kF4mv1dfHPv
dJgfJ/D/TLhArq8AAAD//wMAUEsBAi0AFAAGAAgAAAAhANvh9svuAAAAhQEAABMAAAAAAAAAAAAA
AAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEAWvQsW78AAAAVAQAACwAA
AAAAAAAAAAAAAAAfAQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEAgZC4/cMAAADcAAAADwAA
AAAAAAAAAAAAAAAHAgAAZHJzL2Rvd25yZXYueG1sUEsFBgAAAAADAAMAtwAAAPcCAAAAAA==
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal dir=RTL style='text-align:right;line-height:normal;
      direction:rtl;unicode-bidi:embed'><b><span dir=LTR style='font-size:16.0pt;
      font-family:"Arial",sans-serif;mso-fareast-font-family:Arial;color:black;
      mso-ansi-language:EN-US'>12</span></b><span lang=EN-GB dir=LTR
      style='font-size:16.0pt'><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_62" o:spid="_x0000_s1077" style='position:absolute;
   left:11669;top:6175;width:8115;height:1651;flip:x;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal dir=RTL style='text-align:right;direction:rtl;
      unicode-bidi:embed'><b><span lang=AR-SA style='mso-bidi-font-size:11.0pt;
      font-family:"Arial",sans-serif;mso-fareast-font-family:Arial;color:black;
      mso-ansi-language:EN-US'>مرة واحدة</span></b><b><span lang=AR-SA
      style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;
      mso-fareast-font-family:Arial;color:black;mso-ansi-language:EN-US;
      mso-bidi-language:HE'> </span></b><b><span lang=AR-SA style='mso-bidi-font-size:
      11.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:Arial;
      color:black;mso-ansi-language:EN-US'>كل</span></b><span lang=EN-GB
      dir=LTR style='mso-bidi-language:HE'><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><v:rect id="Rectangle_x0020_55" o:spid="_x0000_s1078" style='position:absolute;
   left:36593;top:15086;width:10370;height:3302;flip:x;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
   <v:textbox style='mso-fit-shape-to-text:t' inset="0,0,0,0">
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal align=center dir=RTL style='text-align:center;
      direction:rtl;unicode-bidi:embed'><span lang=AR-SA style='font-size:10.0pt;
      font-family:"Arial",sans-serif;mso-fareast-font-family:Arial;color:black;
      mso-ansi-language:EN-US'>لأول جرعتين، حقنة واحدة كل ٦ أسابيع</span><span
      lang=EN-GB dir=LTR><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:rect><w:wrap type="topAndBottom"/>
 </v:group><![endif]--><img width="698" height="291" src="file:///C:/Users/alshoma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.png" /><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p dir="RTL"><strong><em>DME</em></strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ستُعالج بحقنة واحدة كل ستة أسابيع لأول خمس مرات حقن.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعد ذلك، قد تحصل على حقنة واحدة كل 3 أشهر. سيحدد طبيبك الفاصل الزمني لعلاجك بناءً على حالة عينك. قد يحتاج بعض المرضى إلى تلقي العلاج كل شهرين. قد يتلقى بعض المرضى العلاج كل 4 أشهر.</p><p dir="RTL"><!--[if gte vml 1]><v:group
 id="Group_x0020_19" o:spid="_x0000_s1028" style='position:absolute;left:0;
 text-align:left;margin-left:182.95pt;margin-top:7.1pt;width:251.55pt;height:154.6pt;
 flip:x;z-index:251673600;mso-width-relative:margin;mso-height-relative:margin'
 coordsize="31958,19651" o:gfxdata="UEsDBBQABgAIAAAAIQDI4TOSFQEAAFICAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSSTW7DIBCF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">
 <v:shape id="Picture_x0020_46" o:spid="_x0000_s1029" type="#_x0000_t75"
  style='position:absolute;left:3700;top:4822;width:8379;height:4019;flip:x;
  visibility:visible;mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
">
  <v:imagedata src="file:///C:/Users/alshoma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image002.jpg"
   o:title="" cropright="42737f"/>
 </v:shape><v:group id="Group_x0020_47" o:spid="_x0000_s1030" style='position:absolute;
  width:31958;height:19651' coordsize="31959,19666" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
">
  <v:shapetype id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
   <v:stroke joinstyle="miter"/>
   <v:path gradientshapeok="t" o:connecttype="rect"/>
  </v:shapetype><v:shape id="Text_x0020_Box_x0020_2" o:spid="_x0000_s1031"
   type="#_x0000_t202" style='position:absolute;left:2666;width:10181;height:4826;
   visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" strokecolor="white [3212]">
   <v:textbox style='mso-fit-shape-to-text:t'>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal align=center dir=RTL style='text-align:center;
      line-height:10.0pt;mso-line-height-rule:exactly;direction:rtl;unicode-bidi:
      embed'><b><span lang=AR-SA style='font-size:10.5pt;font-family:"Arial",sans-serif;
      mso-fareast-font-family:Arial'>أول </span></b><span dir=LTR></span><b><span
      lang=EN-GB dir=LTR style='font-size:10.5pt;font-family:"Arial",sans-serif;
      mso-fareast-font-family:Arial'><span dir=LTR></span>5</span></b><span
      dir=RTL></span><b><span lang=AR-SA style='font-size:10.5pt;font-family:
      "Arial",sans-serif;mso-fareast-font-family:Arial'><span dir=RTL></span>
      جرعات، مرة واحدة كل</span></b><b style='mso-bidi-font-weight:normal'><span
      lang=EN-GB dir=LTR style='font-size:10.5pt'><o:p></o:p></span></b></p>
      <p class=MsoNormal align=center style='text-align:center;line-height:
      10.0pt;mso-line-height-rule:exactly'><b style='mso-bidi-font-weight:normal'><span
      lang=EN-GB style='font-size:10.5pt'><o:p>&nbsp;</o:p></span></b></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="Text_x0020_Box_x0020_26" o:spid="_x0000_s1032" type="#_x0000_t202"
   style='position:absolute;left:4658;top:9472;width:6402;height:4318;
   visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQAxgYuyxQAAANsAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI/RagIx
FETfC/5DuIW+FM1WrLarUYpFUF90bT/gsrlutiY3yybq+vemUOjjMDNnmNmic1ZcqA21ZwUvgwwE
cel1zZWC769V/w1EiMgarWdScKMAi3nvYYa59lcu6HKIlUgQDjkqMDE2uZShNOQwDHxDnLyjbx3G
JNtK6havCe6sHGbZWDqsOS0YbGhpqDwdzk7BfjM5v+6K50nzsx2tTXezxerTKvX02H1MQUTq4n/4
r73WCkbv8Psl/QA5vwMAAP//AwBQSwECLQAUAAYACAAAACEA2+H2y+4AAACFAQAAEwAAAAAAAAAA
AAAAAAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQBa9CxbvwAAABUBAAAL
AAAAAAAAAAAAAAAAAB8BAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQAxgYuyxQAAANsAAAAP
AAAAAAAAAAAAAAAAAAcCAABkcnMvZG93bnJldi54bWxQSwUGAAAAAAMAAwC3AAAA+QIAAAAA
" strokecolor="white [3212]">
   <v:textbox style='mso-fit-shape-to-text:t'>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal align=center dir=RTL style='text-align:center;
      direction:rtl;unicode-bidi:embed'><b><span lang=AR-SA style='font-size:
      10.5pt;font-family:"Arial",sans-serif;mso-fareast-font-family:Arial;
      mso-ansi-language:DE-CH'>أسابيع</span></b><b style='mso-bidi-font-weight:
      normal'><span lang=DE-CH dir=LTR style='font-size:10.5pt;mso-ansi-language:
      DE-CH'><o:p></o:p></span></b></p>
      <p class=MsoNormal align=center style='text-align:center'><b
      style='mso-bidi-font-weight:normal'><span lang=DE-CH style='font-size:
      10.5pt;mso-ansi-language:DE-CH'><o:p>&nbsp;</o:p></span></b></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="Text_x0020_Box_x0020_27" o:spid="_x0000_s1033" type="#_x0000_t202"
   style='position:absolute;top:12043;width:14265;height:7623;visibility:visible;
   mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" strokecolor="white [3212]">
   <v:textbox style='mso-fit-shape-to-text:t'>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal align=center dir=RTL style='text-align:center;
      direction:rtl;unicode-bidi:embed'><b><span lang=AR-SA style='font-size:
      10.5pt;font-family:"Arial",sans-serif;mso-fareast-font-family:Arial;
      mso-ansi-language:EN-US'>بالنسبة لأول </span></b><span dir=LTR></span><b><span
      dir=LTR style='font-size:10.5pt;font-family:"Arial",sans-serif;
      mso-fareast-font-family:Arial;mso-ansi-language:EN-US'><span dir=LTR></span>5</span></b><span
      dir=RTL></span><b><span lang=AR-SA style='font-size:10.5pt;font-family:
      "Arial",sans-serif;mso-fareast-font-family:Arial;mso-ansi-language:EN-US'><span
      dir=RTL></span> جرعات، حقنة واحدة كل</span></b><b style='mso-bidi-font-weight:
      normal'><span lang=EN-GB dir=LTR style='font-size:10.5pt'><o:p></o:p></span></b></p>
      <p class=MsoNormal align=center dir=RTL style='text-align:center;
      direction:rtl;unicode-bidi:embed'><b><span dir=LTR style='font-size:10.5pt;
      font-family:"Arial",sans-serif;mso-fareast-font-family:Arial;mso-ansi-language:
      EN-US'>6</span></b><span dir=RTL></span><b><span lang=AR-SA
      style='font-size:10.5pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
      Arial;mso-ansi-language:EN-US'><span dir=RTL></span> أسابيع</span></b><b
      style='mso-bidi-font-weight:normal'><span dir=LTR style='font-size:10.5pt;
      mso-ansi-language:EN-US'><o:p></o:p></span></b></p>
      <p class=MsoNormal align=center style='text-align:center'><b
      style='mso-bidi-font-weight:normal'><span style='font-size:10.5pt;
      mso-ansi-language:EN-US'><o:p>&nbsp;</o:p></span></b></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="Text_x0020_Box_x0020_2" o:spid="_x0000_s1034" type="#_x0000_t202"
   style='position:absolute;left:16668;top:535;width:10004;height:4826;flip:x;
   visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" strokecolor="white [3212]">
   <v:textbox style='mso-fit-shape-to-text:t'>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal align=center dir=RTL style='text-align:center;
      line-height:10.0pt;mso-line-height-rule:exactly;direction:rtl;unicode-bidi:
      embed'><b><span lang=AR-SA style='font-size:10.5pt;font-family:"Arial",sans-serif;
      mso-fareast-font-family:Arial;mso-ansi-language:DE-CH'>بعد ذلك، مرة واحدة
      كل</span></b><b style='mso-bidi-font-weight:normal'><span lang=DE-CH
      dir=LTR style='font-size:10.5pt;mso-ansi-language:DE-CH'><o:p></o:p></span></b></p>
      <p class=MsoNormal align=center style='text-align:center;line-height:
      10.0pt;mso-line-height-rule:exactly'><b style='mso-bidi-font-weight:normal'><span
      lang=DE-CH style='font-size:10.5pt;mso-ansi-language:DE-CH'><o:p>&nbsp;</o:p></span></b></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="Text_x0020_Box_x0020_39" o:spid="_x0000_s1035" type="#_x0000_t202"
   style='position:absolute;left:18634;top:9472;width:6403;height:4319;
   visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokecolor="white [3212]">
   <v:textbox style='mso-fit-shape-to-text:t'>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal align=center dir=RTL style='text-align:center;
      direction:rtl;unicode-bidi:embed'><b><span lang=AR-SA style='font-size:
      10.5pt;font-family:"Arial",sans-serif;mso-fareast-font-family:Arial;
      mso-ansi-language:DE-CH'>أسبوعًا</span></b><b style='mso-bidi-font-weight:
      normal'><span lang=DE-CH dir=LTR style='font-size:10.5pt;mso-ansi-language:
      DE-CH'><o:p></o:p></span></b></p>
      <p class=MsoNormal align=center style='text-align:center'><b
      style='mso-bidi-font-weight:normal'><span lang=DE-CH style='font-size:
      10.5pt;mso-ansi-language:DE-CH'><o:p>&nbsp;</o:p></span></b></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="Text_x0020_Box_x0020_40" o:spid="_x0000_s1036" type="#_x0000_t202"
   style='position:absolute;left:12847;top:12041;width:19112;height:7624;
   visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQAb3OA4xQAAANsAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI/dagIx
FITvC75DOEJvSs3a+sfWKKVFsN7YVR/gsDlutiYnyybq+vaNUOjlMDPfMPNl56y4UBtqzwqGgwwE
cel1zZWCw371PAMRIrJG65kU3CjActF7mGOu/ZULuuxiJRKEQ44KTIxNLmUoDTkMA98QJ+/oW4cx
ybaSusVrgjsrX7JsIh3WnBYMNvRhqDztzk7B99f0PN4WT9PmZzNam+5mi9WnVeqx372/gYjUxf/w
X3utFUxe4f4l/QC5+AUAAP//AwBQSwECLQAUAAYACAAAACEA2+H2y+4AAACFAQAAEwAAAAAAAAAA
AAAAAAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQBa9CxbvwAAABUBAAAL
AAAAAAAAAAAAAAAAAB8BAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQAb3OA4xQAAANsAAAAP
AAAAAAAAAAAAAAAAAAcCAABkcnMvZG93bnJldi54bWxQSwUGAAAAAAMAAwC3AAAA+QIAAAAA
" strokecolor="white [3212]">
   <v:textbox style='mso-fit-shape-to-text:t'>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal align=center dir=RTL style='text-align:center;
      direction:rtl;unicode-bidi:embed'><b><span lang=AR-SA style='font-size:
      10.5pt;font-family:"Arial",sans-serif;mso-fareast-font-family:Arial'>ثم
      حقنة واحدة كل </span></b><b style='mso-bidi-font-weight:normal'><span
      lang=EN-GB dir=LTR style='font-size:10.5pt'><o:p></o:p></span></b></p>
      <p class=MsoNormal align=center dir=RTL style='text-align:center;
      direction:rtl;unicode-bidi:embed'><b><span dir=LTR style='font-size:10.5pt;
      font-family:"Arial",sans-serif;mso-fareast-font-family:Arial;mso-ansi-language:
      EN-US'>12</span></b><span dir=RTL></span><b><span lang=AR-SA
      style='font-size:10.5pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
      Arial;mso-ansi-language:EN-US'><span dir=RTL></span> أسبوعًا (</span></b><span
      dir=LTR></span><b><span dir=LTR style='font-size:10.5pt;font-family:"Arial",sans-serif;
      mso-fareast-font-family:Arial;mso-ansi-language:EN-US'><span dir=LTR></span>3</span></b><span
      dir=RTL></span><b><span lang=AR-SA style='font-size:10.5pt;font-family:
      "Arial",sans-serif;mso-fareast-font-family:Arial;mso-ansi-language:EN-US'><span
      dir=RTL></span> أشهر) أو <br>
      حسب توصيات طبيبك</span></b><b style='mso-bidi-font-weight:normal'><span
      dir=LTR style='font-size:10.5pt;mso-ansi-language:EN-US'><o:p></o:p></span></b></p>
      <p class=MsoNormal align=center style='text-align:center'><b
      style='mso-bidi-font-weight:normal'><span style='font-size:10.5pt;
      mso-ansi-language:EN-US'><o:p>&nbsp;</o:p></span></b></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape></v:group><w:wrap type="square"/>
</v:group><![endif]--><img width="341" height="212" src="file:///C:/Users/alshoma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image003.png" /></p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><!--[if gte vml 1]><v:shape id="Picture_x0020_5"
 o:spid="_x0000_s1026" type="#_x0000_t75" style='position:absolute;left:0;
 text-align:left;margin-left:229.45pt;margin-top:8.15pt;width:65.95pt;height:31.6pt;
 z-index:251682816;visibility:visible;mso-wrap-style:square;
 mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/alshoma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image002.jpg"
  o:title="" cropleft="38042f" cropright="4695f"/>
</v:shape><v:shape id="Picture_x0020_6" o:spid="_x0000_s1027" type="#_x0000_t75"
 style='position:absolute;left:0;text-align:left;margin-left:284.25pt;
 margin-top:8.2pt;width:65.95pt;height:31.6pt;z-index:251684864;visibility:visible;
 mso-wrap-style:square;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text'>
 <v:imagedata src="file:///C:/Users/alshoma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image004.jpg"
  o:title="" cropleft="24624f" cropright="18113f"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="161" height="42" src="file:///C:/Users/alshoma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image005.png" /></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>طريقة الإعطاء</strong></p><p dir="RTL">يُعطى بيوفيو عن طريق الحقن في عينك (الاستخدام داخل الجسم الزجاجي) من قِبل طبيب عيون.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قبل الحقن، سينظف طبيبك عينك بعناية، لمنع الإصابة بالعدوى. سيُعطيك طبيبك أيضًا قطرة عين (مخدر موضعي) لتخدير العين لتقليل الألم الناجم عن الحقن أو منعه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>مدة استمرار علاج بيوفيو</strong></p><p dir="RTL">يُستخدم بيوفيو لعلاج أمراض العين المزمنة التي تتطلب علاجًا طويل الأجل، وربما يستمر العلاج باستخدامه لعدة أشهر أو سنوات. سيتحقق طبيبك من فعالية العلاج خلال زياراتك المجدولة المنتظمة. قد يفحص طبيبك أيضًا عينيك بين مرات الحقن. إذا كانت تراودك أسئلة حول المدة التي ستستخدم فيها بيوفيو، فاطرحها على طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&zwnj;أ.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا توقفت عن استخدام بيوفيو </strong></p><p dir="RTL">تحدث مع طبيبك قبل إيقاف العلاج. قد يزيد إيقاف العلاج من خطر فقدان الرؤية وقد تسوء رؤيتك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك مزيد من الأسئلة حول استخدام هذا الدواء، فاسأل طبيبك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل كل الأدوية، قد يسبب هذا الدواء آثارًا جانبية، ولكن هذه الآثار لا تصيب كل من يتلقاه. الآثار الجانبية لحقن بيوفيو إما ناتجة عن الدواء نفسه أو عن إجراء الحقن، وغالبًا ما تؤثر على العين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تكون بعض الآثار الجانبية خطيرة</p><p dir="RTL">احصل على مساعدة طبية فورية إذا كنت تعاني من أي مما يلي، وهي علامات على ردود فعل تحسسية أو التهابات أو عدوى:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مفاجئ أو تغير في الرؤية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم، إزعاج متزايد، تفاقم احمرار العين</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا عانيت من أي آثار جانبية خطيرة،<strong> فأخبر طبيبك على الفور.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية المحتملة الأخرى</strong></p><p dir="RTL">تشمل الآثار الجانبية الأخرى التي قد تحدث بعد علاج بيوفيو تلك المدرجة أدناه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">معظم الآثار الجانبية خفيفة إلى معتدلة وستختفي عمومًا في غضون أسبوع بعد كل حقنة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا أصبحت هذه الآثار الجانبية شديدة، فيُرجى إخبار طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة: </strong><em>قد تصيب ما يصل إلى شخص واحد (1) من كل 10 أشخاص</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الطبقة الوسطى من جدار العين (التهاب العنبية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انفصال المادة الشبيهة بالهلام داخل العين (انفصال الجسم الزجاجي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تمزق الشبكية (الجزء الموجود في الجزء الخلفي من العين الذي يكتشف الضوء) أو إحدى طبقاتها (تمزق ظهارة الصباغ الشبكية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض حدة الرؤية (انخفاض حدة البصر)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف في الشبكية (نزيف الشبكية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب القزحية، الجزء الملون من العين (التهاب القزحية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب القزحية والأنسجة المجاورة لها في العين (التهاب القزحية والجسم الهدبي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان مفاجئ للرؤية بسبب انسداد الأوعية الدموية في الجزء الخلفي من العين (انسداد الأوعية الدموية الشبكية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف في العين (نزيف في الجسم الزجاجي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إعتام عدسة العين (عتامة عدسة العين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف من الأوعية الدموية الصغيرة في الطبقة الخارجية من العين (نزيف الملتحمة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بقع متحركة في رؤيتك (الأجسام العائمة الزجاجية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في العين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الضغط داخل العين (زيادة ضغط العين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار في بياض العين (التهاب الملتحمة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رؤية مشوشة أو غير واضحة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خدش القرنية، تلف الطبقة الشفافة من مقلة العين التي تغطي القزحية (خدش القرنية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تلف الطبقة الشفافة من مقلة العين التي تغطي القزحية (التهاب القرنية المنقط)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ردود فعل تحسسية (فرط الحساسية)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة: </strong><em>قد تصيب ما يصل إلى شخص واحد (1) من كل 100&nbsp;</em>شخص</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب شديد داخل العين (التهاب باطن المقلة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العمى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الرؤية المفاجئ بسبب انسداد شريان في العين (انسداد شريان الشبكية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انفصال الشبكية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار العين (فرط دم الملتحمة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة إنتاج الدموع (زيادة الدموع)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شعور غير طبيعي في العين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انفصال إحدى طبقات الشبكية (انفصال ظهارة الصباغ الشبكية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المادة الشبيهة بالهلام داخل العين (التهاب الزجاجية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الجزء الأمامي من العين (التهاب أو توهج غرفة العين الأمامية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم القرنية، الطبقة الشفافة من مقلة العين (وذمة القرنية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الأوعية الدموية في الجزء الخلفي من العين (التهاب وعائي شبكي)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إذا تعرضت لأي آثار جانبية، فتحدث مع الطبيب المتابع لك. يشمل هذا أيّة آثار جانبية محتملة غير مذكورة في هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المحقنة المعبأة مسبقًا</strong></p><p dir="RTL">احفظ هذا الدواء بعيدًا عن رؤية ومتناول الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على العلبة الكرتونية والملصق بعد كلمة &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُخزّن في الثلاجة (2&nbsp;‑&nbsp;8 درجات مئوية).</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تجمّده.</p><p dir="RTL">&nbsp;</p><p dir="RTL">احتفظ بالمحقنة المعبأة مسبقًا في الشريط المغلق وفي علبة الكرتون الخارجية لحمايتها من الضوء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قبل الاستخدام، يمكن حفظ الشريط غير المفتوح مع المحقنة المعبأة مسبقًا في درجة حرارة الغرفة (أقل من 30 درجة مئوية) لمدة تصل إلى 24 ساعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>القنينة</strong></p><p dir="RTL">احفظ هذا الدواء بعيدًا عن رؤية ومتناول الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على العلبة الكرتونية والملصق بعد كلمة &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُخزّن في الثلاجة (2&nbsp;‑&nbsp;8 درجات مئوية).</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تجمّده.</p><p dir="RTL">&nbsp;</p><p dir="RTL">احتفظ بالقنينة في العلبة الكرتونية الخارجية لحمايتها من الضوء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قبل الاستخدام، يمكن حفظ القنينة غير المفتوحة في درجة حرارة الغرفة (أقل من 30 درجة مئوية) لمدة تصل إلى 24 ساعة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المحقنة المعبأة مسبقًا</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي برولوسيزوماب. يحتوي كل مل من محلول الحقن على 120&nbsp;ملغ من برولوسيزوماب. تحتوي كل محقنة معبأة مسبقًا على 19.8&nbsp;ملغ من برولوسيزوماب في محلول 0.165&nbsp;مل. يوفر هذا كمية قابلة للاستخدام لإعطاء جرعة واحدة من محلول 0.05 مل تحتوي على 6&nbsp;ملغ من برولوسيزوماب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي: سترات الصوديوم، السكروز، بوليسوربات 80، ماء للحقن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>القنينة</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعالة هي برولوسيزوماب. يحتوي كل مل من محلول الحقن على 120&nbsp;ملغ من برولوسيزوماب. تحتوي كل قنينة على 27.6&nbsp;ملغ من برولوسيزوماب في محلول 0.23&nbsp;مل. يوفر هذا كمية قابلة للاستخدام لإعطاء جرعة واحدة من محلول 0.05 مل تحتوي على 6&nbsp;ملغ من برولوسيزوماب.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي: سترات الصوديوم، السكروز، بوليسوربات 80، ماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المحقنة المعبأة مسبقًا</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">محلول بيوفيو 120&nbsp;ملغ/مل للحقن في محقنة معبأة مسبقًا (حقن)<u> </u>عبارة عن محلول مائي شفاف إلى غائم قليلًا، عديم اللون مائل إلى البني المصفر قليلًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">حجم العبوة محقنة واحدة معبأة مسبقًا للاستخدام مرة واحدة فقط.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>القنينة</strong></p><p dir="RTL">محلول بيوفيو 120&nbsp;ملغ/مل للحقن (حقن) عبارة عن محلول مائي شفاف إلى غائم قليلًا، عديم اللون مائل إلى البني المصفر قليلًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">حجم العبوة قنينة واحدة وإبرة تصفية واحدة غير حادة (18 جم &times; 1&frac12; بوصة، 1.2&nbsp;مم &times; 40&nbsp;مم، 5&nbsp;ميكرومتر) للاستخدام مرة واحدة فقط.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">حامل ترخيص التسويق لهذا المنتج هو شركة Novartis Europharm Limited، أيرلندا</p><p dir="RTL">www.Novartis.com</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشركات المُصنّعة</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المحقنة المعبأة مسبقًا</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">S.A. ALCON-COUVREUR N.V.</p><p dir="RTL">Rijksweg 14</p><p dir="RTL">2870 Puurs</p><p dir="RTL">بلجيكا</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>القنينة</strong></p><p dir="RTL">Novartis Pharma AG, Stein، سويسرا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ‌د.	تمت آخر موافقة على هذه النشرة في 29 يونيو 2023 من قِبل وكالة الأدوية الأوروبية.
	
‌ه.	للإبلاغ عن أيّ أثر جانبي (آثار جانبية):
•	المملكة العربية السعودية

المركز الوطني للتيُّقظ والسلامة الدوائية (NPC):

o فاكس: +966-11-205-7662
o مركز اتصال الهيئة السعودية للغذاء والدواء: 19999
o البريد الإلكتروني: npc.drug@sfda.gov.sa
o الموقع الإلكتروني: https://ade.sfda.gov.sa/‎ 

قسم سلامة المرضى بشركة نوفارتس كونسالتينغ إي جي - المملكة العربية السعودية:
o الرقم المجاني: 8001240078
o هاتف: +966112658100
o فاكس: +966112658107
o البريد الإلكتروني: adverse.events@novartis.com 

• دول مجلس التعاون الخليجي الأخرى:
- يُرجى الاتصال بالسلطة المختصة ذات الصلة.


        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Beovu 120 mg/ml solution for injection in pre-filled syringe 
Beovu 120 mg/ml solution for injection
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One ml solution for injection contains 120 mg of brolucizumab*.

* Brolucizumab is a humanised monoclonal single chain Fv (scFv) antibody fragment produced in Escherichia coli cells by recombinant DNA technology.

Beovu 120 mg/ml solution for injection in pre filled syringe

Each pre filled syringe contains 19.8 mg brolucizumab in 0.165 ml solution. This provides a usable amount to deliver a single dose of 0.05 ml solution containing 6 mg of brolucizumab.

Beovu 120 mg/ml solution for injection

Each vial contains 27.6 mg brolucizumab in 0.23 ml solution. This provides a usable amount to deliver a single dose of 0.05 ml solution containing 6 mg of brolucizumab.

For the full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection (injection).

Clear to slightly opalescent, colourless to slightly brownish-yellow aqueous solution.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Beovu is indicated in adults for the treatment of</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; neovascular (wet) age‑related macular degeneration (AMD) (see section&nbsp;5.1),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; visual impairment due to diabetic macular oedema (DME) (see section&nbsp;5.1).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Beovu must be administered by a qualified ophthalmologist experienced in intravitreal injections.</p><p>&nbsp;</p><p><u>Posology</u></p><p>&nbsp;</p><p><em><u>Wet AMD</u></em></p><p><em>Treatment initiation &ndash; loading</em></p><p>The recommended dose is 6&nbsp;mg brolucizumab (0.05&nbsp;ml solution), administered by intravitreal injection every 4&nbsp;weeks (monthly) for the first 3&nbsp;doses. A disease activity assessment is suggested 16&nbsp;weeks (4&nbsp;months) after treatment start.</p><p>&nbsp;</p><p>Alternatively, 6&nbsp;mg brolucizumab (0.05&nbsp;ml solution) may be administered every 6&nbsp;weeks for the first 2&nbsp;doses. A disease activity assessment is suggested 12&nbsp;weeks (3&nbsp;months) after treatment start. A third dose may be administered based on disease activity as assessed by visual acuity and/or anatomical parameters at week&nbsp;12.</p><p>&nbsp;</p><p><em>Maintenance treatment</em></p><p>After the last loading dose, the physician may individualise treatment intervals based on disease activity as assessed by visual acuity and/or anatomical parameters. In patients without disease activity, treatment every 12&nbsp;weeks (3&nbsp;months) should be considered. In patients with disease activity, treatment every 8&nbsp;weeks (2&nbsp;months) should be considered (see sections&nbsp;4.4 and 5.1).</p><p>&nbsp;</p><p>If visual and anatomical outcomes indicate that the patient is not benefiting from continued treatment, Beovu should be discontinued.</p><p>&nbsp;</p><p><em><u>DME</u></em></p><p>The recommended dose is 6&nbsp;mg brolucizumab (0.05&nbsp;ml solution) administered by intravitreal injection every 6&nbsp;weeks for the first 5&nbsp;doses.</p><p>&nbsp;</p><p>Thereafter, the physician may individualise treatment intervals based on disease activity as assessed by visual acuity and/or anatomical parameters. In patients without disease activity, treatment every 12&nbsp;weeks (3&nbsp;months) should be considered. In patients with disease activity, treatment every 8&nbsp;weeks (2&nbsp;months) should be considered. After 12&nbsp;months of treatment, in patients without disease activity, treatment intervals up to 16&nbsp;weeks (4&nbsp;months) could be considered (see sections&nbsp;4.4 and 5.1).</p><p>&nbsp;</p><p>If visual and anatomical outcomes indicate that the patient is not benefiting from continued treatment, Beovu should be discontinued.</p><p>&nbsp;</p><p><em><u>Special populations</u></em></p><p><em>Elderly</em></p><p>No dosage adjustment is required in patients aged 65&nbsp;years or above (see section&nbsp;5.2).</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>No dosage adjustment is required in patients with renal impairment (see section&nbsp;5.2).</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>Brolucizumab has not been studied in patients with hepatic impairment. No dosage adjustment is required in patients with hepatic impairment (see section&nbsp;5.2).</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The safety and efficacy of brolucizumab in children and adolescents below 18&nbsp;years of age have not been established. No data are available.</p><p><u>&nbsp;</u></p><p><u>Method of administration</u></p><p><u>&nbsp;</u></p><p>Beovu is for intravitreal use only.</p><p>&nbsp;</p><p>The solution for injection should be inspected visually prior to administration (see section&nbsp;6.6).</p><p>&nbsp;</p><p>The intravitreal injection procedure should be carried out under aseptic conditions, which includes the use of surgical hand disinfection, sterile gloves, a sterile drape and a sterile eyelid speculum (or equivalent). Sterile paracentesis equipment should be available as a precautionary measure. The patient&rsquo;s medical history for hypersensitivity reactions should be carefully evaluated prior to performing the intravitreal procedure (see section&nbsp;4.3). Adequate anaesthesia and a broad‑spectrum topical microbicide to disinfect the periocular skin, eyelid and ocular surface should be administered prior to the injection.</p><p>&nbsp;</p><p>The injection needle should be inserted 3.5 to 4.0&nbsp;mm posterior to the limbus into the vitreous cavity, avoiding the horizontal meridian and aiming towards the centre of the globe. The injection volume of 0.05&nbsp;ml is then delivered slowly; a different scleral site should be used for subsequent injections.</p><p>&nbsp;</p><p>Immediately following the intravitreal injection, patients should be monitored for elevation in intraocular pressure. Appropriate monitoring may consist of a check for perfusion of the optic nerve head or tonometry. If required, sterile equipment for paracentesis should be available.</p><p>&nbsp;</p><p>Following intravitreal injection patients should be instructed to report any symptoms suggestive of endophthalmitis (e.g. eye pain, redness of the eye, photophobia, blurring of vision) without delay.</p><p>&nbsp;</p><p><em><u>Pre‑filled syringe</u></em></p><p>The pre‑filled syringe is for single use only. Each pre‑filled syringe should only be used for the treatment of a single eye.</p><p>&nbsp;</p><p>Since the volume contained in the pre‑filled syringe (0.165&nbsp;ml) is greater than the recommended dose (0.05&nbsp;ml), a portion of the volume contained in the pre‑filled syringe must be discarded prior to administration.</p><p>&nbsp;</p><p>Injecting the entire volume of the pre‑filled syringe could result in overdose. To expel the air bubble along with excess medicinal product, the plunger should be slowly depressed until the edge below the dome of the rubber stopper is aligned with the 0.05&nbsp;ml dose mark (equivalent to 50&nbsp;&micro;l, i.e. 6&nbsp;mg brolucizumab).</p><p>&nbsp;</p><p><em><u>Vial</u></em></p><p>The vial is for single use only. Each vial should only be used for the treatment of a single eye.</p><p>&nbsp;</p><p>Since the volume contained in the vial (0.23&nbsp;ml) is greater than the recommended dose (0.05&nbsp;ml), a portion of the volume contained in the vial must be discarded prior to administration.</p><p>&nbsp;</p><p>Injecting the entire volume of the vial could result in overdose. To expel the air bubble along with excess medicinal product, the air should be carefully expelled from the syringe and the dose adjusted to the 0.05&nbsp;ml mark (equivalent to 50&nbsp;&micro;l, i.e. 6&nbsp;mg brolucizumab).</p><p>&nbsp;</p><p>For instructions on preparation of the medicinal product before administration, see section&nbsp;6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Patients with active or suspected ocular or periocular infections.

Patients with active intraocular inflammation.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Traceability</u></p><p>&nbsp;</p><p>In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p><p>&nbsp;</p><p><u>Endophthalmitis, intraocular inflammation, traumatic cataract, retinal detachment, retinal tear, retinal vasculitis, and/or retinal vascular occlusion</u></p><p>&nbsp;</p><p>Intravitreal injections, including those with Beovu, have been associated with endophthalmitis, intraocular inflammation, traumatic cataract, retinal detachment and retinal tear (see section&nbsp;4.8). Proper aseptic injection techniques must always be used when administering Beovu.</p><p>&nbsp;</p><p>Patients should be instructed to report any symptoms suggestive of the above‑mentioned events without delay.</p><p>&nbsp;</p><p><u>Intraocular inflammation, including retinal vasculitis and/or retinal vascular occlusion</u></p><p>&nbsp;</p><p>Intraocular inflammation, including retinal vasculitis and/or retinal vascular occlusion, has been reported with the use of Beovu (see sections&nbsp;4.3 and 4.8). A higher number of intraocular inflammation events were observed among patients with treatment-emergent antibodies. After investigation, retinal vasculitis and/or retinal vascular occlusion were found to be immune‑mediated events. Intraocular inflammation, including retinal vasculitis and/or retinal vascular occlusion, may occur following the first intravitreal injection and at any time of treatment. These events were observed more frequently at the beginning of the treatment.</p><p>&nbsp;</p><p>Based on clinical studies these events were more frequent in female patients treated with Beovu than male patients (e.g.&nbsp;5.3% females vs.&nbsp;3.2% males in HAWK and HARRIER) and in Japanese patients.</p><p>&nbsp;</p><p>In patients developing these events, treatment with Beovu should be discontinued and the events should be promptly managed. Patients treated with Beovu with a medical history of intraocular inflammation and/or retinal vascular occlusion (within 12&nbsp;months prior to the first brolucizumab injection) should be closely monitored, since they are at increased risk of developing retinal vasculitis and/or retinal vascular occlusion.</p><p>&nbsp;</p><p>The interval between two Beovu doses during maintenance treatment should not be less than 8&nbsp;weeks considering that a higher incidence of intraocular inflammation (including retinal vasculitis) and retinal vascular occlusion was reported in patients with nAMD who received Beovu every 4&nbsp;week maintenance dosing in a clinical study compared to patients who received Beovu every 8 or 12&nbsp;week maintenance dosing in the pivotal Phase&nbsp;III clinical studies.</p><p>&nbsp;</p><p><u>Intraocular pressure increases</u></p><p>&nbsp;</p><p>Transient increases in intraocular pressure have been seen within 30&nbsp;minutes of intravitreal injection with vascular endothelial growth factor (VEGF) inhibitors, including brolucizumab (see section&nbsp;4.8). Special precaution is needed in patients with poorly controlled glaucoma (do not inject Beovu while the intraocular pressure is &ge;30&nbsp;mmHg). Both intraocular pressure and perfusion of the optic nerve head must be monitored and managed appropriately.</p><p>&nbsp;</p><p><u>Bilateral treatment</u></p><p>&nbsp;</p><p>The safety and efficacy of brolucizumab administered in both eyes concurrently have not been studied.</p><p>&nbsp;</p><p><u>Immunogenicity</u></p><p>&nbsp;</p><p>As this is a therapeutic protein, there is a potential for immunogenicity with brolucizumab (see section&nbsp;4.8). Patients should be instructed to inform their physician if they develop symptoms such as eye pain or increased discomfort, worsening eye redness, blurred or decreased vision, an increased number of small particles in their vision, or increased sensitivity to light (see section&nbsp;4.8).</p><p>&nbsp;</p><p><u>Concomitant use of other anti‑VEGF</u></p><p>&nbsp;</p><p>There are no data available on the concomitant use of Beovu with other anti‑VEGF medicinal products in the same eye. Brolucizumab should not be administered concurrently with other anti‑VEGF medicinal products (systemic or ocular).</p><p>&nbsp;</p><p><u>Withholding treatment</u></p><p>&nbsp;</p><p>In intravitreal anti‑VEGF treatments, the dose should be withheld and treatment should not be resumed earlier than the next scheduled treatment in the event of:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a decrease in best‑corrected visual acuity (BCVA) of &ge;30&nbsp;letters compared with the last assessment of visual acuity;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a retinal break;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a subretinal haemorrhage involving the centre of the fovea, or, if the size of the haemorrhage is &ge;50% of the total lesion area;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; performed or planned intraocular surgery within the previous or next 28&nbsp;days.</p><p>&nbsp;</p><p><u>Retinal pigment epithelial tear</u></p><p>&nbsp;</p><p>Risk factors associated with the development of a retinal pigment epithelial tear after anti‑VEGF therapy for wet AMD include a large and/or high pigment epithelial retinal detachment. When initiating brolucizumab therapy, caution should be used in patients with these risk factors for retinal pigment epithelial tears.</p><p>&nbsp;</p><p><u>Rhegmatogenous retinal detachment or macular holes</u></p><p>&nbsp;</p><p>Treatment should be discontinued in subjects with rhegmatogenous retinal detachment or stage&nbsp;3 or 4 macular holes.</p><p>&nbsp;</p><p><u>Systemic effects following intravitreal use</u></p><p>&nbsp;</p><p>Systemic adverse events, including non‑ocular haemorrhages and arterial thromboembolic events, have been reported following intravitreal injection of VEGF inhibitors and there is a theoretical risk that these may relate to VEGF inhibition. There are limited data on safety in the treatment of patients with AMD and DME with a history of stroke, transient ischaemic attacks or myocardial infarction within the last 3&nbsp;months. Caution should be exercised when treating such patients.</p><p>&nbsp;</p><p><u>Sodium content</u></p><p>&nbsp;</p><p>This medicinal product contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per dose, that is to say essentially &ldquo;sodium‑free&rdquo;.</p><p>&nbsp;</p><p><u>Populations with limited data</u></p><p>&nbsp;</p><p>There is limited experience with Beovu treatment in diabetic patients with HbA1c greater than 10% or with proliferative diabetic retinopathy. There is also no experience of treatment with Beovu in diabetic patients with uncontrolled hypertension. This lack of information should be considered by the physician when treating such patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No interaction studies have been performed.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential</u></p><p>&nbsp;</p><p>Women of childbearing potential should use effective contraception during treatment with brolucizumab and for at least one month after the last dose when stopping treatment with brolucizumab.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>&nbsp;</p><p>There are no or limited amount of data from the use of brolucizumab in pregnant women. A study in pregnant cynomolgus monkeys did not indicate any harmful effects with respect to reproductive toxicity. Animal studies are insufficient with respect to reproductive toxicity (see section&nbsp;5.3). Although the systemic exposure after ocular administration is very low due to its mechanism of action, there is a potential risk to embryofoetal development. Therefore, brolucizumab should not be used during pregnancy unless the potential benefit outweighs the potential risk to the foetus.</p><p>&nbsp;</p><p><u>Breast‑</u><u>feeding</u></p><p>&nbsp;</p><p>It is unknown whether brolucizumab is excreted in human milk. In a reproductive toxicity study, brolucizumab was not detected in the maternal milk or infant serum of cynomolgus monkeys (see section&nbsp;5.3). A risk to the breast‑fed newborn/infant cannot be excluded. Brolucizumab is not recommended during breast‑feeding and breast‑feeding should not be started for at least one month after the last dose when stopping treatment with brolucizumab. A decision must be made whether to discontinue breast‑feeding or to abstain from brolucizumab therapy, taking into account the benefit of breast‑feeding for the child and the benefit of therapy for the woman.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>No reproductive or fertility studies have been conducted. VEGF inhibition has been shown to affect follicular development, corpus luteum function and fertility. Based on the mechanism of action of VEGF inhibitiors, there is a potential risk for female reproduction.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Beovu has a minor influence on the ability to drive and use machines due to possible temporary visual disturbances following the intravitreal injection and the associated eye examination. Patients should not drive or use machines until visual function has recovered sufficiently.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>&nbsp;</p><p><em><u>Wet</u></em><em><u> AMD</u></em></p><p>For wet AMD, a total of 1&nbsp;088&nbsp;patients treated with brolucizumab constituted the safety population in two Phase&nbsp;III studies. Of these, 730&nbsp;patients were treated with the recommended dose of 6&nbsp;mg.</p><p>&nbsp;</p><p>The most frequently reported adverse reactions were reduced visual acuity (7.3%), cataract (7.0%), conjunctival haemorrhage (6.3%) and vitreous floaters (5.1%).</p><p>&nbsp;</p><p>The most serious adverse reactions were blindness (0.8%), endophthalmitis (0.7%), retinal artery occlusion (0.8%) and retinal detachment (0.7%).</p><p>&nbsp;</p><p><em><u>DME</u></em></p><p>For DME, a total of 558&nbsp;patients treated with brolucizumab constituted the safety population in two Phase&nbsp;III studies. Of these, 368&nbsp;patients were treated with the recommended dose of 6&nbsp;mg.</p><p>&nbsp;</p><p>The most frequently reported adverse reactions were cataract (9.0%), conjunctival haemorrhage (6.5%) and intraocular pressure increased (5.4%).</p><p>&nbsp;</p><p>The most serious adverse reactions were cataract (9.0%), retinal vascular occlusion (1.1%), retinal artery occlusion (0.8%), and endophthalmitis (0.5%).</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>The adverse reactions experienced following administration of Beovu in clinical studies are summarised in Table&nbsp;1 below.</p><p>&nbsp;</p><p>Adverse reactions (Table&nbsp;1) are listed according to the MedDRA system organ class. Within each system organ class, the adverse reactions are ranked by frequency, with the most frequent reactions first. Frequency categories for each adverse reaction are based on the following convention: very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1&nbsp;000 to &lt;1/100), rare (&ge;1/10&nbsp;000 to &lt;1/1&nbsp;000), very rare (&lt;1/10&nbsp;000), not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p><strong>Table&nbsp;1 Frequencies of adverse reactions in clinical studies</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:625px"><tbody><tr><td style="vertical-align:top"><p><strong>MedDRA System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency category*</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hypersensitivity (including urticaria, rash, pruritus, erythema)</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Eye disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Visual acuity reduced</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Retinal haemorrhage</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Uveitis</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Iridocyclitis</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Iritis</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Retinal vascular occlusion</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Vitreous haemorrhage</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Vitreous detachment</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Retinal tear</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Cataract</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Conjunctival haemorrhage</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Vitreous floaters</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Eye pain</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Intraocular pressure increase</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Conjunctivitis</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Retinal pigment epithelial tear</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Vision blurred</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Corneal abrasion</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Punctate keratitis</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Blindness</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Endophthalmitis</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Retinal detachment</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Conjunctival hyperaemia</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Lacrimation increased</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Abnormal sensation in eye</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Detachment of retinal pigment epithelium</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Vitritis</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Anterior chamber inflammation</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Anterior chamber flare</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Corneal oedema</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Retinal vasculitis</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>*The frequency category for each adverse reaction is based on the most conservative incidence rate from either pooled nAMD or pooled DME Phase&nbsp;III studies.</p></td></tr></tbody></table><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>&nbsp;</p><p><em><u>Immunogenicity</u></em></p><p>There is a potential for an immune response in patients treated with Beovu.</p><p>&nbsp;</p><p><em>Wet</em><em> AMD</em></p><p>After dosing with Beovu for 88&nbsp;weeks, treatment‑emergent anti‑brolucizumab antibodies were detected in 23&ndash;25% of patients.</p><p>&nbsp;</p><p><em>DME</em></p><p>After dosing with Beovu for 96&nbsp;weeks, treatment‑emergent anti‑brolucizumab antibodies were detected in 16‑23% of patients.</p><p>&nbsp;</p><p>Among AMD and DME patients with treatment‑emergent antibodies, a higher number of intraocular inflammation adverse reactions were observed. After investigation, retinal vasculitis and/or retinal vascular occlusion, typically in the presence of intraocular inflammation, were found to be immune‑mediated adverse events related to exposure to Beovu (see section&nbsp;4.4). Anti‑brolucizumab antibodies were not associated with an impact on clinical efficacy.</p><p>&nbsp;</p><p><em><u>Product‑class‑related adverse reactions</u></em></p><p>There is a theoretical risk of arterial thromboembolic events, including stroke and myocardial infarction, following intravitreal use of VEGF inhibitors. A low incidence rate of arterial thromboembolic events was observed in the brolucizumab clinical studies in patients with AMD and DME. There were no major notable differences between the groups treated with brolucizumab and comparator.</p><p><u>&nbsp;</u></p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.</p><p>To report any side effect(s):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Arabia</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</p><p>&nbsp;</p><p>o Fax: +966-11-205-7662</p><p>o SFDA call center: 19999</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patient Safety Department Novartis Consulting AG - Saudi Arabia:</p><p>&nbsp;</p><p>o Toll Free Number: 8001240078</p><p>o Phone: +966112658100</p><p>o Fax: +966112658107</p><p>o Email: adverse.events@novartis.com</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp; Other GCC States:</p><p>-&nbsp; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Overdosing with greater than recommended injection volume may increase intraocular pressure. In the event of overdose, intraocular pressure should therefore be monitored and, if deemed necessary by the treating physician, appropriate treatment should be initiated.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Ophthalmologicals, antineovascularisation agents, ATC code: S01LA06</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Brolucizumab is a humanised monoclonal single chain Fv (scFv) antibody fragment with a molecular weight of ~26&nbsp;kDa.</p><p>&nbsp;</p><p>Increased levels of signalling through the vascular endothelial growth factor A (VEGF‑A) pathway are associated with pathological ocular angiogenesis and retinal oedema. Brolucizumab binds with high affinity to VEGF‑A isoforms (e.g. VEGF<sub>110</sub>, VEGF<sub>121</sub>, and VEGF<sub>165</sub>), thereby preventing binding of VEGF‑A to its receptors VEGFR‑1 and VEGFR‑2. By inhibiting VEGF‑A binding, brolucizumab suppresses endothelial cell proliferation, thereby reducing pathological neovascularisation and decreasing vascular permeability.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>&nbsp;</p><p><em><u>Wet AMD</u></em></p><p>In the HAWK and HARRIER studies, anatomical parameters related to leakage of blood and fluid that characterise choroidal neovascularisation (CNV) were part of the disease activity assessments guiding treatment decisions. Reductions in central subfield thickness (CST) and in presence of intraretinal/subretinal fluid (IRF/SRF) or sub‑retinal pigment epithelium (sub‑RPE) fluid were observed in patients treated with Beovu as early as 4&nbsp;weeks after treatment initiation and up to week&nbsp;48 and week&nbsp;96.</p><p>&nbsp;</p><p>At week&nbsp;16, the reduction in CST was statistically significant on Beovu versus aflibercept in both studies (HAWK: ‑161 vs. ‑134&nbsp;microns; HARRIER: ‑174 vs. ‑134&nbsp;microns). This decrease from baseline in CST was also statistically significant at week&nbsp;48 (HAWK: ‑173 vs. ‑144&nbsp;microns; HARRIER: ‑194 vs. ‑144&nbsp;microns), and maintained to the end of each study at week&nbsp;96 (HAWK: ‑175 vs. ‑149&nbsp;microns; HARRIER: ‑198 vs. ‑155&nbsp;microns).</p><p>&nbsp;</p><p>At week&nbsp;16, the percentage difference in patients with IRF and/or SRF fluid was statistically significant on Beovu versus aflibercept in both studies (HAWK: 34% vs. 52%; HARRIER: 29% vs. 45%). This difference was also statistically significant at week&nbsp;48 (HAWK: 31% vs. 45%; HARRIER: 26% vs. 44%), and maintained to the end of each study at week&nbsp;96 (HAWK: 24% vs. 37%; HARRIER: 24% vs. 39%).</p><p>&nbsp;</p><p>At week&nbsp;16, the percentage difference in patients with sub‑RPE fluid was statistically significant on Beovu versus aflibercept in both studies (HAWK: 19% vs. 27%; HARRIER: 16% vs. 24%). This difference was also statistically significant at week&nbsp;48 (HAWK: 14% vs. 22%; HARRIER: 13% vs. 22%), and maintained to the end of each study at week&nbsp;96 (HAWK: 11% vs. 15%; HARRIER: 17% vs. 22%).</p><p>&nbsp;</p><p>In these studies, for patients treated with Beovu, reductions in CNV lesion size were observed as early as 12&nbsp;weeks, and at weeks&nbsp;48 and 96 after treatment initiation.</p><p>&nbsp;</p><p><em><u>DME</u></em></p><p>In the KESTREL and KITE studies, related anatomical parameters were part of the disease activity assessments guiding treatment decisions. Reductions in CST and in presence of IRF/SRF were observed in patients treated with Beovu as early as 4&nbsp;weeks after treatment initiation and up to week&nbsp;52. These reductions were maintained up to week&nbsp;100.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p><em><u>Wet AMD</u></em></p><p>The efficacy and safety of Beovu were assessed in two randomised, multicentre, double‑masked, active‑controlled Phase&nbsp;III studies (HAWK and HARRIER) in patients with neovascular (wet) AMD. A total of 1,817&nbsp;patients were treated in these studies for two years (1&nbsp;088 on Beovu and 729 on comparator aflibercept). Patient ages ranged from 50 to 97&nbsp;years, with a mean age of 76&nbsp;years.</p><p>&nbsp;</p><p>In both studies, after the first three monthly doses (weeks&nbsp;0, 4 and 8), brolucizumab patients were treated every 12&nbsp;weeks, with the option of adjusting to a dosing interval every 8&nbsp;weeks based on disease activity. Disease activity was assessed by a physician during the first 12‑week interval (at weeks&nbsp;16 and 20) and at each subsequent scheduled 12‑weekly treatment visit. Patients who showed disease activity (e.g. decreased visual acuity, increased CST and/or presence of IRF/SRF or sub‑RPE fluid) at any of these visits were adjusted to an 8‑weekly treatment interval. The comparator aflibercept was administered every 8&nbsp;weeks after the first 3&nbsp;monthly doses.</p><p>&nbsp;</p><p><em>Results</em></p><p>The primary efficacy endpoint for the studies was the change from baseline in best corrected visual acuity (BCVA) to week&nbsp;48, as measured by the early treatment diabetic retinopathy study (ETDRS) letter score, with the primary objective being to demonstrate non‑inferiority of Beovu versus aflibercept. In both studies, Beovu (administered in an every 12&nbsp;weeks or an every 8&nbsp;weeks regimen) demonstrated non‑inferior efficacy to aflibercept 2&nbsp;mg (administered every 8&nbsp;weeks). The visual acuity gains observed in the first year were maintained in the second year.</p><p>&nbsp;</p><p>Detailed results of both studies are shown in Table&nbsp;2 and in Figure&nbsp;1 below.</p><p>&nbsp;</p><p><strong>Table&nbsp;2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>Visual acuity outcomes at weeks 48 and 96 in Phase&nbsp;III ‑ HAWK and HARRIER studies</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:661px"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>HAWK</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>HARRIER</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Efficacy outcome</strong></p></td><td style="vertical-align:top"><p><strong>Week</strong></p></td><td style="vertical-align:top"><p><strong>Beovu</strong></p><p><strong>(n=360)</strong></p></td><td style="vertical-align:top"><p><strong>Aflibercept</strong></p><p><strong>2&nbsp;mg</strong></p><p><strong>(n=360)</strong></p></td><td style="vertical-align:top"><p><strong>Difference</strong></p><p><strong>(95% CI) brolucizumab &ndash; aflibercept</strong></p></td><td style="vertical-align:top"><p><strong>Beovu</strong></p><p><strong>(n=370)</strong></p></td><td style="vertical-align:top"><p><strong>Aflibercept</strong></p><p><strong>2&nbsp;mg</strong></p><p><strong>(n=369)</strong></p></td><td style="vertical-align:top"><p><strong>Difference</strong></p><p><strong>(95% CI) brolucizumab &ndash; aflibercept</strong></p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>Mean change from baseline in BCVA (measured by ETDRS letters score)</strong></p></td><td style="vertical-align:top"><p>48</p></td><td style="vertical-align:top"><p>6.6</p><p>(SE=0.71)</p></td><td style="vertical-align:top"><p>6.8</p><p>(SE=0.71)</p></td><td style="vertical-align:top"><p>‑0.2</p><p>(‑2.1, 1.8)</p><p>P&lt;0.0001<sup>&nbsp;a)</sup></p></td><td style="vertical-align:top"><p>6.9</p><p>(SE=0.61)</p></td><td style="vertical-align:top"><p>7.6</p><p>(SE=0.61)</p></td><td style="vertical-align:top"><p>-0.7</p><p>(-2.4, 1.0)</p><p>P &lt;0.0001<sup>&nbsp;a)</sup></p></td></tr><tr><td style="vertical-align:top"><p>36 &ndash; 48<sup>&nbsp;b)</sup></p></td><td style="vertical-align:top"><p>6.7 (SE=0.68)</p></td><td style="vertical-align:top"><p>6.7</p><p>(SE=0.68)</p></td><td style="vertical-align:top"><p>0.0</p><p>(‑1.9, 1.9)</p><p>P&lt;0.0001<sup>&nbsp;a)</sup></p></td><td style="vertical-align:top"><p>6.5</p><p>(SE=0.58)</p></td><td style="vertical-align:top"><p>7.7</p><p>(SE=0.58)</p></td><td style="vertical-align:top"><p>‑1.2</p><p>(‑2.8, 0.4)</p><p>P=0.0003<sup>&nbsp;a)</sup></p></td></tr><tr><td style="vertical-align:top"><p>96</p></td><td style="vertical-align:top"><p>5.9</p><p>(SE=0.78)</p></td><td style="vertical-align:top"><p>5.3</p><p>(SE=0.78)</p></td><td style="vertical-align:top"><p>0.5</p><p>(‑1.6, 2.7)</p></td><td style="vertical-align:top"><p>6.1</p><p>(SE=0.73)</p></td><td style="vertical-align:top"><p>6.6</p><p>(SE=0.73)</p></td><td style="vertical-align:top"><p>‑0.4</p><p>(‑2.5,1.6)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>% of patients who gained at least 15&nbsp;letters of vision</strong></p></td><td style="vertical-align:top"><p>48</p></td><td style="vertical-align:top"><p>33.6</p></td><td style="vertical-align:top"><p>25.4</p></td><td style="vertical-align:top"><p>8.2</p><p>(2.2, 15.0)</p></td><td style="vertical-align:top"><p>29.3</p></td><td style="vertical-align:top"><p>29.9</p></td><td style="vertical-align:top"><p>‑0.6</p><p>(‑7.1, 5.8)</p></td></tr><tr><td style="vertical-align:top"><p>96</p></td><td style="vertical-align:top"><p>34.2</p></td><td style="vertical-align:top"><p>27.0</p></td><td style="vertical-align:top"><p>7.2</p><p>(1.4, 13.8)</p></td><td style="vertical-align:top"><p>29.1</p></td><td style="vertical-align:top"><p>31.5</p></td><td style="vertical-align:top"><p>‑2.4</p><p>(‑8.8, 4.1)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>% of patients who lost visual acuity (%) (&ge;15&nbsp;letters of BCVA loss)</strong></p></td><td style="vertical-align:top"><p>48</p></td><td style="vertical-align:top"><p>6.4</p></td><td style="vertical-align:top"><p>5.5</p></td><td style="vertical-align:top"><p>0.9</p><p>(‑2.7, 4.3)</p></td><td style="vertical-align:top"><p>3.8</p></td><td style="vertical-align:top"><p>4.8</p></td><td style="vertical-align:top"><p>‑1.0</p><p>(‑3.9, 2.2)</p></td></tr><tr><td style="vertical-align:top"><p>96</p></td><td style="vertical-align:top"><p>8.1</p></td><td style="vertical-align:top"><p>7.4</p></td><td style="vertical-align:top"><p>0.7</p><p>(‑3.6, 4.6)</p></td><td style="vertical-align:top"><p>7.1</p></td><td style="vertical-align:top"><p>7.5</p></td><td style="vertical-align:top"><p>‑0.4</p><p>(‑3.8, 3.3)</p></td></tr><tr><td colspan="8" style="vertical-align:top"><p>BCVA: best corrected visual acuity; missing data are imputed using last observation carried forward (LOCF) method</p><p>ETDRS: early treatment diabetic retinopathy study</p><p>SE: standard error</p><p><sup>a)</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; P-value referring to the non-inferiority hypothesis with a non-interiority margin of 4.0&nbsp;letters.</p><p><sup>b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Key secondary endpoint, accounting for differences in timing of Beovu and aflibercept treatments.</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Figure&nbsp;1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mean change in visual acuity from baseline to week&nbsp;96 in HAWK and HARRIER studies</strong></p><p>&nbsp;</p><p><strong>HAWK</strong></p><p>&nbsp;</p><p><sub><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Object_x0020_3" o:spid="_x0000_i1028" type="#_x0000_t75"
 style='width:448.5pt;height:252.75pt;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDRlK0FRgEAACEEAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKyTTW7CMBCF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">
 <v:imagedata src="file:///C:/Users/alshoma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.png"
  o:title="" cropright="-29f"/>
 <o:lock v:ext="edit" aspectratio="f"/>
</v:shape><![endif]--><img width="598" height="337" src="file:///C:/Users/alshoma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image002.png" /></sub></p><p><strong>HARRIER</strong></p><p>&nbsp;</p><p><sub><!--[if gte vml 1]><v:shape
 id="Chart_x0020_13" o:spid="_x0000_i1027" type="#_x0000_t75" style='width:6in;
 height:252pt;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQDRlK0FRgEAACEEAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKyTTW7CMBCF
95V6B8vbihhYVFVFYNGfZdsFPcDUnhCrjm15DA237xCI1CKoQGUTJ7Hnvc9v7MmsbZxYYSIbfClH
xVAK9DoY6xelfJ8/D+6koAzegAseS7lGkrPp9dVkvo5Igqs9lbLOOd4rRbrGBqgIET3PVCE1kPkz
LVQE/QkLVOPh8Fbp4DP6PMgbDTmdPGIFS5fFU8u/tyQJHUnxsF248SolxOishsykauXNnstg51Bw
ZbeGahvphjGkOujQOmrPcwhVZTWaoJcN0xcUE4KhGjE3rujGY1YMcXwvO8RX7kKyBsUbpPwCDe9Y
aWfjR4BklEnwxT2h/mVUbMqOix4IaA9/p9gn9Le9rhmKVDdczJpT6wRPQ8h8tlB1z571/yS/5E7j
2O/E+FKd6OOgGvhanAbzI5QLhdH7qu6CT78BAAD//wMAUEsDBBQABgAIAAAAIQCtMD/xwQAAADIB
AAALAAAAX3JlbHMvLnJlbHOEj80KwjAQhO+C7xD2btN6EJGmvYjgVfQB1mTbBtskZOPf25uLoCB4
m2XYb2bq9jGN4kaRrXcKqqIEQU57Y12v4HTcLdYgOKEzOHpHCp7E0DbzWX2gEVN+4sEGFpniWMGQ
UthIyXqgCbnwgVx2Oh8nTPmMvQyoL9iTXJblSsZPBjRfTLE3CuLeVCCOz5CT/7N911lNW6+vE7n0
I0KaiPe8LCMx9pQU6NGGs8do3ha/RVXk5iCbWn4tbV4AAAD//wMAUEsDBBQABgAIAAAAIQB5qBCp
GQIAAJcKAAAfAAAAY2xpcGJvYXJkL2RyYXdpbmdzL2RyYXdpbmcyLnhtbOxWW46bMBTdiuUFDJhX
AIVIVUbtT1WNmhVYxgQkYyPbTUlXX79IJzNRp8qk7U++CNf3nnNfPmRN6m+Kyl2PJ6rAPDKuatLA
XuupjiJFejpi9SAmys1ZJ+SItXmV+6iV+PvA9yOLkjguItJjqeFmTVpZS8p2ww/6gZNeyAWzldei
PnqmAN5JMXqaeRM/VEWaF+vIss7eejTWFMWlNx43/vkrSou3oouqRAFzCV+CyMx3ExgxkaKBISF+
2Frrk/S45MvhSYKhbWACAccjbeBOSzzsew22gnNKtGkKgtHJPYQbg6vjBZ5yyLieOzmGXuIrOjni
gZuEcS26DswNzJOyyFYlBMcGVlVWVIXNCNd01oCY8xgCYo5QklZFmdmzyOdgnSap9Ccq3p0PsEAN
ZAOnLjd8+Ky0p1ooLB3jtyhcCTa0HwfGLKRbbLplEhwwayAmhHKdhjLPPG0ij1j13rE1v4IX42Fg
fkJ2BZU+Muoz/kpNm91tunpaZonMIJDrzMV83RKZsTBu2CxtZ6q7GXH8NnHgs9S068xm/0vyE6Or
XPDbkY8DF/JS9XpeWt55vmUD/Nzd9XUSEexnQujv+5np72pjnqNV/kobkzzNXqjbZXG8HF5UeRlA
3yWOxW/EMbc3zN4no6X/RRzTOFmheOXEsUQIFYnN6LU4Zigvs7s43sXx+VfkJBFejO/i+GfiGD3/
I7r5CQAA//8DAFBLAwQUAAYACAAAACEAB8F59IIBAABFBAAAHwAAAGNsaXBib2FyZC9kcmF3aW5n
cy9kcmF3aW5nMS54bWykU8tOwzAQvCPxD5bvNCl9CEVNe2gpQkJQCfiAleMkFokd2W5I/551YtQQ
QKD2Ynlt7+zs7HixasqC1FwboWRMx6OQEi6ZSoTMYvr6sr26ocRYkAkUSvKYHrihq+XlxQKiTEOV
C0YQQZoIYppbW0VBYFjOSzAjVXGJd6nSJVgMdRYkGt4RuSyC6zCcByUISZdHqA1YIHstToAqFHvj
yRpkDQYhCxb1TzzHgp2PDJGs73T1XO20Y84e650mIokpKiehRIlo4C/8MwyDQVZ2BGhSXbr3Kk1J
06Ic3Npi8MYShoez6c18GmIBhncTlM4FXZX86Yc8lt/+kYmEusK46ZHxI91qbMSRcq22Q25Phh3P
Pjte56AtGU96nQ+z+sgPOCvTqYLyDSt4rX4BcKw81hluYY4w2oRF7c7b4xR3dEgeQP/HXjhowfhG
sX3Jpe0+guYFWPyBJheVoURHzlD6Phk7RdsRtXK4jvuxE+Mc/3x1wVFxrDH4QP2q31h8AAAA//8D
AFBLAwQUAAYACAAAACEAQW7dH04KAAB3LAAAGwAAAGNsaXBib2FyZC9jaGFydHMvY2hhcnQxLnht
bOxa3XPbuBF/70z/Bx4nD7m5sSR+i5rIN7ZyaW/qNJ7YyUPfIBKSWIEED4RsK399F5+UFIPxpbnr
NGM/yCSwAHYXu4sfdvnq54eaeHeYdRVt5n4wmvgebgpaVs167n+4fXM29b2Oo6ZEhDZ47u9x5/98
/te/vCpmxQYxftOiAnswSdPNirm/4bydjcddscE16ka0xQ30rSirEYdXth6XDN3D5DUZh5NJOpaT
+HoC9BUT1KhqzHj2lPF0taoK/JoWuxo3XHHBMEEcNNBtqrYzsxVBysLPZqyrgtGOrviooPVYTWaE
gsmCZGylOgcllYjjIJ/E3h0ic3/ij0UjQc1aNeDm7MONamR015S4XFDWwHYc0NfF7IJwzBqYakEb
DlxrfdVP0niN2HbXngG7LQi5rEjF91Js//wVzL3YUNCH9x7/tqsY7uZ+EcS9CuLfq4BJNp6OQ72v
IGwQzzq+J1gJFExCIe3YritZeIMIWaJiK3RzQGxJ+34x8FQZYlRB2FvUvrtj3nIdzH3CA9/jD/BU
buFpuYZ9JDwUbfBUbuEJFQUoEij0g2mBftViaSLTEhkaUIqiAUWph8S0JKYlNS2p721I1WxBkeKf
760o+btqME/KAKQrCGHQjtPbihP8GhPMcXlgC8WsJZRfMIwEIUF7uuPiqUbNDpEr+656bhFbY66G
Vw2YlVro4S0t9X7gco1V4/6xxge99CiIg2kaJEEIG5gm0TTRg1R/PIrSZJLl5jee/nImN6+Y3ZsZ
pmEYBHme5lE2nYZZpibYmG4Yn0zCOMqCPImSSRqI/vGpYNDQyww6xAsRg4QC1uA+LcQVNZ+KWKxU
i9whtl9QQo+8CiwNMzGyKo2UipqyEjPNlmrhD4Ku4+w9Xomn1fnNBmMe/PDi8kUgmJSt0L9AEPcE
RcsX4M1a81IU0ebBUiIGCIq780tM73Ze6tVr72Uzj7LJj2KqOyl1CzLBSz+lepHrw6NmqL0GAdCM
NN49hO4wzXPfK1A791lTwiJo1lFSlW8qQuSLiMl4QbRs4B1SxSdUMgoJ1Yt5xTC8WuGCX3Vc7Ucn
FxX7wrZKf92+XlI4Q0R8KytUU1gcaIH76pO2Mr3ZauzJgvKo+CJbSsY8CWMpWEOFVF9kE1TV81kg
aSjNrv5sGy9ehLMX8JPazQQqu5nq9FqAz5z/DYMTISLJ5JkmW083PNTecbrjk+MN7k0i0CYRuwhC
TTB1EUSaIAhdFEJxwrwCKWRvZj0XiaYInXymhsLJaGYonJxONUXk5DQ3FE5OA+NDsZPVwOrUyWtg
tBo7mQ2MXhMnt3BYKsUmbnaNZlM3u0a1qZtdo9vUza5RbuZm12g3c7IbGu1OneyGRrtTJ7uh0e7U
yW5otJs72ZX+Lsw2P2EXXLv3UfVioqN2dAhIYmMe8/dL4e/wI+eUwbufC6J579l/sL9Ho8zlrkZ7
iYvA6C4ZOUmsZY6cu2Qsc2AWY5nJyLmR1jJHkYtdY5mpm11jmambXev4QzTGNgeWsq6fjnIXx9b3
U/cuWecfWsvoeIjGKHmIpteyc8cDq2anVL2WnXtlA8CAlm0EGDALGwJSt13YGJCOJJR67GCyQeAz
moEooN2/qynlBmUqXIIfDuCMxjAnUFBDtgMoqFvcUHDxX0BBtCLVErMCA2IIDSBM8z8XEKqLTPTt
QWH32w4xfcvoMaHGSE/BhAOcfQNcWF5LXGivAbGykuVuuSQ4en10Ezg0HT3udDgYq0S/Tx3/DEuf
Yak0QHNbsGfTMyw90os9lb5bWLoQsBR+/tewNHYDHgNLT9B4f4k0sHQAOhhYOoAKesjkhGc9YnJi
aAOYMjegNHgpcyMUA5iykVNoC0uHaAwsdaJo6/iZGyNbUDogkwWl2ch5rwqMhofmMSoemqfXsXst
o+QhsG20nLpvGTYApO6dsLB0ALQfwFKndR3AUifYPoClJ5bxrWBpebUknUylbej9FV7jpvwH3h8h
kg56PiKdftPlBdG2QPyfqNb5t4P2G8webb8W8NNkLA/oLyUMurGpPNkF8lnWVIJN8aRB8iOYGz38
qtPYQZbl0zCN9RoHHRJ5QoL3MK0L6OhCZl8P6I4n6AoEI9ZCS5RVIIIs5Ch+6qp5ix70vAeEpcyr
H+kRPVxTXXRZKgDHRQZeTKswP6uKjciHLmm5v2YA8SBB2vEbUdqQL61o0RnZEq/eXzOv+zT38wlU
1JYi6+tV8nc39xuopImqGqu2UFFr6I18AjLUYSG9yhGf5knZemmTtxP5JwU7IRN1rMbj+xavoDA3
9xegnSWrBCnkcpGrp+ge74E0sBJGZoS1eEzMxUBAUcea+7aGhWb8/LYCo3t5j/G2g+uLaBG/MAJ+
QUVgOUqR8KD02ufzT2sYX1GmiJNJHkRxHMRZlISpKjYVM+MyoyyfBNk0TMIwmQJZrm47g1UGCsVR
4PHIWMylxaahTbLcNoC0A+lzIbyxLsg8vak5FIVEiVSkk+e+zjqBidAdeOUVVI1wCRl+ZZc1+jdl
t1WxfQspeMWWNCh56wCLd3dyGAQRxRo6ofdqykflEUUFmXBXNYUVWBaUF+oWOOmaNZS5yBoqxgVn
kP88McKn5fSfWmrgD6rOoTzPY5TP/bNUuQC4VdcWbyrW8SvU8WvEoIYMFT/YNP4OflYgI1goIVDX
raCyK9qhEEfZJ9+7Z6JWom+nHmoKaFYC6ZcFh3ep9W/v61A8EfV2qIF/ye/3nXV7KJyX9P4WbqE+
+F7HoQNixZNjwU91c0b4I6FAdGCkOo4igegoOtEBBv15IIDzSGhcxLqTUGC9XW0eFGihaN5d6Eqb
tmTZhnXUFUXPf2FGlUWKN2XbmpYsyQUYnGoTRifNHVrfrVadqXEGoE3ZLixduMfNtmrVEH0rb+jb
HeHV1R0BR1A95kSzRw1kjj47c9S0B0fIwFkjwokRVPMDbnm82MFMw4cRMQI9H0aP2+DQYfTxwoOi
erPG3orR2p6v3ksoq8MHFd2PnpjzzzyiolGQR2E2iZMwmUymSdZXys0RMwrCLIlDCL3TKI2DNJeV
dDgyjs9HaOiPzu/4kGog2t3qqOA8p9IoFheIrziGhg9qAVKeDx8Vur6bw+f4/jBwCMmuS8wBzerw
XVclXKxUSJY47ENTHX/lIQFY3zoZyTw3OKs9VZxGHCZRLq7KaHYKI2G4GgUPR9//yCuhuKMQ+WSR
nb7C9AHiOHYUs6/A1mGSRWmegPYghKWAopUabNjKJznAaohYYRZFKcQu1W8/AEqmWRBAWItSmAaA
uB6vazNwp8/TeDqFSaI0TKdxqj8hApGPmYeGXq4/IvA97vTPSPP/AmkK67BeIXzlY9W9a4i2Ug0m
y6prLwGxbrsLjT7XqFXmKnInrwEbduL2AMmDY9hmP9EzTjz0hRV8iSjmhBPmiErdC09d3Pmh1fEB
BPN98S6i1tR39d8B0eGgFR+ZkteII4/Bd3HwIdmvpcr4Cjz+oRUfsx4r5HCMiEM7+KjuZoNaQPV2
BnPJlsqT3wuf/wcAAP//AwBQSwMEFAAGAAgAAAAhAGHMWdX6BQAAKRkAACIAAABjbGlwYm9hcmQv
dGhlbWUvdGhlbWVPdmVycmlkZTEueG1s7FnPb9s2FL4P2P8g6L7aTvyjDuoUiX80W5O2qN0OPdIW
LbGmRIGkk/o2tKddBgzohh1WYLcdhmEFVmDFLvtjAqTYuj9ij5QskTbdNEEGFMNsILCo7z1+fO/x
e5Ry4+aTmHrHmAvCko5fu1b1PZxMWECSsOM/GA0+ue57QqIkQJQluOMvsPBv7n780Q20IyMc47tg
y0mAPfCTiB3U8SMp051KRUzgNhLXWIoTuDdlPEYSLnlYCTg6Af8xrWxVq81KjEji74LDCeVDZYW9
BMUw193plEywvhXMagohFqJLuXeMaMcHFwE7GeEn0vcoEhJudPyq/viV3RsVtJMbUbnB1rAb6E9u
lxsEsy09Jw/HxaT1eqPe3Cv8awCV67h+q9/sNwt/GoAmE5zkXEyfjf32fq+RYw1Q9tPhu9fqbdcs
vOF/e43zXkN9LbwGZf7ra/jBoAtRtPAalOEba/h6vbXVrVt4DcrwzTV8q7rXq7csvAZFlCSzNXS1
0dzuLldbQKaMHjjh7UZ90NrKnZcoqIaiutQUU5bITbUWo8eMDwCggBRJknhykeIpmkBNdhElY068
QxJGUHgpSpiA4epWdVDdhr/qW9e/dETQDkaGteIFTMTakOLjiQknqez4n4FX34CcvX59+vTV6dPf
Tp89O336Sz63dmXZHaAkNO3e/vj13y++8P769Ye3z7/Jpl7FCxP/5ucv3/z+x7vcw4rLUJx9+/LN
q5dn333150/PHd73OBqb8BGJsfDu4BPvPothgQ7+eMwvZjGKEDEt9pJQoASpWRz++zKy0HcWiCIH
bh/bcXzIQWpcwFvzxxbhYcTnkjg83o5iC3jEGN1n3BmF22ouI8yjeRK6J+dzE3cfoWPX3F2UWFnu
z1PQWOJy2Y2wRfMeRYlEIU6w9NQ9NsPYsbpHhFhxPSITzgSbSu8R8fYRcYZkRMZWNZVGBySGvCxc
BCHfVmyOHnr7jLpW3cPHNhL2BqIO8iNMrTDeQnOJYpfLEYqpGfBDJCMXyeGCT0xcX0jIdIgp8/oB
FsJlc5fDeo2k3waZcaf9iC5iG8klmbl8HiLGTGSPzboRilMXdkiSyMR+KmZQosi7x6QLfsTsHaKu
IQ8o2ZjuhwRb6T5fDR6AwpqUygJRd+bckctbmFn1O1zQKcJaaqABWLoek+RckV+R98a/J+8gomff
v3Cs6Gok3e3YyscFxXyPE+duOliR8E24VeHuMh6QD1+3e2ie3MOwVdab1/+y/b9s+/952d60n69e
rEt9BulWx9bsuK4P7/HGs/uUUDqUC4oPhT6+C+hKwQAGlZ1+JMXFs1wawU+1k2ECCxdypG08zuTn
REbDCKVwxq/5ykkocteh8FIm4Oivh52+FZ7O4yMWZI+stZp6PM3EQyBZjlcbxTg8bsgM3WyVj2GF
e802FBmTjICyvQgJYzKbxLaDRGs5qIKkH84haA4SemVXwqLtYHFduV+mao0FUCuyAscmDw5bHb9R
BxMwgqcqRHGg8pSlepldHcKrzPSmYFoVAGeIZQWUmW4rrhuXp1b33pm2SBjlZpPQkdE9TEQIXt7o
Fyp5CvMNsRblksZFc90uU2rRU6FY7oaSRuv6u4Jx2VyD3ao20MRUCpp4Jx2/ud2AkpmgtONP4dEf
fsYp1I5Qx11EQ3hFNpE82/CXUZaUC9lDIsoCrkUnU4OYSMw9SuKOr5ZfVANNtIZobrUtEIQPllwb
ZOVDIwdJt5OMp1M8kWbajREV6ewSFD7bBc672vzyYGXJ5pDuYRSceGM65/cRlFijVVMBDIiAN0C1
LJoBgVeahZCV9bfSmHLZNd8p6hrKxhFNI5R3FFPMM7iW8oKOvipiYFzla4aAGiHJG+E4VA3WDKrV
TYuukXHY2HXPN1KRM0Sz7JmWqqiu6RZTa4ZlG1iJ5eWavMFqGWJol2aHz5r0quS2l1q3ck4ougQE
vIifo+u+R+s3qJWTWdQU43UZVpqdj9q9Y7nAc6i9T5Mwmk9z6XYlbkWPcE4Hg5fq/GC3WrUwNF2e
K3WkrX9v7P4DAAD//wMAUEsDBAoAAAAAAAAAIQCdK5PaDCYAAAwmAAAzAAAAY2xpcGJvYXJkL2Vt
YmVkZGluZ3MvTWljcm9zb2Z0X0V4Y2VsX1dvcmtzaGVldC54bHN4UEsDBBQABgAIAAAAIQDdK4tY
bAEAABAFAAATAAgCW0NvbnRlbnRfVHlwZXNdLnhtbCCiBAIooAACAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACslE1PwzAMhu9I/IcqV9Rm44AQ
WrcDH0eYxPgBoXHXaG0Sxd7Y/j1u9iGEyiq0Xmq1id/nrR1nMts2dbKBgMbZXIyzkUjAFk4bu8zF
x+IlvRcJkrJa1c5CLnaAYja9vposdh4w4WyLuaiI/IOUWFTQKMycB8srpQuNIn4NS+lVsVJLkLej
0Z0snCWwlFKrIaaTJyjVuqbkecuf904C1CiSx/3GlpUL5X1tCkXsVG6s/kVJD4SMM+MerIzHG7Yh
ZCehXfkbcMh749IEoyGZq0CvqmEbclvLLxdWn86tsvMiHS5dWZoCtCvWDVcgQx9AaawAqKmzGLNG
GXv0fYYfN6OMYTywkfb/onCPD+J+g4zPyy1EmR4g0q4GHLrsUbSPXKkA+p0CT8bgBn5q95VcfXIF
JLVh6LZH0XN8Prfz4DzyBAf4fxeOI9pmp56FIJCB05B2HfYTkaf/4rZDe79o0B1sGe+z6TcAAAD/
/wMAUEsDBBQABgAIAAAAIQC1VTAj9AAAAEwCAAALAAgCX3JlbHMvLnJlbHMgogQCKKAAAgAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAArJJNT8Mw
DIbvSPyHyPfV3ZAQQkt3QUi7IVR+gEncD7WNoyQb3b8nHBBUGoMDR3+9fvzK2908jerIIfbiNKyL
EhQ7I7Z3rYaX+nF1ByomcpZGcazhxBF21fXV9plHSnkodr2PKqu4qKFLyd8jRtPxRLEQzy5XGgkT
pRyGFj2ZgVrGTVneYviuAdVCU+2thrC3N6Dqk8+bf9eWpukNP4g5TOzSmRXIc2Jn2a58yGwh9fka
VVNoOWmwYp5yOiJ5X2RswPNEm78T/XwtTpzIUiI0Evgyz0fHJaD1f1q0NPHLnXnENwnDq8jwyYKL
H6jeAQAA//8DAFBLAwQUAAYACAAAACEAgT6Ul/MAAAC6AgAAGgAIAXhsL19yZWxzL3dvcmtib29r
LnhtbC5yZWxzIKIEASigAAEAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAArFJNS8QwEL0L/ocw
d5t2FRHZdC8i7FXrDwjJtCnbJiEzfvTfGyq6XVjWSy8Db4Z5783Hdvc1DuIDE/XBK6iKEgR6E2zv
OwVvzfPNAwhi7a0egkcFExLs6uur7QsOmnMTuT6SyCyeFDjm+CglGYejpiJE9LnShjRqzjB1Mmpz
0B3KTVney7TkgPqEU+ytgrS3tyCaKWbl/7lD2/YGn4J5H9HzGQlJPA15ANHo1CEr+MFF9gjyvPxm
TXnOa8Gj+gzlHKtLHqo1PXyGdCCHyEcffymSc+WimbtV7+F0QvvKKb/b8izL9O9m5MnH1d8AAAD/
/wMAUEsDBBQABgAIAAAAIQDSFvAHhAEAALsCAAAPAAAAeGwvd29ya2Jvb2sueG1sjJJNTyMxDIbv
K/EfotxpZlCpUNUUgQBtLyskduGcJp6O1XwpSRm6v36dmS3Ligsn26+Tx3ac1fWbs+wVUsbgJW9n
DWfgdTDod5L/+vlwfsVZLsobZYMHyY+Q+fX67NtqCGm/DWHPCOCz5H0pcSlE1j04lWchgqdMF5JT
hcK0EzkmUCb3AMVZcdE0C+EUej4RlukrjNB1qOEu6IMDXyZIAqsKtZ97jPlEc/orOKfS/hDPdXCR
EFu0WI4jlDOnl5udD0ltLY391l6eyOR+QjvUKeTQlRmhxNTkp3nbRrTtNPJ61aGF5+nZmYrxh3K1
iuXMqlzuDRYwki8oDAP8J6RDvD2gpWw7n180XKzfV/GYKKg7eUYY8j+9huwV898BqXs0BurDv6A3
YZCctn784A+j/IKm9JJfLeaUnqTvgLu+SH7ZkEbFxIdq42Kp6miZHwd6qstu6QdVu6k9c5aWSE7a
mHYknK5pZfVjYtXUgyM+WHjC38ASdJLfTOdP/279BwAA//8DAFBLAwQUAAYACAAAACEA+R89WNcA
AAAoAQAAFAAAAHhsL3NoYXJlZFN0cmluZ3MueG1sXI/RTsMwDEXfkfgHy0/wwNJtqIMpySSQ+AHg
A0LqtZEap4vTCv6eDGkS2uO9Pr6+1ofvOMJCWUJig+tVg0DsUxe4N/j58fbwhCDFcefGxGTwhwQP
9vZGixSouywGh1KmvVLiB4pOVmkirpNjytGVKnOvZMrkOhmIShzVpmlaFV1gBJ9mLgYfEWYOp5le
L9pqCVYX+045kMBWq2K1Ont//vn0Xibna6WaLZQXQgtXlHXHMXxR9jQV2EDs4Y7Ntn2+v+ZeKC0z
tBdi1/wjVP3U/gIAAP//AwBQSwMEFAAGAAgAAAAhAKic9QC8AAAAJQEAACMAAAB4bC93b3Jrc2hl
ZXRzL19yZWxzL3NoZWV0MS54bWwucmVsc4SPwQrCMBBE74L/EPZu0noQkaa9iNCr6Aes6bYNtknI
RtG/N+BFQfA07A77ZqdqHvMk7hTZeqehlAUIcsZ31g0azqfDaguCE7oOJ+9Iw5MYmnq5qI40YcpH
PNrAIlMcaxhTCjul2Iw0I0sfyGWn93HGlMc4qIDmigOpdVFsVPxkQP3FFG2nIbZdCeL0DDn5P9v3
vTW09+Y2k0s/IlTCy0QZiHGgpEHK94bfUsr8LKi6Ul/l6hcAAAD//wMAUEsDBBQABgAIAAAAIQDB
FxC+TgcAAMYgAAATAAAAeGwvdGhlbWUvdGhlbWUxLnhtbOxZzYsbNxS/F/o/DHN3/DXjjyXe4M9s
k90kZJ2UHLW27FFWMzKSvBsTAiU59VIopKWXQm89lNJAAw299I8JJLTpH9EnzdgjreUkm2xKWnYN
i0f+vaen955+evN08dK9mHpHmAvCkpZfvlDyPZyM2Jgk05Z/azgoNHxPSJSMEWUJbvkLLPxL259+
chFtyQjH2AP5RGyhlh9JOdsqFsUIhpG4wGY4gd8mjMdIwiOfFsccHYPemBYrpVKtGCOS+F6CYlB7
fTIhI+wNlUp/e6m8T+ExkUINjCjfV6qxJaGx48OyQoiF6FLuHSHa8mGeMTse4nvS9ygSEn5o+SX9
5xe3LxbRViZE5QZZQ26g/zK5TGB8WNFz8unBatIgCINae6VfA6hcx/Xr/Vq/ttKnAWg0gpWmttg6
65VukGENUPrVobtX71XLFt7QX12zuR2qj4XXoFR/sIYfDLrgRQuvQSk+XMOHnWanZ+vXoBRfW8PX
S+1eULf0a1BESXK4hi6FtWp3udoVZMLojhPeDINBvZIpz1GQDavsUlNMWCI35VqM7jI+AIACUiRJ
4snFDE/QCLK4iyg54MTbJdMIEm+GEiZguFQpDUpV+K8+gf6mI4q2MDKklV1giVgbUvZ4YsTJTLb8
K6DVNyAvnj17/vDp84e/PX/06PnDX7K5tSpLbgclU1Pu1Y9f//39F95fv/7w6vE36dQn8cLEv/z5
y5e///E69bDi3BUvvn3y8umTF9999edPjx3a2xwdmPAhibHwruFj7yaLYYEO+/EBP53EMELEkkAR
6Hao7svIAl5bIOrCdbDtwtscWMYFvDy/a9m6H/G5JI6Zr0axBdxjjHYYdzrgqprL8PBwnkzdk/O5
ibuJ0JFr7i5KrAD35zOgV+JS2Y2wZeYNihKJpjjB0lO/sUOMHau7Q4jl1z0y4kywifTuEK+DiNMl
Q3JgJVIutENiiMvCZSCE2vLN3m2vw6hr1T18ZCNhWyDqMH6IqeXGy2guUexSOUQxNR2+i2TkMnJ/
wUcmri8kRHqKKfP6YyyES+Y6h/UaQb8KDOMO+x5dxDaSS3Lo0rmLGDORPXbYjVA8c9pMksjEfiYO
IUWRd4NJF3yP2TtEPUMcULIx3LcJtsL9ZiK4BeRqmpQniPplzh2xvIyZvR8XdIKwi2XaPLbYtc2J
Mzs686mV2rsYU3SMxhh7tz5zWNBhM8vnudFXImCVHexKrCvIzlX1nGABZZKqa9YpcpcIK2X38ZRt
sGdvcYJ4FiiJEd+k+RpE3UpdOOWcVHqdjg5N4DUC5R/ki9Mp1wXoMJK7v0nrjQhZZ5d6Fu58XXAr
fm+zx2Bf3j3tvgQZfGoZIPa39s0QUWuCPGGGCAoMF92CiBX+XESdq1ps7pSb2Js2DwMURla9E5Pk
jcXPibIn/HfKHncBcwYFj1vx+5Q6myhl50SBswn3Hyxremie3MBwkqxz1nlVc17V+P/7qmbTXj6v
Zc5rmfNaxvX29UFqmbx8gcom7/Lonk+8seUzIZTuywXFu0J3fQS80YwHMKjbUbonuWoBziL4mjWY
LNyUIy3jcSY/JzLaj9AMWkNl3cCcikz1VHgzJqBjpId1KxWf0K37TvN4j43TTme5rLqaqQsFkvl4
KVyNQ5dKpuhaPe/erdTrfuhUd1mXBijZ0xhhTGYbUXUYUV8OQhReZ4Re2ZlY0XRY0VDql6FaRnHl
CjBtFRV45fbgRb3lh0HaQYZmHJTnYxWntJm8jK4KzplGepMzqZkBUGIvMyCPdFPZunF5anVpqr1F
pC0jjHSzjTDSMIIX4Sw7zZb7Wca6mYfUMk+5YrkbcjPqjQ8Ra0UiJ7iBJiZT0MQ7bvm1agi3KiM0
a/kT6BjD13gGuSPUWxeiU7h2GUmebvh3YZYZF7KHRJQ6XJNOygYxkZh7lMQtXy1/lQ000RyibStX
gBA+WuOaQCsfm3EQdDvIeDLBI2mG3RhRnk4fgeFTrnD+qsXfHawk2RzCvR+Nj70DOuc3EaRYWC8r
B46JgIuDcurNMYGbsBWR5fl34mDKaNe8itI5lI4jOotQdqKYZJ7CNYmuzNFPKx8YT9mawaHrLjyY
qgP2vU/dNx/VynMGaeZnpsUq6tR0k+mHO+QNq/JD1LIqpW79Ti1yrmsuuQ4S1XlKvOHUfYsDwTAt
n8wyTVm8TsOKs7NR27QzLAgMT9Q2+G11Rjg98a4nP8idzFp1QCzrSp34+srcvNVmB3eBPHpwfzin
UuhQQm+XIyj60hvIlDZgi9yTWY0I37w5Jy3/filsB91K2C2UGmG/EFSDUqERtquFdhhWy/2wXOp1
Kg/gYJFRXA7T6/oBXGHQRXZpr8fXLu7j5S3NhRGLi0xfzBe14frivlzZfHHvESCd+7XKoFltdmqF
ZrU9KAS9TqPQ7NY6hV6tW+8Net2w0Rw88L0jDQ7a1W5Q6zcKtXK3WwhqJWV+o1moB5VKO6i3G/2g
/SArY2DlKX1kvgD3aru2/wEAAP//AwBQSwMEFAAGAAgAAAAhAGPioBQKAwAAwgcAAA0AAAB4bC9z
dHlsZXMueG1spFVtb5swEP4+af/B8ndqoCFLIqBqmiJV2qZJTaV9dcAkVv2CjNOSTfvvO/OSUHXa
svYL+I7z47vnHh/xVSMFemKm5lolOLjwMWIq1wVX2wQ/rDNvhlFtqSqo0Iol+MBqfJV+/BDX9iDY
/Y4xiwBC1QneWVstCKnzHZO0vtAVU/Cl1EZSC6bZkroyjBa12yQFCX1/SiTlCncIC5mfAyKpedxX
Xq5lRS3fcMHtocXCSOaLu63Shm4EpNoEE5qjJpiacDihdb06RPLc6FqX9gJAiS5LnrPXuc7JnND8
hASwb0MKIuKHXeFpXGpla5TrvbJAP6C7pBePSj+rzH1yzi4qjesf6IkK8ISYpHGuhTbIAtlQa+A8
ikrWRdxQwTeGO2dJJReHzt3ua/vTx0kObLko4vLoXzVs4kIcswpdAuBIYyDcMqMyMFC/Xh8qOF6B
NjqYNu4f0VtDD0EYjTaQ9sA03mhTgBZPfAyuNBastJCo4dude1tdwXOjrYWWpXHB6VYrKlwpHchx
AeXkTIh7p9fv5QvspkRqLzNp74oEg/IdCcMSCumXHV5nOPwxWoc9gr0Esv4fFjXlEf8duxGtKnFY
tiT2mng32rXgWyVZJ880BmF1Jno2tFqzppWto6Upe26AjRHlLwg/UoecVhP81Q0HAarvy0ebPReW
qz+QDZhF87J9YA/6QIMAHqq2k4O5gnvkHJ1+YJKBCBJsdzB0hhvEVcEaBgLorhVxQut1dlZ8q8hW
kGeFg3AH3Z4V30l8LOu2bOLIgFPdqGulfeQZdFywku6FXR8/Jvi0/sIKvpcwEvuob/xJ2xYiwaf1
Z3fPgqm7o9DjzzVQAm+0NzzBP2+Xn+ar2yz0Zv5y5k0uWeTNo+XKiyY3y9Uqm/uhf/NrNHPfMXHb
/wNcqWCyqAXMZdMX2yd/f/IleGR06bcTBtIe5z4Pp/51FPhedukH3mRKZ95sehl5WRSEq+lkeRtl
0Sj36I0z3idBMMz4JogWlksmuBp6NXRo7IUmgfmXIsjQCXL6+aa/AQAA//8DAFBLAwQUAAYACAAA
ACEAywPnYYkEAABBEwAAGAAAAHhsL3dvcmtzaGVldHMvc2hlZXQxLnhtbJRY35OiOBB+v6r7Hyhe
rxYEFdRStma0tm4ermpr79dzBoJSA8RLMs7Of3+dRCQEY/RJ7HS6v+5054Nef/3Z1N4JU1aRduNH
wcT3cJuTomr3G//vv759Wfge46gtUE1avPE/MfO/Zr/+sv4g9I0dMOYeWGjZxj9wflyFIcsPuEEs
IEfcwkpJaIM4/KX7kB0pRoXc1NRhPJkkYYOq1lcWVvQeG6QsqxzvSP7e4JYrIxTXiAN+dqiOrLPW
5PeYaxB9ez9+yUlzBBOvVV3xT2nU95p89bJvCUWvNcT9M5qhvLMt/4zMN1VOCSMlD8BcqICOY16G
yxAsZeuigghE2j2Ky43/FK12ceKH2Vom6J8KfzDt2ePo9U9c45zjAs7J90T+Xwl5E4ovIJqASSYV
hEmU8+qEt7iuN/4uhiP8TzqBR3AQXjzoz523b/LEvlOvwCV6r/mW1P9WBT+AV3B7Fv4gH7/jan/g
IJ0H6RwyIxK0Kj53mOVwMgAoiOeXcHaIo2xNyYcHpwxm2BGJmolWM98TRmap0LYYyda52PYk9snd
sIFBuKcsWocniCE/azwrDYj3ojEdamzHGvFQYzf2MrlohBDBJQyRVi2M6wnosAtlgV2g7u3JuJ7j
a9LtVak8y85Oj3yAa/oILqGs7JUyaQdEceGfS3K6eoKS9Fgly+sp/m22DksRAfwO8j6VEUyD1Mi2
ks9M+a73esosUUBh3J9doXwlCgUcKv6ULQzEM4l4buBV0sSoiN76KevraZBzqN370Qrl22gjoyif
5wpuYAJW8iQwDmTXuzhl/Z4BZHGwd5evUHZANrL2nJwhG9C2Sp4Elkymj8ASyrdhxWazpZZMKnkS
LK83u6DBu7MllB2wzA5anGEZdbpV8kTroMEhLh+BJZQdsMw2WUpY+mHJK2ur5KlWdwNYEbxG3J8u
qX0b2NRsCNgj2joZdcR5IbXVlyCxB6B1bJCtB/ejdrNMzcIHDwqaWfnnhTTodwyz9hCjRD2l2KDN
zOKHPRZoasEO7SFSiSysomVtZjYA7LEcqFroK3OYs4d4InITxcxsAdijgPU3g+qB80KqleAQ2kOk
ELlZYT5qgu76N3kXjAnM9v586PKP3Lf/fNQE3TVvMhYYU9AsvB/pBAB1dPu1SmrfvjqSURN0V/0I
mlqwZ00nATc0NwskoyborvsRNLUAb8nX6SnSicANzc0EyagNOioYQeu4wAIt1rnACU1q3z7Q1GwD
2CM71HiZ68Q2So91JnADczNBajYBeFBXh/kVclmw3GqxzgRuaG4mWIy+OWxMAK4VZgtJxToTuKG5
mWBhNgF4EAjmgfkudF6wvgzFOhe4od3x0WA2AXiwHOiYJIbfijoXuKG5uWA5aoKOC4xv4i18V5vE
OoSmc4EbmpsLlqM26LhgBK1bMGtNTSjU0OCI9vgPRPdVy7wal3KyABxB1fRhEsAzJ0cxbxBjiFfC
OWm6fweYN2EYHUwCCKwkhHd/4JsQBio1/o4oZ15O3sXEQnTrRerRVQVjFfpSRHJm0qvDwOEy/Mr+
BwAA//8DAFBLAwQUAAYACAAAACEAYpZRl1sBAAB1AgAAEQAIAWRvY1Byb3BzL2NvcmUueG1sIKIE
ASigAAEAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAjJJRT4MwFIXfTfwPpO9QyjLnCLBEzR7U
RRNZNL417WVrhJa0Vca/t8CGLPrgY3vO/XrOTZPVoSq9L9BGKJkiEoTIA8kUF3KXom2+9q+RZyyV
nJZKQopaMGiVXV4krI6Z0vCsVQ3aCjCeI0kTszpFe2vrGGPD9lBREziHdGKhdEWtO+odrin7oDvA
URhe4Qos5dRS3AH9eiSiI5KzEVl/6rIHcIahhAqkNZgEBP94LejK/DnQKxNnJWxbu07HuFM2Z4M4
ug9GjMamaYJm1sdw+Ql+2zy+9FV9IbtdMUBZwlnMNFCrdLYRTCujCus9FYVg4G0N6ARPHN02S2rs
xi2+EMBv2uxBaGNb717tHVPJBP+2uDf6SsNDwD0XMh4qnZTX2e1dvkZZFJKlHy58ssjJPJ4t4ih8
7xKczXehh4vqmOMfxGiZExLPHXQ+IZ4AWZ/7/KNk3wAAAP//AwBQSwMEFAAGAAgAAAAhAKlLRQEv
AQAA8wEAABQAAAB4bC90YWJsZXMvdGFibGUxLnhtbGyRy2rDMBBF94X+wzCrdtHIccBtQ5TQpAQC
pYsm/QDFHscCPYwk5/H3le2kYNrlXN07c2Y0W5y1giM5L63hOB4lCGRyW0hz4Pi9Wz+9IPggTCGU
NcTxQh4X8/u7WRB7RRDTxnOsQqinjPm8Ii38yNZk4ktpnRYhlu7AfO1IFL4iClqxNEkypoU0CLKI
YxGM0LH7rm0aq0L6WonL50B0VHJ8G09XaYYQbBDKf9nTtrKnSB65O6KldQW593O5iX0TnPecK6sa
bTzktjGB42SoDxkA2SDVvaY3wiXZYwMZ6AM8GD55Th7/s09udlEquSeXUx0gvYWy1y7EOuAr2nXk
NlwUbUxpwce91tL50Bu6DVvtQ/yR2isEJ2uKPxGP17r60K+atJD9vPkPAAAA//8DAFBLAwQUAAYA
CAAAACEAEeB6AZMBAAApAwAAEAAIAWRvY1Byb3BzL2FwcC54bWwgogQBKKAAAQAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAACckk1v2zAMhu8D9h8M3Rs53VAMgayiSDf0sGEB4rZnVaZjobIkiKyR
9NdPstHEWXvqjR8vXj4iJa73vS0GiGi8q9hyUbICnPaNcbuK3de/Ln6wAkm5RlnvoGIHQHYtv34R
m+gDRDKARbJwWLGOKKw4R91Br3CR2i51Wh97RSmNO+7b1mi49fqlB0f8siyvOOwJXAPNRTgasslx
NdBnTRuvMx8+1IeQgKWoPSlbmx5kKfgpETchWKMVpdfLP0ZHj76l4udegxV83hSJegv6JRo6ZI95
KrZaWVingbJVFkHwU0HcgcrL3CgTUYqBVgNo8rFA85rWecmKJ4WQMSs2qGiUo4SbZVMyxjYgRfno
4zN2AISCJ8FUHMO5dh6b73I5ClJwLswGE0hqnCPWhizg33ajIn1AvJwTjwwT74SzzXzTzDnf+OQ0
6T/vte+DcofUOEa/jXvG+1D7W0Xwts7zoth2KkKTLnBc97Eg7tImo80m6065HTRvmveNfPyH6efL
5dWi/Famu85qgp/+uPwHAAD//wMAUEsBAi0AFAAGAAgAAAAhAN0ri1hsAQAAEAUAABMAAAAAAAAA
AAAAAAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEAtVUwI/QAAABMAgAA
CwAAAAAAAAAAAAAAAAClAwAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEAgT6Ul/MAAAC6AgAA
GgAAAAAAAAAAAAAAAADKBgAAeGwvX3JlbHMvd29ya2Jvb2sueG1sLnJlbHNQSwECLQAUAAYACAAA
ACEA0hbwB4QBAAC7AgAADwAAAAAAAAAAAAAAAAD9CAAAeGwvd29ya2Jvb2sueG1sUEsBAi0AFAAG
AAgAAAAhAPkfPVjXAAAAKAEAABQAAAAAAAAAAAAAAAAArgoAAHhsL3NoYXJlZFN0cmluZ3MueG1s
UEsBAi0AFAAGAAgAAAAhAKic9QC8AAAAJQEAACMAAAAAAAAAAAAAAAAAtwsAAHhsL3dvcmtzaGVl
dHMvX3JlbHMvc2hlZXQxLnhtbC5yZWxzUEsBAi0AFAAGAAgAAAAhAMEXEL5OBwAAxiAAABMAAAAA
AAAAAAAAAAAAtAwAAHhsL3RoZW1lL3RoZW1lMS54bWxQSwECLQAUAAYACAAAACEAY+KgFAoDAADC
BwAADQAAAAAAAAAAAAAAAAAzFAAAeGwvc3R5bGVzLnhtbFBLAQItABQABgAIAAAAIQDLA+dhiQQA
AEETAAAYAAAAAAAAAAAAAAAAAGgXAAB4bC93b3Jrc2hlZXRzL3NoZWV0MS54bWxQSwECLQAUAAYA
CAAAACEAYpZRl1sBAAB1AgAAEQAAAAAAAAAAAAAAAAAnHAAAZG9jUHJvcHMvY29yZS54bWxQSwEC
LQAUAAYACAAAACEAqUtFAS8BAADzAQAAFAAAAAAAAAAAAAAAAAC5HgAAeGwvdGFibGVzL3RhYmxl
MS54bWxQSwECLQAUAAYACAAAACEAEeB6AZMBAAApAwAAEAAAAAAAAAAAAAAAAAAaIAAAZG9jUHJv
cHMvYXBwLnhtbFBLBQYAAAAADAAMABMDAADjIgAAAABQSwMEFAAGAAgAAAAhAHaFahVWBgAADxoA
ABoAAABjbGlwYm9hcmQvdGhlbWUvdGhlbWUxLnhtbOxZS28bNxC+F+h/WOy9sd6KjciBrUfcxE6C
SEmRI6WldhlzlwuSsqNbkZx6KVAgLXpogN56KIoGaIAGvfTHGHDQpj+iQ+5DpETFD7hAUMQCjN3Z
b4bDmdlvSO6Nm09j6h1hLghLOn71WsX3cDJhAUnCjv9wNPjsuu8JiZIAUZbgjj/Hwr+5/eknN9DW
hJJ0zBAPRhGOsQeGErGFOn4kZbq1sSEmIEbiGktxAs+mjMdIwi0PNwKOjmGAmG7UKpXWRoxI4m+D
RakM9Sn8S6RQggnlQ2UGewmKYfR70ymZYI0NDqsKIeaiS7l3hGjHB5sBOx7hp9L3KBISHnT8iv7z
N7ZvbKCtXInKNbqG3kD/5Xq5QnBY02PycFwO2mg0G62d0r4GULmK67f7rX6rtKcBaDKBmWa+2Dbb
tW4jxxqg7NJhu9fu1asW3rBfX/F5p6l+Fl6DMvuNFfxg0IUoWngNyvDNFXxzd3O3Z9vXoAzfWsG3
Kzu9Rtuyr0ERJcnhCrrSbNW7xWxLyJTRPSd8s9kYtGu58QUKqqGsLjXElCVyXa3F6AnjAwAoIEWS
JJ6cp3iKJlCTXUTJmBNvn4QRFF6KEiZAXKlVBpU6/Fe/hr7SGUVbGBnayi/wRKyIlD+emHCSyo5/
G6z6BuT0zZuTZ69Pnv1+8vz5ybNf87G1KUtvDyWhqffup2/+efml9/dvP7578W029DJemPi3v3z1
9o8/32ceZrwIxel3r96+fnX6/dd//fzCYX2Ho7EJH5EYC+8uPvYesBgm6PAfj/nFNEYRIqbGThIK
lCA1isN+X0YW+u4cUeTA7WI7jo84UI0LeGv2xHJ4GPGZJA6Ld6LYAh4wRncZd0bhjhrLCPNoloTu
wfnMxD1A6Mg1dhclVpb7sxQ4lrhMdiNsuXmfokSiECdYeuoZO8TYMbvHhFhxPSATzgSbSu8x8XYR
cYZkRMZWNS2U9kgMeZm7HIR8W7E5eOTtMuqadQ8f2Uh4NxB1OD/C1ArjLTSTKHaZHKGYmgHfRzJy
OTmc84mJ6wsJmQ4xZV4/wEK4dO5xmK+R9DtAM+60H9B5bCO5JIcum/uIMRPZY4fdCMWpCzskSWRi
PxeHUKLIu8+kC37A7DdE3UMeULI23Y8IttJ9Nhs8BIY1XVoUiHoy445c3sLMqt/hnE4R1lQDDcDi
9ZgkZ5L8Er03/zt6BxI9/eGlY0ZXQ+luw1Y+LkjmO5w436a9JQpfh1sm7i7jAfnwebuHZsl9DK/K
avP6SNsfadv/39P2uvf56sl6wc9A3WrZmi3X9eI9Xrt2nxJKh3JO8b7Qy3cBXSkYgFDp6T0qLvdy
aQSX6k2GASxcyJHW8TiTXxAZDSOUwhq/6isjochNh8JLmYClvxY7bSs8ncUHLMi2rNWq2p5m5CGQ
XMgrzVIO2w2ZoVvtxTasNK+9DfV2uXBA6V7ECWMw24m6w4l2IVRB0ptzCJrDCT2zK/Fi0+HFdWW+
SNWKF+BamRVYNnmw2Or4zQaogBLsqhDFgcpTluoiuzqZV5npdcG0KgDWEEUFLDK9qXxdOz01u6zU
zpFpywmj3GwndGR0DxMRCnBenUp6HjcumuvNRUot91Qo9HhQWgs32tff58Vlcw16y9xAE5MpaOId
d/xWvQklM0Fpx5/C1h8u4xRqR6jlLqIhHJpNJM9e+MswS8qF7CERZQHXpJOxQUwk5h4lccdX0y/T
QBPNIdq3ag0I4YN1bhNo5UNzDpJuJxlPp3gizbQbEhXp7BYYPuMK51Otfnmw0mQzSPcwCo69MZ3x
BwhKrNmuqgAGRMAJUDWLZkDgSLMkskX9LTWmnHbNM0VdQ5kc0TRCeUcxyTyDayov3dF3ZQyMu3zO
EFAjJHkjHIeqwZpBtbpp2TUyH9Z23bOVVOQM0lz0TItVVNd0s5g1QtEGlmJ5uSZveFWEGDjN7PAZ
dS9T7mbBdUvrhLJLQMDL+Dm67jkaguHaYjDLNeXxKg0rzs6ldu8oJniGa+dpEgbrtwqzS3Ere4Rz
OBBeqvOD3nLVgmharCt1pF2fJw5Q6o3DaseHTwRwNvEUruAjgw+ympLVlAyu4MsBtIvsuL/j5xeF
BJ5nkhJTLyT1AtMoJI1C0iwkzULSKiQt39Pn4vAtRh2J+15x7A09LD8mz9cW9jec7X8BAAD//wMA
UEsDBBQABgAIAAAAIQBnA+6GzgAAAKwBAAAqAAAAY2xpcGJvYXJkL2RyYXdpbmdzL19yZWxzL2Ry
YXdpbmcxLnhtbC5yZWxzrJDNasMwDIDvg72D0X1W0sMYo04vpdDr6B5AOMoPTWxjqWV9+5kWxgKF
XnqRkIQ+fWi9+Zknc+YsYwwOaluB4eBjO4bewfdh9/YBRpRCS1MM7ODCApvm9WX9xRNpWZJhTGIK
JYiDQTV9IoofeCaxMXEoky7mmbSUucdE/kg946qq3jH/Z0CzYJp96yDv2xWYwyWVy4/ZsetGz9vo
TzMHvXMCtXhxAVLuWR1Ye+vcYm2LK+B9jfqZGn6grAuNa0fwmv48cPHj5hcAAP//AwBQSwMEFAAG
AAgAAAAhAOMokxgLAQAAbAIAACYAAABjbGlwYm9hcmQvY2hhcnRzL19yZWxzL2NoYXJ0MS54bWwu
cmVsc6ySTUsDMRCG74L/IczdZHcFEWm2FxV6EEFbPJaYzG5Cd5OQibr990ax4ELFS28zvMw7z3ws
ltM4sHdM5IKXUPMKGHodjPO9hM36/uIaGGXljRqCRwl7JFi252eLJxxULkVkXSRWXDxJsDnHGyFI
WxwV8RDRF6ULaVS5pKkXUemd6lE0VXUl0m8PaGeebGUkpJW5BLbex9L5f+/QdU7jbdBvI/p8pIXQ
VqW8IUzPVsUyCVur1GOWwLkwSX2UqekQNLyggzhO1ZyS6mcnMxocX9F8XYHEg9MpUOjy9m7SOGxf
QtqRRcx8Gmj6i7A+JWEu98TH8ibJGZxxfitipteHxYnZj7SfAAAA//8DAFBLAQItABQABgAIAAAA
IQDRlK0FRgEAACEEAAATAAAAAAAAAAAAAAAAAAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0A
FAAGAAgAAAAhAK0wP/HBAAAAMgEAAAsAAAAAAAAAAAAAAAAAdwEAAF9yZWxzLy5yZWxzUEsBAi0A
FAAGAAgAAAAhAHmoEKkZAgAAlwoAAB8AAAAAAAAAAAAAAAAAYQIAAGNsaXBib2FyZC9kcmF3aW5n
cy9kcmF3aW5nMi54bWxQSwECLQAUAAYACAAAACEAB8F59IIBAABFBAAAHwAAAAAAAAAAAAAAAAC3
BAAAY2xpcGJvYXJkL2RyYXdpbmdzL2RyYXdpbmcxLnhtbFBLAQItABQABgAIAAAAIQBBbt0fTgoA
AHcsAAAbAAAAAAAAAAAAAAAAAHYGAABjbGlwYm9hcmQvY2hhcnRzL2NoYXJ0MS54bWxQSwECLQAU
AAYACAAAACEAYcxZ1foFAAApGQAAIgAAAAAAAAAAAAAAAAD9EAAAY2xpcGJvYXJkL3RoZW1lL3Ro
ZW1lT3ZlcnJpZGUxLnhtbFBLAQItAAoAAAAAAAAAIQCdK5PaDCYAAAwmAAAzAAAAAAAAAAAAAAAA
ADcXAABjbGlwYm9hcmQvZW1iZWRkaW5ncy9NaWNyb3NvZnRfRXhjZWxfV29ya3NoZWV0Lnhsc3hQ
SwECLQAUAAYACAAAACEAdoVqFVYGAAAPGgAAGgAAAAAAAAAAAAAAAACUPQAAY2xpcGJvYXJkL3Ro
ZW1lL3RoZW1lMS54bWxQSwECLQAUAAYACAAAACEAZwPuhs4AAACsAQAAKgAAAAAAAAAAAAAAAAAi
RAAAY2xpcGJvYXJkL2RyYXdpbmdzL19yZWxzL2RyYXdpbmcxLnhtbC5yZWxzUEsBAi0AFAAGAAgA
AAAhAOMokxgLAQAAbAIAACYAAAAAAAAAAAAAAAAAOEUAAGNsaXBib2FyZC9jaGFydHMvX3JlbHMv
Y2hhcnQxLnhtbC5yZWxzUEsFBgAAAAAKAAoAAgMAAIdGAAAAAA==
">
 <v:imagedata src="file:///C:/Users/alshoma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image003.png"
  o:title=""/>
 <o:lock v:ext="edit" aspectratio="f"/>
</v:shape><![endif]--><img width="576" height="336" src="file:///C:/Users/alshoma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image004.png" /></sub></p><p>&nbsp;</p><p>These visual acuity gains were achieved with 56% and 51% of patients treated with Beovu on a 12‑weekly dosing interval at week&nbsp;48, and with 45% and 39% of patients at week&nbsp;96 in HAWK and HARRIER, respectively. Among patients identified as eligible for the 12‑weekly regimen during the first 12‑week interval, 85% and 82% remained on the 12‑weekly dosing interval up to week&nbsp;48. Of patients on the 12‑weekly interval at week&nbsp;48, 82% and 75% remained on the 12‑weekly dosing interval up to week&nbsp;96.</p><p>&nbsp;</p><p>Treatment effects in evaluable subgroups (e.g. age, gender, race, baseline visual acuity, baseline retinal thickness, lesion type, lesion size, fluid status) in each study were generally consistent with the results in the overall populations.</p><p>&nbsp;</p><p>Disease activity was assessed by changes in visual acuity and/or anatomical parameters, including CST and/or presence of IRF/SRF or sub‑RPE. Disease activity was assessed throughout the studies. Anatomical parameters of disease activity were decreased at week&nbsp;48 and at week&nbsp;96 for Beovu compared to aflibercept (see &ldquo;Pharmacodynamic effects&rdquo;).</p><p>&nbsp;</p><p>The percentage difference in patients with disease activity at week&nbsp;16 was statistically significant on Beovu versus aflibercept (24% vs 35% in HAWK, p=0.0013; 23% vs 32% in HARRIER, p=0.0021).</p><p>&nbsp;</p><p>In both studies, Beovu demonstrated clinically meaningful increases from baseline in the pre‑specified secondary efficacy endpoint of patient‑reported outcomes, reported through the National Eye Institute Visual Function Questionnaire (NEI VFQ‑25). The magnitude of these changes was similar to that seen in published studies, which corresponded to a 15‑letter gain in BCVA. Patient‑reported outcome benefits were maintained in the second year.</p><p>&nbsp;</p><p>No clinically meaningful differences were found between Beovu and aflibercept in changes from baseline to week&nbsp;48 in NEI VFQ‑25 total score and subscales (general vision, ocular pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, colour vision and peripheral vision).</p><p>&nbsp;</p><p>The results of the Beovu arms of the HAWK and HARRIER studies, where Beovu was administered every 4&nbsp;weeks (monthly) for the first 3&nbsp;doses (loading) followed by maintenance dosing every 12 or 8&nbsp;weeks, were replicated in a population pharmacokinetic/pharmacodynamic model simulation study where Beovu was administered every 6&nbsp;weeks for the first 2&nbsp;or 3 doses (loading) followed by maintenance dosing every 12 or 8&nbsp;weeks.</p><p>&nbsp;</p><p><em><u>DME</u></em></p><p>The efficacy and safety of Beovu were assessed in two randomised, multicentre, double-masked, active‑controlled Phase&nbsp;III studies (KESTREL and KITE) in patients with visual impairment due to diabetic macular oedema. A total of 926&nbsp;patients were treated in these studies for two years (558 on brolucizumab and 368 on aflibercept 2&nbsp;mg). Patient ages ranged from 23 to 87&nbsp;years, with a mean age of 63&nbsp;years.</p><p>&nbsp;</p><p>In both studies, after the first five doses (weeks&nbsp;0, 6, 12, 18 and 24), brolucizumab patients were treated every 12&nbsp;weeks, with the option of adjusting to a dosing interval every 8&nbsp;weeks based on disease activity. Disease activity was assessed by a physician during the first 12‑week interval (at weeks&nbsp;32 and 36) and at each subsequent scheduled treatment visit. Patients who showed disease activity (e.g. decreased visual acuity, increased CST) at any of these visits were adjusted to an every 8&nbsp;weeks treatment interval. In year&nbsp;2 of KITE, patients who showed no disease activity could be extended to a 16‑week treatment interval. The comparator aflibercept was administered every 8&nbsp;weeks after the first 5&nbsp;monthly doses.</p><p>&nbsp;</p><p><em>Results</em></p><p>The primary efficacy endpoint for the studies was the change from baseline in BCVA to week&nbsp;52, as measured by the ETDRS letter score, with the primary objective being to demonstrate non‑inferiority of Beovu versus aflibercept 2&nbsp;mg. In both studies, Beovu (administered in an every 12&nbsp;weeks or an every 8&nbsp;weeks regimen) demonstrated non‑inferior efficacy to aflibercept 2&nbsp;mg (administered every 8&nbsp;weeks).</p><p>&nbsp;</p><p>The results of KESTREL and KITE also demonstrated non‑inferiority of Beovu versus aflibercept 2&nbsp;mg for the key secondary endpoint (average change from baseline in BVCA over the period week&nbsp;40 to week&nbsp;52).</p><p>&nbsp;</p><p>The visual acuity gains observed in the first year were maintained in the second year.</p><p>&nbsp;</p><p>Detailed results of both studies are shown in Table&nbsp;3 and in Figure&nbsp;2 below.</p><p>&nbsp;</p><p><strong>Table&nbsp;3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Visual acuity outcomes at weeks&nbsp;52 and 100 in Phase&nbsp;III - KESTREL and KITE studies</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:648px"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p><strong>KESTREL</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>KITE</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Efficacy outcome</strong></p></td><td style="vertical-align:top"><p><strong>Week</strong></p></td><td style="vertical-align:top"><p><strong>Beovu</strong></p><p><strong>(n=189)</strong></p></td><td style="vertical-align:top"><p><strong>Aflibercept</strong></p><p><strong>2&nbsp;mg</strong></p><p><strong>(n=187)</strong></p></td><td style="vertical-align:top"><p><strong>Difference</strong></p><p><strong>(95% CI) brolucizumab &ndash; aflibercept</strong></p></td><td style="vertical-align:top"><p><strong>Beovu</strong></p><p><strong>(n=179)</strong></p></td><td style="vertical-align:top"><p><strong>Aflibercept</strong></p><p><strong>2&nbsp;mg</strong></p><p><strong>(n=181)</strong></p></td><td style="vertical-align:top"><p><strong>Difference</strong></p><p><strong>(95% CI) brolucizumab&ndash; aflibercept</strong></p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="3"><p><strong>Change from baseline in BCVA </strong><strong>(measured by ETDRS letters score) &ndash; LS mean (SE)</strong></p></td><td style="vertical-align:top"><p>52</p></td><td style="vertical-align:top"><p>9.2</p><p>(0.57)</p></td><td style="vertical-align:top"><p>10.5</p><p>(0.57)</p></td><td style="vertical-align:top"><p>‑1.3</p><p>(‑2.9, 0.3)</p><p>P &lt;0.001<sup>a</sup></p></td><td style="vertical-align:top"><p>10.6</p><p>(0.66)</p></td><td style="vertical-align:top"><p>9.4</p><p>(0.66)</p></td><td style="vertical-align:top"><p>1.2</p><p>(‑0.6, 3.1)</p><p>P &lt;0.001<sup>a</sup></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>40‑52</p></td><td style="vertical-align:top"><p>9.0</p><p>(0.53)</p></td><td style="vertical-align:top"><p>10.5</p><p>(0.53)</p></td><td style="vertical-align:top"><p>‑1.5</p><p>(‑3.0, 0.0)</p><p>P &lt;0.001<sup>a</sup></p></td><td style="vertical-align:top"><p>10.3</p><p>(0.62)</p></td><td style="vertical-align:top"><p>9.4</p><p>(0.62)</p></td><td style="vertical-align:top"><p>0.9</p><p>(‑0.9, 2.6)</p><p>P &lt;0.001<sup>a</sup></p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>100</p></td><td style="vertical-align:top"><p>8.8</p><p>(0.75)</p></td><td style="vertical-align:top"><p>10.6</p><p>(0.75)</p></td><td style="vertical-align:top"><p>‑1.7</p><p>(‑3.8, 0.4)</p></td><td style="vertical-align:top"><p>10.9</p><p>(0.85)</p></td><td style="vertical-align:top"><p>8.4</p><p>(0.85)</p></td><td style="vertical-align:top"><p>2.6</p><p>(0.2, 4.9)</p></td><td><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Gain of at least 15&nbsp;letters in BCVA from baseline or BCVA &ge;84&nbsp;letters (%)</strong></p></td><td style="vertical-align:top"><p>52</p></td><td style="vertical-align:top"><p>36.0</p></td><td style="vertical-align:top"><p>40.1</p></td><td style="vertical-align:top"><p>‑4.1</p><p>(‑13.3, 5.9)</p></td><td style="vertical-align:top"><p>46.8</p></td><td style="vertical-align:top"><p>37.2</p></td><td style="vertical-align:top"><p>9.6</p><p>(‑0.4, 20.2)</p></td><td><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>100</p></td><td style="vertical-align:top"><p>39.2</p></td><td style="vertical-align:top"><p>42.2</p></td><td style="vertical-align:top"><p>‑3.0</p><p>(‑12.5, 6.3)</p></td><td style="vertical-align:top"><p>50.4</p></td><td style="vertical-align:top"><p>36.9</p></td><td style="vertical-align:top"><p>13.6</p><p>(3.3, 23.5)</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="9" style="vertical-align:top"><p>BCVA: best corrected visual acuity;<em> </em>BCVA assessments after start of alternative DME treatment in the study eye were censored and replaced by the last value prior to start of this alternative treatment.</p><p>ETDRS: early treatment diabetic retinopathy study</p><p>LS: least-square</p><p>SE: standard error</p><p><sup>a</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; P‑value referring to the non‑inferiority hypothesis with a non‑inferiority margin of 4.0&nbsp;letters</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Figure&nbsp;2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mean change in visual acuity from baseline to week&nbsp;100 in KESTREL and KITE studies</strong></p><p>&nbsp;</p><p><strong>KESTREL</strong></p><p><!--[if gte vml 1]><v:shape id="Chart_x0020_75"
 o:spid="_x0000_i1026" type="#_x0000_t75" style='width:453.75pt;height:257.25pt;
 visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQBy3imDVwEAAG4EAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKyUyU7DMBBA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">
 <v:imagedata src="file:///C:/Users/alshoma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image005.png"
  o:title=""/>
 <o:lock v:ext="edit" aspectratio="f"/>
</v:shape><![endif]--><img width="605" height="343" src="file:///C:/Users/alshoma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image006.png" /></p><p>&nbsp;</p><p><strong>KITE</strong></p><p><!--[if gte vml 1]><v:shape id="Chart_x0020_119"
 o:spid="_x0000_i1025" type="#_x0000_t75" style='width:453.75pt;height:248.25pt;
 visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQB7D+HPTgEAAOYDAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKyTyU7DMBBA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">
 <v:imagedata src="file:///C:/Users/alshoma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image007.png"
  o:title="" cropbottom="-26f"/>
 <o:lock v:ext="edit" aspectratio="f"/>
</v:shape><![endif]--><img width="605" height="331" src="file:///C:/Users/alshoma1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image008.png" /></p><p>&nbsp;</p><p>These visual acuity gains were achieved with 55% and 50% of patients treated with Beovu on a 12‑weekly dosing interval at week&nbsp;52, and 44% and 37% of patients treated with Beovu on a 12‑weekly or 12‑weekly/16‑weekly dosing interval at week&nbsp;100 in KESTREL and KITE, respectively. Among patients identified as eligible for the 12‑weekly regimen during the first 12‑week interval, approximately 70% remained on at least the 12‑weekly interval at week&nbsp;100 in both studies. In KITE, 25% of patients were treated with Beovu on a 16‑weekly dosing interval at week&nbsp;100.</p><p>&nbsp;</p><p>Treatment effects in evaluable subgroups (e.g. age, gender, baseline HbA1c, baseline visual acuity, baseline central subfield thickness, DME lesion type, duration of DME since diagnosis, retinal fluid status) in each study were generally consistent with the results in the overall populations.</p><p>&nbsp;</p><p>In KESTREL and KITE, disease activity was assessed throughout the studies by changes in visual acuity and/or anatomical parameters, including CST and/or presence of IRF/SRF. The reduction in CST from baseline was maintained up to week&nbsp;100. At week&nbsp;100, the proportion of patients with IRF/SRF was lower in patients treated with Beovu (42% KESTREL and 41% KITE) compared to patients treated with aflibercept 2&nbsp;mg (54% KESTREL and 57% KITE).</p><p>&nbsp;</p><p>Diabetic retinopathy severity score (DRSS) was assessed in the KESTREL and KITE studies. At baseline, 98.1% of patients in both KESTREL and KITE had gradable DRSS scores. Based on the pooled analysis, Beovu showed non‑inferiority to aflibercept 2&nbsp;mg in the proportion of subjects with at least a 2‑step improvement from baseline in DRSS at week&nbsp;52, using a non‑inferiority margin of 10%. Estimated proportions were 28.9% and 24.9% in Beovu and aflibercept 2&nbsp;mg, respectively, resulting in a treatment difference of 4.0% (95% CI:&nbsp;[‑0.6, 8.6]). At week&nbsp;100, the proportion of patients with a &ge;2‑step improvement from baseline to week&nbsp;100 in the DRSS score was 32.8% with Beovu and 29.3% with aflibercept 2&nbsp;mg in KESTREL and 35.8% with Beovu and 31.1% with aflibercept 2&nbsp;mg in KITE.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The European Medicines Agency has waived the obligation to submit the results of studies with Beovu in all subsets of the paediatric population in neovascular AMD and DME (see section&nbsp;4.2 for information on paediatric use).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Beovu is administered directly into the vitreous to exert local effects in the eye.</p><p>&nbsp;</p><p><u>Absorption and distribution</u></p><p>&nbsp;</p><p>After intravitreal administration of 6&nbsp;mg brolucizumab per eye to patients with nAMD, the geometirc mean C<sub>max</sub> of free brolucizumab in the plasma was 49.0&nbsp;ng/ml (range: 8.97 to 548&nbsp;ng/ml) and was attained in 1&nbsp;day.</p><p><u>&nbsp;</u></p><p><u>Biotransformation and elimination</u></p><p>&nbsp;</p><p>Brolucizumab is a monoclonal antibody fragment and no metabolism studies have been conducted. As a single‑chain antibody fragment, free brolucizumab is expected to undergo elimination through both target‑mediated disposition via binding to free endogenous VEGF, passive renal elimination and metabolism via proteolysis.</p><p>&nbsp;</p><p>After intravitreal injections, brolucizumab was eliminated with an apparent systemic half‑life of 4.3&nbsp;&plusmn;&nbsp;1.9&nbsp;days. Concentrations were generally near or below the quantitation limit (&lt;0.5&nbsp;ng/ml) approximately 4&nbsp;weeks after dosing in most patients. Brolucizumab did not accumulate in the serum when administered intravitreally every 4&nbsp;weeks.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em><u>Elderly</u></em></p><p>There were no relevant differences in systemic pharmacokinetics following intravitreal injection in a study with 22&nbsp;patients aged 65 to 74&nbsp;years, 18&nbsp;patients aged 75 to 84&nbsp;years and 3&nbsp;patients aged &ge;85&nbsp;years.</p><p>&nbsp;</p><p><em><u>Renal impairment</u></em></p><p>The systemic pharmacokinetics of brolucizumab was evaluated in nAMD patients with normal renal function (&ge;90&nbsp;ml/min [n=21]),<em> </em>with mild (60 to &lt;90&nbsp;ml/min [n=22]) or moderate (30 to &lt;60&nbsp;ml/min [n=7]) renal impairment. While the mean systemic clearance values for patients with mild or moderate renal impairment were generally lower than patients with normal renal function, no significant impact of mild and moderate renal impairment on the overall systemic exposure to brolucizumab was observed. No patients with severe (&lt;30&nbsp;ml/min) renal impairment were studied.</p><p>&nbsp;</p><p><em><u>Hepatic impairment</u></em></p><p>Brolucizumab has not been studied in patients with hepatic impairment. Mild to severe hepatic impairment should have no impact on the overall systemic exposure to brolucizumab, because metabolism occurs via proteolysis and does not depend on hepatic function.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies have been conducted on the carcinogenic or mutagenic potential of brolucizumab.</p><p>&nbsp;</p><p>In pregnant cynomolgus monkeys, brolucizumab was administered once every 4&nbsp;weeks by intravitreal injection at dose levels resulting in maximal systemic exposures 6‑fold higher than those in humans at the maximum recommended dose (based on serum C<sub>max</sub>). There was no impact on embryofoetal development, pregnancy or parturition, or on the survival, growth or postnatal development of offspring. Nevertheless, based on its pharmacological effect, brolucizumab should be regarded as potentially teratogenic and embryo-foetotoxic.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium citrate</p><p>Sucrose</p><p>Polysorbate 80</p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Pre filled syringe: 2 years
Vial: 2 years

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pre‑filled syringe</u></p><p>&nbsp;</p><p>Store in a refrigerator (2&deg;C&nbsp;‑&nbsp;8&deg;C).</p><p>Do not freeze.</p><p>Keep the pre‑filled syringe in its sealed blister and in the outer carton in order to protect from light. Prior to use, the unopened blister may be kept at room temperature (below 30&deg;C) for up to 24&nbsp;hours.</p><p><u>&nbsp;</u></p><p><u>Vial</u></p><p>&nbsp;</p><p>Store in a refrigerator (2&deg;C&nbsp;‑&nbsp;8&deg;C).</p><p>Do not freeze.</p><p>Keep the vial in the outer carton in order to protect from light.</p><p>Prior to use, the unopened vial may be kept at room temperature (below 30&deg;C) for up to 24&nbsp;hours.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pre‑filled syringe</u></p><p>&nbsp;</p><p>0.165&nbsp;ml sterile solution in a pre‑filled syringe (type&nbsp;I glass) with a bromobutyl rubber plunger stopper and a syringe cap consisting of a white, tamper‑evident rigid seal with a grey bromobutyl rubber tip cap including a Luer lock adapter. The pre‑filled syringe has a plunger rod and a purple finger grip, and is packed in a sealed blister.</p><p>&nbsp;</p><p>Pack size of 1&nbsp;pre‑filled syringe.</p><p>&nbsp;</p><p><u>Vial</u></p><p>&nbsp;</p><p>0.230&nbsp;ml sterile solution in a glass vial with a coated rubber stopper sealed with an aluminium cap with a purple plastic flip‑off disk.</p><p>&nbsp;</p><p>Pack size of 1&nbsp;vial and 1&nbsp;blunt filter needle (18G&nbsp;x&nbsp;1&frac12;&Prime;, 1.2&nbsp;mm&nbsp;x&nbsp;40&nbsp;mm, 5&nbsp;&mu;m).</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pre‑filled syringe</u></p><p>&nbsp;</p><p>The pre‑filled syringe contains more than the recommended dose of 6&nbsp;mg. The extractable volume of the pre‑filled syringe (0.165&nbsp;ml) is not to be used in total. The excess volume should be expelled prior to injection. Injecting the entire volume of the pre‑filled syringe could result in overdose. To expel the air bubble along with the excess medicinal product, slowly push the plunger until the edge below the dome of the rubber stopper is aligned with the black dosing line on the syringe (equivalent to 0.05&nbsp;ml, i.e., 6&nbsp;mg brolucizumab).</p><p>&nbsp;</p><p>The solution should be inspected visually upon removal from the refrigerator and prior to administration. If particulates or cloudiness are visible, the pre‑filled syringe must not be used and appropriate replacement procedures followed.</p><p>&nbsp;</p><p>The pre‑filled syringe is sterile and for single use only. Do not use if the packaging, or pre‑filled syringe are damaged or expired. Detailed instructions for use are provided in the package leaflet.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local regulations.</p><p>&nbsp;</p><p><u>Vial</u></p><p>&nbsp;</p><p>The vial contains more than the recommended dose of 6&nbsp;mg. The extractable volume of the vial (0.23&nbsp;ml) is not to be used in total. The excess volume should be expelled prior to injection. Injecting the entire volume of the vial could result in overdose. The injection dose must be set to the 0.05&nbsp;ml dose mark, i.e. 6&nbsp;mg brolucizumab.</p><p>&nbsp;</p><p>The solution should be inspected visually upon removal from the refrigerator and prior to administration. If particulates or cloudiness are visible, the vial must not be used, and appropriate replacement procedures must be followed.</p><p>&nbsp;</p><p>The content of the vial and the filter needle are sterile and for single use only. Do not use if the packaging, vial and/or filter needle are damaged or expired. Detailed instructions for use are provided in the package leaflet.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Marketing Authorization Holder for this Product is Novartis Europharm Limited, Ireland
www.Novartis.com 

Manufacturers;
•	Pre-filled syringe: Manufactured by Alcon-Couvreur, Puurs, Belgium.
•	Vial: Manufactured by Novartis Pharma AG, Stein, Switzerland.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Approved by EMA in 29-Jun-2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>